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Iron has been linked with the neurodegenerative process in Parkinson’s disease (PD) as 
autopsied Parkinsonian showed increases in iron level in the brain, especially in the basal 
ganglia. Treatment with the blood-brain barrier (BBB) permeable iron chelator, deferiprone 
(CP20) shows improvement in motor symptoms among PD patients possibly by 
neuroprotective mechanism. However, serious side effects such as agranulocytosis and 
neutrocytopenia limit its use especially for the elderly PD patients that are more prone 
such toxicity. A series of CP20 derivatives with chiral functional group have been 
developed by chemical modification and showed better toxicity profiles than CP20 when 
tested in rodents. However, the structural modifications of CP20 might change their brain 
permeability profile and reduce their effectiveness as neuroprotective agents. For this 
reason, the aim of the studies reported in this thesis was to investigate the brain 
permeability of CP20 derivatives by in situ brain perfusion. In addition, a CP20 derivative 
that is conjugated with glucose was also investigated as a strategy to improve BBB 
permeation. This was followed by investigation of the neuroprotective capability on 
dopaminergic cell death in in vitro and in vivo models of cell death in PD. The effect of 
functional group chirality on the biological experiments were also evaluated. 
 
Seven out of eight of the CP20 derivatives tested showed successful brain penetration as 
assessed by in situ brain perfusion. From these seven brain penetrant CP20 derivatives, 
one (CP84) show superior brain uptake, three CN128, CN226 and CN228) showed 
comparable brain uptake, and three (CN116, CN118 and CN126) showed lower brain 
uptake than CP20. Glucose conjugated CP20 derivative failed to cross the BBB.  The in 
vitro neuroprotection study in SH-SY5Y neuroblastoma cells revealed neuroprotective 
effect of the brain penetrant CP20 derivatives against H2O2-, 6-OHDA-, and FeNTA- but 
not MG-132-induced cell death. Some of the CP20 derivatives showed better 
neuroprotection at equimolar concentration of CP20. In both studies, molecules chirality 
did not have effect on in situ brain permeability or in vitro neuroprotection. One CP20 
derivative (CN128) was selected for in vivo neuroprotection study with 6-OHDA rat model 
of PD. CN128 showed comparable neuroprotection of dopaminergic neurons in the nigro-
striatal dopamine pathway. In conclusion, these studies showed that all but the glucose-
conjugated derivative of CP20 can permeate the BBB and are neuroprotective in 
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experimental models of PD suggesting these novel iron chelators may be used as potential 
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1 General Introduction 
 Parkinson’s disease (PD) 
Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s disease which affects 1% of the population over 60 years of age and the 
incidence increases with age (de Lau and Breteler, 2006). The disease is characterised 
by progressive cardinal motor symptom which include bradykinesia, rigidity, resting 
tremor, gait dysfunction and postural instability (Jankovic, 2008). Non-motor symptoms 
can also occur including depression, anxiety, autonomic dysfunction, cognitive 
impairment, and sleep disturbance (Jankovic, 2008). With increasing life expectancy, it is 
estimated that the world-wide population of PD patients will double by 2050 (Schapira and 
Jenner, 2011). Current therapy focuses on symptomatic management of the motor 
symptoms, however, there is currently no available treatment to prevent the progress of 
the disease, and this remains a serious unmet clinical need. 
 
 Aetiology of PD 
PD is a multifactorial neurodegenerative disease that involves genetic, environmental or 
combination of both factors in inducing cell death (Warner and Schapira, 2003). Extensive 
years of research has unveiled mutated genes and environmental toxins that could cause 
PD. Familial-type of PD which involves genetic mutations only account for less than 10% 
of PD cases and is normally characterised by early age of onset (<40 years old) (Gasser, 
2009). The rest of the reported cases of PD is sporadic without definite causes (>90%) 
which usually affect population of age more than 40 years old (de Lau and Breteler, 2006). 
The cases of sporadic PD also corroborate the theory that aging as an important risk factor 
in developing PD (Zhang et al., 2000). 
 
Although familial-type of PD only accounts for less than 10% of PD population, the 
discovery of mutated-genes identified by genetic linkage analysis and genome wide 
association studies is an important breakthrough and provide explanation of the molecular 
mechanism underlying the pathogenesis of PD (Klein and Westenberger, 2012). These 
genes express proteins that are involved in cell regulation and protection which include 
protein degradation, antioxidant and mitochondria homeostasis. To date, 28 genes 
associated with PD have been identified with five of them are the most studied (Lin and 
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Farrer, 2014, Pankratz and Foroud, 2007). These genes are SNCA (encode for α-
synuclein), LRRK2 (encode for leucine-rich repeat kinase-2), parkin (encode for parkin), 
PINK1 (encode for phosphatise and tensin homologue induced putative kinase-1) and DJ-
1 (encode for DJ-1).   
 
SNCA is the first PD-associated gene that was identified in ‘Contursi kindred’ of Italian 
descent (Golbe et al., 1999). Mutation in this gene lead to accumulation and aggregation 
of fibrillar α-synuclein as a major component of LB, a signature and a post-mortem 
diagnostic criterion for familial and sporadic PD (Chai and Lim, 2013). Remarkably, 
cytosolic dopamine can form an adduct with α-synuclein protofibril, stabilise it and inhibit 
conversion to α-synuclein fibril (Conway et al., 2001). Although this may seem as 
neuroprotective, the dopamine-α-synuclein protofibril adduct is capable of disrupting the 
cellular membrane by forming pore-like structure which might suggest the selective 
dopaminergic neuron loss in PD (Tosatto et al., 2012). This finding also provides the role 
of α-synuclein not only in familial-PD, but also in sporadic-PD.  
 
Mutation in LRRK2 is the most common cause of familial PD in the world characterised by 
hyper-phosphorylation activity of mutated LRRK2, a tyrosine kinase like protein (Chai and 
Lim, 2013). Elevated phosphorylation of LRKK2 substrates which include MAP kinase and 
peroxiredoxin underlies the pathogenesis of LRRK2 mutation (Boon et al., 2014).  
 
Parkin function as E3 ligase associated with the ubiquitin-proteasome system which 
degrades unwanted proteins (Riley et al., 2013). Mice expressing mutant parkin and parkin 
knock-out mice have been shown to exhibit features of PD pathology and symptom such 
as mitochondrial dysfunction, age-dependent hypokinetic motor deficits and dopaminergic 
neuron degeneration (Lu et al., 2009, Palacino et al., 2004).  
 
PINK-1 mutations are prevalent in PD patients of Asian descent by 20-fold than European 
descent (Kilarski et al., 2012). This gene encodes for mitochondrial membrane-bound 
serine/threonine kinase that involves in the recruitments of protein for mitophagy (Zhou et 
al., 2008). Study of PD-related PINK-1 mutant expressed in human neuroblastoma cell 
line revealed dysfunction of mitophagy as the cause of apoptosis while overexpression of 
wild-type PINK-1 was found to be neuroprotective (Petit et al., 2005).  
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DJ1 encodes for peroxiredoxin-like peroxidase that is localised in mitochondria and 
capable to scavenge mitochondrial H2O2 (Andres-Mateos et al., 2007). Base on the fact 
that DJ1 protein involve as a mitochondrial antioxidant, it can be deduced that mutation of 
DJ1 could predispose dopaminergic neurons to oxidative stress, consistent with finding 
observed in MPTP treated DJ1-deficient mice (Kim et al., 2005).  
 
Although genetic mutations have contributed greatly to the understanding of pathogenesis 
of PD, they do not explain most sporadic PD cases. Therefore, some suggest that 
environmental agents are the main causal factor, and this is supported with the following 
evidence. The notion that environmental toxins could induce PD come from the 
observation of four young drug abusers that developed chronic Parkinsonism. This chronic 
Parkinsonism was later revealed to be cause by the contamination with the meperidine 
analogue, 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) after using illicit drugs 
intravenously. The ability of MPTP to induce neurochemical, pathological and clinical 
features of PD suggest that other toxins could also induce PD (Dick et al., 2007). Indeed, 
epidemiological studies reveal the positive correlation between exposure to pesticides with 
developing PD (Gorell et al., 1998, Petrovitch et al., 2002, Semchuk et al., 1992). This has 
been confirmed in the laboratory whereby injection of pesticides such as rotenone and 
paraquat into rodents induce loss of nigral dopaminergic neurons (Greenamyre et al., 
2003, Peng et al., 2004). Consumption of well water by rural population associated with 
agricultural industry have also been linked to an increased risk of PD (Gatto et al., 2009, 
Priyadarshi et al., 2001). The involvement of metals in the aetiology of PD has been 
demonstrated from epidemiological studies. It is evident that people chronically exposed 
to welding manganese fumes exhibited PD-like clinical features (Jankovic, 2008). Indeed, 
metals such as iron and copper has been reported to accumulate within the SNPc of 
autopsied Parkinsonian brain. These metals contribute to the production of H2O2 during 
the non-enzymatic oxidation of dopamine and the conversion of H2O2 to OH●- by Fenton 
reaction (Dexter et al., 1989, Earle, 1968). Based on the epidemiological data, there is a 
clear link between environmental factors with PD. Nevertheless, some people may be 
more prone to developing PD when expose to toxins than the other. This might suggest 
that both genetics and environmental factors could be the plausible explanation for 
idiopathic PD. Although the causal factors are still not fully understood, PD has well 
defined pathological features that is discussed next. 
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 Pathology of PD 
Two important pathological features characterise PD in autopsied brains namely the loss 
of dopaminergic neurons within SNPc and accumulation of intracellular inclusions within 
the cell body of surviving neurons termed as Lewy bodies (LBs) (Antony et al., 2013). 
 
Loss of dopaminergic neurons within SNPc occurs progressively without causing the 
cardinal motor symptoms of PD until approximately 50% of nigral dopaminergic cell bodies 
have degenerated and about 70% of striatal dopamine content has depleted (Cheng et 
al., 2010, Delaville et al., 2011). This is because, normal function of nigro-striatal pathway 
in controlling voluntary movement is maintain by compensatory mechanisms which include 
increase dopamine turnover and increase in post-synaptic dopamine D2 receptors in the 
striatum (Navntoft and Dreyer, 2016). In addition to the loss of nigral dopaminergic 
neurons that defines the motor symptom in PD, loss of noradrenaline neurones in locus 
coeruleus (LC), serotonin neurones in the dorsal raphe nuclei (RN) and cholinergic 
neurones in nucleus basalis of Meynert (NBM) which causes non-motor symptoms to 
occur (Ferrer, 2011, Olanow et al., 2009a). Non-motor symptoms associated with 
neurodegeneration in these areas include anxiety and depression that are related to the 
loss of noradrenergic and serotonergic neurons while dementia is linked to the 
degeneration of the cholinergic neurons (Calabresi et al., 2006, Hanagasi and Emre, 
2005). Neuron loss is also found in areas some distance from SNPc such as the olfactory 
system, the dorsal motor nucleus of the vagus (DMNV) and the peripheral nervous system 
(PNS) although to a lesser extent (Visanji et al., 2013). 
 
The second pathological feature of PD is the accumulation of globular LBs in surviving 
neurons within SNPc (Antony et al., 2013). LBs are eosinophilic proteinaceous 
cytoplasmic inclusions mainly compose of α-synuclein aggregates as well as ubiquitin, 
neurofilaments and parkin (Wakabayashi et al., 2013). Besides SNPc, LBs are also found 
in other brain areas that experience degeneration (Braak et al., 2003, Olanow and 
Prusiner, 2009b). The role of LBs in pathology of PD is remained elusive. LBs are initially 
thought to be toxic to the neurons since they are related to neuronal loss (Wakabayashi 
et al., 2006). However, later discoveries suggest that α-synuclein oligomers and 
protofibrils are cytotoxic, while the formation of fibrillar LBs containing α-synuclein 
aggregates may be cytoprotective (Wakabayashi et al., 2013). Therefore, although LBs 
may serve as the pathological marker of PD, it does not necessarily indicate that the 
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inclusions are the cause of cell death. Nevertheless, LBs are clearly associated with the 
progressive cell death in the basal ganglia. Having said this, the mechanism of cell death 
in PD brain is described in the following section. 
 
 Cell death mechanism in PD  
Neurodegeneration in PD started with neuronal cell death. There are two type of neuronal 
cell death mechanism namely apoptosis and necrosis that are mainly differentiate by their 
morphology (Nikoletopoulou et al., 2013). Cells undergo apoptosis morphologically exhibit 
shrinkage, chromatin and cytoplasmic condensation, nuclear fragmentation and budding 
of the plasma membrane forming smaller apoptotic bodies (Elmore, 2007). Membrane-
bound apoptotic bodies are destructed by controlled phagocytosis which does not induce 
inflammatory reaction. Changes in cell morphologies and cell destruction are regulated 
genetically by pro-apoptotic molecules such as caspases which requires ATP-dependent 
steps for activation (Tsujimoto, 1997, Zamaraeva et al., 2005). On the contrary, cells 
undergo necrosis show extensive cytoplasmic vacuolisation and swelling. Cell are 
destructed by spontaneous ruptures of cell membrane and releases of cell’s content that 
initiate inflammatory response (Nikoletopoulou et al., 2013). Necrosis is a passive form of 
cell death which does not require ATP and occurs in response to toxic insults or 
spontaneous insults such as stroke or trauma (Stoica and Faden, 2010). 
 
Evidence from in vitro and in vivo studies, as well as post-mortem on Parkinsonian brains 
lean towards apoptosis as the primary mechanism of cell death in PD. However, necrosis 
is also suggested as a possible mechanism of cell death although there has not been 
sufficient evidence supporting this view (Jellinger, 2000). In vitro studies using primary rat 
ventral mesencephalic cultures, and rat pheochromocytoma PC-12 and SH-SY5Y cell 
lines expose to MPP+, the toxic metabolite of MPTP, induce morphological and 
biochemical hallmarks of apoptosis (Walkinshaw and Waters, 1994, Blum et al., 1997, 
Lotharius et al., 1999, Viswanath et al., 2001). Similarly, dopamine and 6-OHDA also 
induces morphological and biochemical changes in PC12 cell line with characteristics of 
that apoptosis. The protection conferred by overexpression of antiapoptotic protein Bcl-2 
and pre-treatment with caspase in this toxins-induced cell death further support apoptosis 
as the chief mechanism of cell death (Offen et al., 1997, Takai et al., 1998). 
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In addition to the in vitro studies, data from in vivo PD models strongly suggest the 
involvement of apoptosis in dopaminergic cell death in SNPc. Mice treated with MPTP 
exhibits increased number of apoptotic markers such as DNA fragmentation, caspases 
and JNK activation, and upregulation of bax mRNA (Saporito et al., 2000, Tatton and Kish, 
1997, Vila et al., 2001). Inhibition of caspase-3 substrate and JNK ablation of the pro-
apoptotic Bax gene as well as overexpression of Bcl-2 protein appears to be protective 
against MPTP-induced cell death in mice (Wang et al., 2004, Cosi et al., 1996, Vila et al., 
2001, Offen et al., 1997, Yang et al., 1998). Likewise, studies from 6-OHDA-lesioned rats 
also display a typical morphology of cells undergoing apoptosis in basal ganglia which was 
confirmed by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling 
(TUNEL) staining (He et al., 2000, Marti et al., 2002). Interestingly, the dose of 6-OHDA 
use to induce lesion seem to determine the preferred cell death pathway, where high 
concentration of 6-OHDA exclusively causes cell necrosis (Jeon et al., 1995). This support 
the theory that cells can decide which appropriate route of cell death mechanism 
depending on the specific situation (Nikoletopoulou et al., 2013).  
 
Finally, evidence from autopsies performed on brain tissue of PD patients reveal the 
presence of apoptotic neurons in SNPc, morphologically characterised by chromatin 
condensation, cell shrinkage and DNA fragmentation in dying neurones (Mochizuki et al., 
1996, Anglade et al., 1997, Tatton et al., 1998). In addition to the well-defined morphology 
characteristics of apoptosis, molecular markers of apoptosis such as Bax and caspase-3 
have been reported to increase (Anglade et al., 1997, Tatton, 2000, Hartmann, 2004). 
Besides apoptosis, the presence of necrotic neurons was also evidence in the post-
mortem brain suggesting involvement of more than one type of cell death mechanism in 
PD brain (Anglade et al., 1997). 
 
To conclude, evidence from in vitro and in vivo studies as well as from brain autopsies 
support apoptosis as the primary mechanism of cell death neuronal degeneration of PD, 
although necrosis could also occur depending on the specific situation. The exact cause 
of apoptosis in PD brain is remain elusive but oxidative stress, mitochondrial dysfunction, 
ubiquitin proteasome system impairment and inflammation might partly contribute to the 
process. 
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 Pathogenesis of cell death in PD 
Many factors are implicated in the neuronal cell death cascade observed in PD. The 
initiator of the cascade is unknown, but they are deleterious and potential targets for 
disease-modifying agents. For this reason, it is essential to fully understand the 
mechanisms associated with cell death. These mechanisms described in detail below 
include the dysfunctions in the protein degradation systems: oxidative stress, 
mitochondrial dysfunction, ubiquitin proteasome system impairment and inflammation. 
 
 Oxidative stress 
Oxidative stress is defined as the imbalance between reactive oxygen species (ROS) 
production and endogenous anti-oxidant systems. ROS such as superoxide anions (O2-), 
hydrogen peroxide (H2O2), hydroxyl radicals (OH●-) and peroxy radicals (O2-2) are 
continuously produce as by-products of the of mitochondrial electron-transport chain 
(ETC). Under normal physiological condition, ROS participates in the immunity and 
autophagy processes in cells (Sena and Chandel, 2012). A defence mechanism consisting 
of enzymes such as superoxide dismutase (SOD), catalase, glutathione (GSH) and 
glutathione proxidae (GPx) convert these radicals into harmless molecules (Turrens, 
2003). Excessive ROS production causes oxidation of cellular macromolecules such as 
proteins, DNA and lipids which results in their damage and loss of membrane integrity 
(Popa-Wagner et al., 2013). Remarkably, aging process appears to increase the incidence 
of oxidative stress as shown by elevated level of oxidised proteins (carboxyls and nitro-
protein adducts), DNA (8-Hydroxy-2-guanosine) and lipid (4-hydroxynonenal and 
malondialdehyde) in PD brain suggesting age as one of the risk factor in 
neurodegeneration process (Mariani et al., 2005, Dexter et al., 1994, Cardoso et al., 2005). 
 
Abnormal activity of antioxidant defence mechanism such as GSH appears to play a role 
in precipitating oxidative stress in PD. Evidence from post mortem brain of PD patients 
showed simultaneous increased level of SOD but reduced levels of GSH within the SNPc 
suggesting accumulation of H2O2 due to inability of GPx to reduce H2O2 to H2O (Jenner 
and Olanow, 1996, Sian et al., 1994, Sofic et al., 1992, Perry and Yong, 1986). Similarly, 
the reduction of GSH levels was also seen in the autopsied brain of incidental Lewy body 
disease (ILBD) patients which are considered to represent the early-stage PD, thus 
suggesting oxidative stress might occur earlier before PD develop (DelleDonne et al., 
CHAPTER 1: GENERAL INTRODUCTION 
29 
 
2008). Increase ROS production due to abnormal antidefense mechanism impaired 
Complex I of ETC due to thiol oxidation of critical residues (Genestra, 2007). Conversely, 
impairment of Complex I by neurotoxins such as rotenone also reduce GSH production by 
inhibition of glutathione reductase also by thiol oxidation (Chinta and Andersen, 2008, Li 
et al., 2003). Either way, this imbalance results in mitochondrial dysfunction and eventually 
cell death (Dias et al., 2013). 
 
Dopaminergic neurons in the basal ganglia are inherently prone to oxidative stress due to 
the nature of dopamine metabolism in generating ROS. Spontaneous auto-oxidation of 
dopamine creates O2-, H2O2 and reactive quinone (Izumi et al., 2005). Additionally, 
enzymatic conversion of dopamine to 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanilic acid (HVA) by monoamine-oxidase B (MAO-B) generates H2O2 (Meiser et al., 
2013). Nevertheless, dopamine metabolism alone cannot explain neurodegeneration in 
PD since other non-dopaminergic neurons in brain also undergo degeneration (Braak et 
al., 2003). Increase of iron as well as decrease iron storage protein, ferritin level seen in 
basal ganglia exacerbates oxidative stress by undergo Fenton reaction with H2O2 
generates highly reactive OH●- (Dexter et al., 1987, Dexter et al., 1989, Sofic et al., 1992, 
Sofic et al., 1988).  
 
 Mitochondrial dysfunction 
Mitochondria serve the role as the energy factory for cells by producing the adenosine 
triphosphate (ATP) molecules, the primary energy source that facilitates many of the 
energy-dependent biochemical reactions within cells. Accumulating lines of evidence has 
shown abnormalities of the mitochondrial respiratory chain in PD. Production of ATP 
involves series of electrons transport and oxidative phosphorylation through Complex I-IV 
of mitochondrial ETC, which finally end up with reduction of O2 to H2O. Impairment of 
electrons transfer along ETC such as inhibition of Complex I by environmental toxins MPP+ 
and rotenone cause oxidative stress due to increase of electrons leakage and deficiency 
in ATP production (Keane et al., 2011, Betarbet et al., 2000). Indeed, early evidence of 
mitochondrial dysfunction in PD come from investigation of drug users and farmers 
inflicted with MPP+ and rotenone toxicity respectively. Besides increase in ROS 
production, inhibition or impairment of mitochondrial ETC causes inability of Na+/K+ 
ATPase pumps to maintain membrane potential due to inadequate ATP production 
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(Sherer et al., 2003). This lead to partial depolarisation of neurons and increase sensitivity 
of excitatory N-methyl-D-aspartate (NMDA) receptor to glutamate resulting in excitotoxicity 
by accumulation of intracellular Ca2+. Furthermore, firing of glutamate from subthalamic 
nucleus to SNPc in PD further exacerbate the condition and lead to cell death (Keane et 
al., 2011). 
 
Reduction in activity and reduce amount of mitochondrial Complex I in the SNPc and 
frontal cortex of autopsied PD patient brain have been reported (Mizuno et al., 1989, 
Schapira et al., 1990). Interestingly, mitochondria isolated from PD patients’ platelet also 
showed a reduction in Complex I activity. Formation of cybrid cell line containing the 
isolated mitochondria was more prone to MPP+-induced cell loss suggesting a widespread 
pathology of mitochondrial dysfunction (Schapira et al., 1990, Parker et al., 2008). Indeed, 
genetic factors may contribute to the impairment of mitochondrial function as exemplified 
by increased levels of mitochondrial DNA (mtDNA) deletions in the striatum of PD patients 
(Ikebe et al., 1990) 
 
Studies on transgenic mouse model further support the role play by genetic factors such 
as gene mutations in mitochondrial dysfunction. Evidence from mitochondrial transcription 
factor (Tfam) knock-out mouse reveal progressive degeneration of dopaminergic neurons 
and progressive motor deficits (Ekstrand et al., 2007). Gene mutation in PINK1 that 
encodes for mitochondrial membrane kinase is associated with autosomal recessive forms 
of PD (Gandhi et al., 2006). This is supported by PINK1 knock-out mice that exhibit 
impairment in dopamine release mitochondrial respiration, as well as increased sensitivity 
to oxidative stress (Gautier et al., 2008, Kitada et al., 2007).  
 
 Ubiquitin proteasome system (UPS) impairment 
The ubiquitin proteasome system (UPS) is an ATP-dependant protein degradation 
pathways for unwanted intracellular proteins that are misfolded, mutated and damaged to 
smaller peptides. Degradation of unwanted proteins is important for maintaining cell 
homeostasis (Wang and Maldonado, 2006). Additionally, UPS is involved in the regulation 
of many cellular processes such as cell cycle and division, development and 
differentiation, apoptosis, cell trafficking and morphogenesis of neuronal networks 
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(Ciechanover, 1998). Besides protein, UPS also play a role in degradation of defective 
mitochondria.  
 
The mechanism of protein degradation by UPS involve two separate but related 
components. Protein for degradation is firstly marked with ubiquitin (Ub) with a series of 
Ub activating, conjugating and ligating enzymes (Glickman and Ciechanover, 2002). Poly-
ubiquited protein is a substrate for multisubunit tubular proteasome, the second 
components of UPS that function to digest the tagged protein into smaller peptides. Poly-
ubiquitination only serve to mark unwanted protein for recognition by proteasome, that is 
later release into cytoplasm and hydrolysed to ubiquitin monomers (Gong and Leznik, 
2007). Therefore, dysfunction of the UPS including poly-ubiquitin hydrolysis are implicated 
in degeneration of dopaminergic neurons in PD. 
 
Defect in one or both components of UPS machinery lead to accumulation of tagged and 
un-tagged unwanted proteins that are toxic to the cells by forming insoluble aggregates. 
Indeed, fail in UPS system might be related to the presence of inclusion body such as LBs 
that contain ubiquitinated α-synuclein (McNaught et al., 2004, McNaught et al., 2002a, 
Olanow et al., 2004). This hypothesis is confirmed in in vitro studies whereby inhibition of 
UPS with inhibitors such epoxomicin and lactacystin in neuronal cells result in 
accumulation of ubiquitinated proteins. Additionally, this cell exhibit increases in 
inflammatory markers such as cyclooxygenase-2 (COX2) and prostaglandin-E2 (PGE2) 
(Rockwell et al., 2000), that activate cell death mechanism (McNaught et al., 2002b). 
Similar observation is replicated in in vivo study in which case administration of N- 
benzyloxy-carbonyl-Ile-Glu(O-t-butyl)-Ala-leucinal (PSI) and epoxomicin to rodents 
caused nigrostriatal degeneration with simultaneous formation of LB inclusions consisting 
of ubiquitin and α- synuclein (McNaught et al., 2004, Zeng et al., 2006, Bukhatwa et al., 
2009) 
 
Mutation of genes that encodes for component in UPS system also play a role in 
impairment of protein degradation. Mutation in parkin and UCHL1 genes that encode for 
ubiquitin ligase and ubiquitin hydrolase cause familial forms of PD (Cordato and Chan, 
2004). In addition, UPS activity appears to decrease in autopsied brain of sporadic PD 
patients which may suggest contribution of environmental factors in UPS dysfunction 
(McNaught and Jenner, 2000, McNaught et al., 2003). 




To conclude, impairment of UPS by proteasomes inhibitors and gene mutations that 
encode for UPS components promote the accumulation of misfolded or damaged proteins, 
as well as the formation of Lbs. This evidence supports the role of UPS impairment in the 
pathogenesis of dopaminergic cell death in PD. 
 
 Inflammation 
Evidence from post mortem brain of PD patient reveal increase level of inflammatory 
markers and mediators in SNPc as assessed by immunohistochemical technique. The 
type of inflammatory markers and mediators present at raised levels include interleukin-
1β (IL-1β), interleukin-6 (IL-6), tumour necrosis factor-α (TNFα), interferon-γ (IFNγ) and 
prostaglandin-E2 (PGE2) (Wu et al., 2008, Teismann and Schulz, 2004, Long-Smith et al., 
2009, Hirsch and Hunot, 2009). The presence of raised inflammatory markers are not 
restricted in brain parenchyma, but also in cerebrospinal fluid (CSF) of PD patients 
suggesting that this could serve as a biomarker as part of diagnosis of PD (Dobbs et al., 
1999, Nagatsu et al., 2000). Additionally, there is a consistent and substantial increase in 
the number of activated resident immune cells of the brain in the SN of post-mortem PD 
brains when compared to control which suggest their involvement in neuroinflammatory-
induced nigrostriatal dopamine neurone degeneration (Wu et al., 2002). 
 
Studies in animal model of PD involving inflammation has given more insight into the 
involvement of microglia in PD brain. Lipopolysaccharide (LPS), a pro-inflammatory 
endotoxin from Gram-negative bacteria induce inflammation by interacting with Toll-like 
receptor 4 (TLR-4) expressed on cell surface (Pålsson-McDermott and O'Neill, 2004). 
Injection of this endotoxin into rodents SNPc lead to dopaminergic cell death through the 
reaction with inflammatory insults. The inflammation response to LPS is mediated by 
microglia, a resident macrophage in the CNS because neurons do not express TLR-4 (Liu 
and Bing, 2011, Castano et al., 1998). The mechanism of inflammation generated by 
microglia upon LPS exposure is unclear, but is thought to involve increase production of 
pro-inflammatory cytokines (TNF-α, IL-1β, IL-2 and IL-6), proteinases, eicosanoids and 
nitric oxide (NO) to the site of injection that is toxic to the cells and promote persistent 
degeneration (Knott et al., 2000, Czlonkowska et al., 2002, Zhang et al., 2005, Beal, 2003, 
Long-Smith et al., 2009). For example, inhibition of inducible NO synthase (iNOS) activity 
in microglia attenuate LPS induce inflammation in rats (Iravani et al., 2005, Iravani et al., 
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2002, Dutta et al., 2008, Arimoto and Bing, 2003). This is because, excessive NO is 
capable to react with superoxide radicals to produce highly reactive peroxynitrite radicals, 
which damage cellular proteins and DNA by forming adducts with them (Hald and 
Lotharius, 2005). To summarise, post mortem on human brain and studies on animal 
model of PD support the damaging role of glial cell in mediating inflammation that lead to 
dopaminergic cell death in SNPc. 
 
 Irons and their role in PD 
Excessive iron accumulation by two-fold of age-matched normal brain, has been observed 
within the SNPc of Parkinsonian brain (Sofic et al., 1988, Dexter et al., 1987). Although 
iron does accumulate progressively in SNPc as people aged, this iron is tightly regulated 
by intracellular iron storage protein, ferritin and therefore confer little or no toxicity 
(Daugherty and Raz, 2015, Zecca et al., 2004). The reason why SNPc is prone to iron 
accumulation remain unclear. Dopamine oxidation product (neuromelanin) (Zecca et al., 
2001), neuroinflammation (Ward et al., 2009, Frank-Cannon et al., 2009), changes in BBB 
permeability (Mills et al., 2010, Gerlach et al., 2006) and malfunction of iron homeostasis 
(Mills et al., 2010) have all been proposed to be the contributing factors. The toxicity of 
iron in PD is central on the ability of iron to undergo Fenton reaction with H2O2 to produce 
OH●-, the most harmful ROS because of its high reactivity with biomolecules such as 
protein, lipid and DNA (Sharma et al., 2012). Unlike O2- and H2O2 that are converted to O2 
and H2O by antioxidant enzymes (catalase, glutathione peroxidase and superoxide 
dismutase), no enzymes exist to scavenge OH●- (Rosario de la Torre et al., 1996). 
Therefore, excess accumulation of OH●- due to iron-catalyse Fenton reaction causes 
cellular death (Pinto et al., 2003). The excessive production of OH●- could contribute to the 
pathogenesis of PD by causing sequence of pathogenic events such as oxidative stress, 
mitochondrial dysfunction, ubiquitin proteasome system (UPS) impairment and 
inflammation as described in Section 1.1.4 (Mounsey and Teismann, 2012). For example, 
oxidative stress confers by excessive OH●- production through iron-catalysed Fenton 
reaction may cause mitochondrial membrane oxidation. This leads to mitochondrial 
dysfunction and reduction of ATP synthesis. This would implicate cellular protein 
degradation that requires energy in the form of ATP causing UPS impairment and followed 
by cell death (Mounsey and Teismann, 2012).  
 
CHAPTER 1: GENERAL INTRODUCTION 
34 
 
 Iron chelators  
Intracellularly iron is stored by sequestering into ferritin (Ponka et al., 1998). Ferritin is an 
oligomeric protein composed of an apoprotein shell of 24 subunits that forms a hollow 
protein shell which capable of storing up to 4500 iron atoms (Pan et al., 2009). The 24 
subunits are heteropolymers of light (L) and heavy (H) chain subunits. Both H and L 
subunits cooperate for the iron mineral core formation (Sammarco et al., 2008, Boyd et 
al., 1985). The H subunit of ferritin has ferroxidase activity for oxidation of Fe2+ to Fe3+ as 
iron is internalised and packed into the ferritin mineral core. On the other hand, L subunits 
enhance oxidation activity by increasing the binding affinity of ferric iron at the nucleation 
sites of the iron core (Levi and Rovida, 2015, Pfaffen et al., 2013). Not all intracellular iron 
is stored within ferritin. About 5% of intracellular iron is available in cytoplasm and form a 
complex with various population of ligands such as glutathione, ascorbate and citrate. Iron 
bound to these ligands is not properly co-ordinated and therefore is redox active. This 
chelatable intracellular redox-active iron complex is widely known as the cellular labile iron 
pool (LIP) (Kruszewski, 2003, Kakhlon and Cabantchik, 2002, Cabantchik, 2014). LIP play 
an important role as an immediate transitory pool for the biosynthesis of iron-associated 
protein such as mitochondrial iron-sulfur-cluster and metalloenzymes (Cabantchik, 2014). 
The level of LIP is normally under tight control because non-coordinated free iron can 
generate oxygen derived free radicals and render tissue damage as in extreme cases of 
iron overload (Halliwell and Gutteridge, 1984). However, in extreme cases of iron overload, 
the changes might exceed the cell homeostatic capacity, thus compromising its integrity. 
In this situation, the oxidative stress impose by excessive LIP could be minimise by 
administration of iron chelators (Glickstein et al., 2005, Kakhlon and Cabantchik, 2002). 
 
Iron chelators are primarily indicated for the treatment of systemic iron-overload as seen 
in Thalassemia patient due to chronic blood transfusion (Saliba et al., 2015, Cianciulli, 
2008). Introduction of the first iron chelators in the market in 1960 significantly improve the 
quality of life and life expectancy of Thalassemia patients (Chaston and Richardson, 
2003). Before the first iron chelation therapy is available, most chronically transfused 
patients died in their teens and twenties due to toxicity associated with iron overload 
(Sheth, 2014, Poggiali et al., 2012). Since the first introduction of iron chelators for clinical 
use, researchers have successfully developed much better iron chelators molecules that 
use in clinics. Nowadays, there are three options for iron chelation therapy available for 
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the treatment of iron overload which is discussed below (Poggiali et al., 2012, Sheth, 
2014).  
 
 Deferrioxamine (DFO) 
Deferrioxamine (DFO, Desferal®) is a microbial siderophore derived from Streptomyces 
pilosus and show selectivity towards ferric ion (Fe3+) (Zhou et al., 2012). DFO has high 
iron affinity constant (pFe3+=26.6) and chelates iron in a hexadentate fashion 
[FeIII(DFO)1+1 iron complex]. Ferrioxamine, the 1:1 iron complex of DFO has net positive 
charge (+1) and does not permeate plasma membrane due to its low lipophilicity (logD7.4 
= -2). DFO enter the liver via carrier-mediated transport and interacts with both 
hepatocelluar and reticuloendothelial iron stores which later promote both biliary and 
urinary iron excretion (Hershko, 1978). DFO is a complex molecule and therefore has a 
large molecular weight (560 Da) which render it orally inactive due to limited 
gastrointestinal tract permeability. DFO is the first authorised iron chelator for the 
treatment of iron overload in Thalassemia patient in 1960. It is developed and marketed 
by Ciba-Geigy and has been extensively use in the clinics before the emergence of orally 
active iron chelators (Bernhardt, 2007). Due to lack of oral permeability, DFO is 
administered by intravenous or subcutaneous routes. Unfortunately, DFO has an 
extremely short half-life in the plasma (~10 minutes) due to extensive metabolism and 
rapid renal clearance. Because of this, DFO is continuously infuse systematically for 8-
12h per day, 5-7 days per week at a standard dose of 40 mg/kg/day to achieve body iron 
homeostasis. Some major side effects that are associated with DFO infusion are depletion 
of body iron stores, neurotoxicity and abnormalities of cartilage formation (Porter et al., 
1989). Because of its administration route, longer treatment time, high cost and severe 
side effects patient compliance is often poor (Porter et al., 1989).  
 
 Deferasirox (DFX) 
Deferasirox (DFX, Exjade®, ICL670) is a triazole iron chelator. DFX prefer trivalent ion 
such as Fe3+ over divalent ions. DFX has pFe3+ that is comparable to deferoxamine (22.5) 
and chelates iron in a tridentate fashion [FeIII(DFX)2]3- iron complex]. The 1:2 iron complex 
of DFX has a net -3 charge under physiological condition and can permeates plasma 
membranes easily due to its high lipophilicity (logD7.4 = 1.0) (Zhou et al., 2012). The low 
molecular weight of DFX (373 Da) facilitates its absorption from the gastrointestinal tract 
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which makes it orally active. Indeed, DFX is the second orally active iron chelator use in 
the clinic for removal of excessive iron accumulation in Thalassemia patient due to routine 
blood transfusions and the first orally active iron chelators approved worldwide. DFX 
promotes iron excretion approximately four to five times more effective than DFO in 
hypertransfused rat model. Furthermore, the pattern of iron excretion produced by DFX is 
distinct from DFO. A substantial proportion of DFO-chelated iron derived from 
reticuloendothelial (RE) cells is excreted in the urine. On the other hand, DFX-chelated 
iron excretion is limited to the bile regardless of whether it is derived from RE or 
hepatocellular stores (Hershko et al., 2001). DFX was approved for human use in 2005 by 
FDA and marketed by Novartis (Zhou et al., 2012). DFX has long plasma half-life upon 
oral consumption and therefore is taken only once daily. DFX has been demonstrated to 
be efficient in removing liver iron from regularly transfused patients but appear to be less 
effective in removing cardiac iron (Wood et al., 2010, Cappellini et al., 2010). High 
lipophilicity of DFX contributes to great affinity towards plasma albumin (>98%) and 
therefore is less toxic by limiting its distribution to peripheral tissues (Weiss et al., 2006). 
Kidney toxicity is the prevalent side effect of this chelator (Rafat et al., 2009). 
 
 Deferiprone (CP20) 
Deferiprone (CP20) is 1, 2-dimethyl derivative of 3-hydroxypyridin-4-ones (HPOs) iron 
chelator. HPOs like CP20 prefer trivalent ions such as Fe3+ and not physiologically 
important divalent ions such as Zn2+, Cu2+, Mn2+ and Co2+ (Hider et al., 2000). However, 
although CP20 shows very high affinity towards Fe3+, it still can bind to Fe2+ under aerobic 
conditions and autoxidise them to Fe3+ (Harris, 1977). CP20 has pFe3+ that is comparable 
to deferoxamine (20.5) and chelates iron in a bidentate fashion [FeIII(CP20)3 iron 
complex]. In contrast to ferrioxamine, the 1:3 iron complex of CP20 is neutral in charge 
and therefore can permeate plasma membrane to removes potentially toxic iron such as 
in iron-loaded liver, cardiac and brain tissues (Hider et al., 2000, Jamuar and Lai, 2012). 
CP20 is relatively hydrophilic (LogD7.4=-0.77) in comparison to DFO and DFX. The low 
molecular weight of CP20 (139 Da) facilitates its absorption from the gastrointestinal tract 
which makes it orally active. Indeed, CP20 is the first orally active iron chelator use in the 
clinic for removal of excessive iron accumulation in Thalassemia patient due to routine 
blood transfusions. CP20 was authorised to enter the European Union and Canadian 
markets by European Medicines in 2002 and was approved by the FDA in 2011. It is 
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marketed by Apotex Inc. Toronto, Canada as Ferriprox™ (Zhou et al., 2012). Despite all 
the advantages, CP20 suffered from extensive glucuronidation at the 3-hydroxyl in the 
liver after oral consumption, and therefore has lower bioavailability and short half-life (3-4 
hours) in the plasma. Because of this, large dose of CP20 is required to achieve body iron 
homeostasis which is 75 mg/kg/day. Consequently, some major side effects are 
associated with the use of CP20 which includes musculoskeletal and joint pains, 
neutropenia, agranulocytosis and gastric intolerance (Fisher et al., 2013, Kontoghiorghes, 
1995, Hoffbrand, 2005, Hoffbrand et al., 2003). 
 
 Novel HPO iron chelators as potential treatment for PD 
One noticeable effect of CP20 is the improvement of motor symptom and slower disease 
progression in Parkinson’s disease (PD) patients (Devos et al., 2014, Abbruzzese et al., 
2011). It is established that interruption of iron homeostasis in the basal ganglia of PD 
patients contribute to the progression of the disease (Griffiths et al., 1999, Hopes et al., 
2012, Hopes et al., 2016). Indeed, iron dysregulation in the substantia nigra is 
hypothesised to be the primary or secondary factor that initiate or exacerbate the death of 
dopaminergic neurons in this brain region (Liddell, 2015, Munoz et al., 2016, Urrutia et al., 
2014). This is because, iron-binding protein such as transferrin and ferritin cannot keep up 
with the excess influx of iron into the mitochondrial matrix and therefore increase the 
reduction-oxidation (redox) reaction of ferrous iron (Fe2+) with hydrogen peroxide (H2O2) 
which is abundant in mitochondria as a by-product of oxidative respiration (Kudin et al., 
2004). The redox reaction coined as Fenton reaction produce the mischievous hydroxyl 
radicals (OH●-) that initiate the chain of radical reaction which ultimately lead to cell death 
(Liddell, 2015, Munoz et al., 2016, Urrutia et al., 2014)  
This positive effect of CP20 in PD patients undoubtedly due to the ability of CP20 to enter 
the brain via passive membrane diffusion in addition to their ability to chelate labile iron in 
brain (Glickstein et al., 2005, Hider et al., 2011a). In fact, CP20 has been reported to not 
only chelate excess iron in the brain region, the CP20-iron complex formed in the brain 
was also able to permeate out and redistribute iron the circulated transferrin in plasma 
(Evans et al., 2012, Abbruzzese et al., 2011, Ayton et al., 2016, Cabantchik et al., 2013). 
Furthermore, CP20 at the dose indicated for PD patients did not interfere with normal 
systemic iron balance (Abbruzzese et al., 2011, Ayton et al., 2016, Cabantchik et al., 
2013).  
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However, CP20 suffered from extensive first-pass metabolism in the liver on its 3-hydroxyl 
(3-OH) group to glucuronidation (45% in rat and 85% in man) lead to a very low 
bioavalaibility in plasma upon oral dosing (Singh et al., 1992). The 3-OH group on the 
HPO molecule is important for the iron chelation activity of CP20, therefore extensive 







Figure 1.1.1: a) CP20 molecular structure with oxygen ligand (3-OH) available to form bond 
with iron b) CP20 glucuronide structure which is pharmacologically inactive. 
Thus, very large and frequent oral doses (75 mg/kg daily) was needed to keep the iron-
overload patients in the negative-iron state albeit CP20 route of administration was more 
feasible than desferioxamine. Although the aim of treatment with CP20 in PD patients was 
slightly different and therefore lower dosage was indicated (30 mg/kg daily), it was still 
considered as high (Devos et al., 2014, Abbruzzese et al., 2011). Moreover, due to the 
prevalence of PD in the elderly, the high and frequent doses are inconvenience, and this 
contribute to the low compliance among patients, and thus reducing the success rate of 
the treatment (Hirsch et al., 2016).  
Concerted efforts have been taken to minimise or eliminate the metabolism of CP20 by 
modification of CP20 structure. The approached involved the functionalisation of the 
pyridinone ring with bulkier alkyl side chains with the aims to hinder or limit the access of 
drug metabolising enzymes active site to the labile 3-OH group (Li et al., 2015, Novakovic 
et al., 2004). One of the molecules, CP94 showed a promising result in rats with lower 
glucuronidation at the 3-OH side (Porter et al., 1990). Unfortunately, the result did not 
translate into man where 85% of the administrated dose was recovered in the urine as a 
3-OH glucuronide metabolite (Porter et al., 1993, Porter et al., 1994). Another promising 
molecule, CP40 and CP41 were synthesised by adding OH functional group to N1 (Hider 
and Liu, 2003). However, this approach cause reduction in lipophilicity, and thus contribute 
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to lower absorption from GIT and possibly not efficient to get into the brain (Fredenburg et 
al., 1996, Singh et al., 1996).  
Recently, a range of novel HPO iron chelators were synthesised by alteration of CP20 
structure by adding substituent at the N1 and/or C2 of HPO ring in the Professor Robert 
C. Hider laboratory at King’s College London in collaboration with Zhejiang University 
China (Hider et al., 2011a). The HPO were designed to minimise the glucuronidation 
reaction by adding chiral alkyl substituent containing -OH functional group at N1. The 
strategy to add substituent containing -OH with chiral centre to the N1 is due to the 
observation that drug metabolising enzymes are stereo-specific in which one 
strereosiomer would be more susceptible to metabolism than the other (Molenda et al., 
1994, Nguyen et al., 2006). In contrast to CP40 and CP41, this structural modification did 
not lead to lower lipophilicity, but rather increase in lipophilicity due to additional alkyl 
group. At the same time, the modification of the structure does not cause signification 
alteration of the ferric ion (Fe3+) affinity constant, pFe3+ compared to CP20. Therefore, it 
was expected to be more efficacious than CP20 in removing iron upon oral dosing at the 
same dose. Indeed, a preliminary study with rats has showed increased bioavailability and 
efficacy of these compounds to remove excess iron compared to CP20 due to reduction 
in the first-pass metabolism upon oral dosing (Lu, 2016, Hider et al., 2011a).  
Remarkably, the lethal dose for these novel iron chelators obtained from acute toxicities 
study performed on mice were found to be higher than CP20 (Hider et al., 2011a). This 
also negates the claimed of Kontoghiorghes et al. (1993) that increasing HPO lipophilicity 
lowered the LD50. These findings lead to the potential development of these set of 
compounds as a clinical drug better than CP20. Moreover, higher efficacy means lower 
doses and frequency are required to give to patients, therefore increase patients’ 
compliance and saving cost. As mentioned earlier, CP20 has been demonstrated to 
improved symptoms in PD patient. Therefore, one potential future application of this new 
set of compounds is for the treatment of PD that is better than CP20 in term of efficacy for 
chelating iron, high in potency and possibly fewer side effects. Theoretically, in order for a 
drug to elicit it effect in the brain, it must able to cross the blood-brain barrier (BBB) (Abbott 
et al., 2010).  
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 The blood-brain barrier (BBB) 
The brain is the integration centre of communicating neurons that make up the nervous 
system (Abbott et al., 2010, Bundgaard and Abbott, 2008b). The nature of neuronal 
communications via ion propagation along the axons is achieve by differences in ionic 
concentration between interstitial fluid and intracellular fluid which warrant a delicate 
control (Kress and Mennerick, 2009, Holcman and Yuste, 2015). Disturbance with the ionic 
balance between interstitial fluid and intracellular fluid is therefore catastrophic as it affects 
the body universally. To prevent this to happen, the brain is protected with three levels of 
protective barrier which are arachnoid membrane-cerebrospinal fluid barrier (ACSFB), 
blood-cerebrospinal fluid barrier (BCSFB) and blood-brain barrier (BBB) (Abbott et al., 
2010, Liddelow, 2011, Abbott, 2005, Engelhardt and Sorokin, 2009). ACSFB and BCSFB 
barrier sites are located at the level of the epithelial cells that make up the arachnoid 
membrane and choroid plexus. On the other hand, BBB barrier site is at the level of 
endothelial cells brain capillary that make up brain capillary. These sites share the same 
characteristics such as complex tight junctions that seal the paracellular route and 
expression of transporters to transport nutrients, electrolytes and metabolites into or out 
of the brain (Luissint et al., 2012, Tietz and Engelhardt, 2015, Upadhyay, 2014b, Abbott 
et al., 2010).  
Although these three levels of protective barrier share the same characteristics as 
mentioned, the degree of the restrictiveness was different. BBB showed the most 
restrictive barrier with transendothelial resistance (TEER) reaching up to 2000 Ω.cm in 
vivo (Wong et al., 2013, Wang et al., 2017, Srinivasan et al., 2015). TEER is a measure 
of differences in electrolytes concentration between blood and interstitial fluid (ISF) which 
indicates the junction tightness in allowing electrolytes movements between compartment. 
In perspective, peripheral TEER is just below 10 Ω.cm. On the other hand, TEER for A-
CSFB and CP-CSFB are less than BBB but higher than the peripheral epithelial membrane 
(Srinivasan et al., 2015). The variation of barrier restriction with BBB at the level of brain 
capillary endothelial cells (BCEC) having the highest restriction is an evolutionary process 
that mainly to protect the brain parenchyma from the fluctuation of electrolytes in brain ISF 
as explained earlier (Bundgaard and Abbott, 2008a, Mayer et al., 2009).  
The brain arteries on the surface of meningeal layer penetrate deeper brain tissue and 
braches into smaller capillaries (Cipolla, 2009). The capillary branches are so extensive 
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with a surface area of 15 m2 per kg brain (Pardridge, 2002b, Hitchcock and Pennington, 
2006). One capillary branch at least serves 1 neuron with proximity between capillaries 
and neuron is 8-13 µm (Cipolla, 2009). In addition to that, 30% of systemic blood perfused 
to the brain despite its weight being just 0.02% of the weight in 70 kg man (Cipolla, 2009). 
To put this in perspective, the liver, which is 0.07% of body weight, receives only 5% of 
systemic blood (Abbott et al., 2010). The total length of brain capillaries is 450 km (Cipolla, 
2009). The extensive blood perfusion into the brain reflect it high metabolic demand for 
nutrients suited with the active physiological functions in integrating the neuronal 
communications (Raichle and Gusnard, 2002, Bélanger et al., 2011, Mergenthaler et al., 
2013). At the same time, the compensatory mechanism to maintain ISF homeostasis such 
as active efflux pump requiring energy. Therefore, it is understood why brain need a huge 
blood perfusion to get the nutrients it needs for neurons and for maintaining the barrier 
functions.  
Taking into account the total length of brain capillaries, and the fact that a large proportion 
of circulating blood is directed to these blood vessels, and that the BBB has a large surface 
area and is at close proximity to the individual neurons, there is significant interest in 
developing CNS drugs that have improved BBB penetration (Hitchcock and Pennington, 
2006). Since BBB equipped with multitude transporters and receptors with overlap 
specificity for micro- and macromolecules, this can be an advantage to manipulate the 
transport systems into transporting CNS-active drug (Pardridge, 2005, Pulicherla and 
Verma, 2015, Banks, 2016, Pardridge, 2002a, Upadhyay, 2014a). The research into 
circumventing BBB by various approach has become an area of active research 
(Papademetriou and Porter, 2015, Hendricks et al., 2015, Misra et al., 2003). This is 
because, up to 90% of CNS-drug in the initial stage of development failed to get into the 
brain despite showing promising pharmacological effect in in vitro studies (Misra et al., 
2003, Pardridge, 2005, Basavaraj and Betageri, 2014). If this could be rectified earlier 
during the drug discovery and development process, other approach can be taken for 
example by converted into prodrugs, encapsulation with nanoparticles or changing the 
drug molecular structure. This can save the cost later when it reaches the pre-clinical stage 
(Papademetriou and Porter, 2015, Hendricks et al., 2015, Misra et al., 2003). 
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 Overcoming the BBB 
The major problem that hinders delivery of drug molecules to brain is the presence of the 
BBB which limit the movement of water and lipid soluble molecules from blood to brain. 
Therefore, molecules that are targeted against diseases in the CNS must be effectively 
passing the BBB to reach the brain via the blood compartment. Paracellular diffusion is a 
non-saturable and noncompetitive movement of molecules such as water between cells 
(O'Donnell and Maddrell, 1983, Pantzar et al., 2006). However, it is absence at the BBB, 
due to the presence of complex tight junctions. The following briefly described the 
available transport mechanism for molecules brain uptake: 
 
▪ Passive membrane diffusion is a non-saturable and noncompetitive movement 
across cells that utilise by lipophilic molecules such as ethanol.  
 
▪ Carrier-mediated transporters are expressed on BCEC to facilitate the entry of 
essential polar metabolites, such as glucose and amino acids due to the tightness 
of brain endothelial cells (Begley and Brightman, 2003). The expression of these 
carriers is often polarized which mean they are co-localized on both the luminal 
and abluminal membranes of the brain capillary endothelium to optimize substrates 
transport into the brain (Begley, 2004). Carrier-mediated transport utilise 
membrane protein carriers that recognise specific solute molecule. Solute like 
glucose bind to carrier triggers a conformational change of the carrier; which 
results in uptake (Egleton and Davis, 2005). 
 
▪ Endocytosis can be isolated into bulk-phase (pinocytosis) endocytosis and 
mediated endocytosis (receptor and absorptive mediated) (Pardridge, 2005). 
Pinocytosis is the noncompetitive, non-saturable, temperature and energy 
dependent non-specific uptake of extracellular fluids. It occurs to a very limited 
degree in the endothelial cells of the cerebral microvasculature (Pardridge, 1995). 
Receptor-mediated endocytosis provides a means for selective uptake of high 
molecular weight molecules by specific type receptors present on the luminal 
membrane (Nicholson and Sykova, 1998). Cells have different receptors for the 
uptake of many different types of ligands, including hormones, growth factors, 
enzymes, and plasma proteins (Pardridge, 2007, Duffy et al., 1988). Absorptive-
mediated endocytosis is triggered by an electrostatic interaction between a 
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positively charged substance (charge moiety of a peptide) and the negatively 
charged plasma membrane surface such as glycocalyx. It has a lower affinity and 
higher capacity than receptor-mediated endocytosis (Bickel et al., 2001).  
 
Multiple strategies have been reported to overcome the BBB for successful brain uptake 
such as direct injection of drugs into the CNS (intrathecal), nanoparticle carrier systems 
for large drug delivery, and chemical modification of drugs to improve small drug delivery 
(Pardridge, 2005, Pulicherla and Verma, 2015, Banks, 2016, Pardridge, 2002a, 
Upadhyay, 2014a). One of the best strategies for improving brain uptake for low molecular 
weight molecule such as CP20 (139.1 Da) is by alteration of the chemical structure to 
increase the lipophilicity, so that its propensity to cross the brain via passive membrane 
diffusion would also increase. Alternatively, CP20 attaches with endogenous substrate for 
carrier-mediated transporter such as glucose or amino acid is also possible. 
 
 Passive membrane diffusion 
Passive membrane diffusion at BBB is driven by the gradient between the extracellular 
and intracellular concentration of molecules (Avdeef, 2011, Sugano et al., 2010, Avdeef, 
2001). The ability of small molecules to permeate through the membrane lipid bilayer is 
governed by their physicochemical properties such as lipophilicity, polarity and size. 
(Lipinski et al., 2001) had proposed a range of optimum physicochemical properties 
termed the ‘Rule of Five’ as guidelines for discovery and development of drug-like 
molecules. A molecule is more likely to be successfully developing into drug if it has the 
following properties namely a molecular weight smaller than 500 Da, a lipophilicity (logP) 
smaller than 5, 5 or fewer hydrogen bond donors and 10 or fewer hydrogen bond acceptors 
(Lipinski et al., 2001, Lipinski et al., 1997). 
 
Molecular weight smaller than 500 Da: Large molecules that have a cross sectional 
area (CSA) more than 80A is energetically unfavourable due to the need to displace large 
number of lipid molecules in the biological membrane (Fischer et al., 1998). Indeed, the 
diffusion of molecules across biological membrane is inversely related with their CSA. 
Since CSA need to be determined experimentally or using specific software for estimation, 
approximation to molecular weight is often use due to ease of getting the value by a simple 
calculation. It has been estimated that molecular weight between 300 to 400Da 
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correspond to be around 80A (Fischer et al., 1998, Pardridge, 2003). This mark the 
rationale of the maximum limit of molecular weight for drug-like molecules as suggested 
by Lipinski et al. (2001). 
 
Lipophilicity (logP) smaller than 5: A good balance between solubility in water or lipid 
is paramount in development of drug-like molecules. Due to the nature of biological 
membranes which compose of lipid bilayer, molecules with low lipophilicity would have 
low level of partition into the membrane and therefore slow down the diffusion processes 
(Smith et al., 2014, Tsinman et al., 2011). Conversely, highly lipophilic molecules would 
have difficulty to dissolve in aqueous media and may precipitate out from the solution. 
Furthermore, lipophilic molecules tend to trap within the biological membrane and thus 
would not reach the target site across the cell membranes. The systemic distribution of 
lipophilic molecules would also be limited due to their high affinity toward plasma protein 
especially albumin (Smith et al., 2014, Tsinman et al., 2011, Lipinski et al., 2001). 
 
Polarity (5 or fewer hydrogen bond donors and 10 or fewer hydrogen bond 
acceptors): The sums of the surface of all polar atoms in a molecule dictate the overall 
polarity of a molecule. Hydrogen bond donor (HBD) and acceptor (HBA) play an important 
role in determining the overall polarity. High polarity would increase molecules solubility in 
water but solubility in lipid would be limited, and vice versa. Therefore, it is suggested that 
the cut off point for polarity would be 5 or fewer HBD and 10 or fewer HBA (Lipinski et al., 
2001). 
 
The ‘Rule of Five Guidelines’ is originally devise to assist in the discovery and development 
of drug-like molecules that would be likely to permeate gastrointestinal tract (GIT) after 
oral administration (Lipinski et al., 2001). However, due to it is the first comprehensive 
guidelines in the field pharmaceutical research, it is also widely used as a guide for 
discovery of new molecules intended for BBB permeation with some success (Pajouhesh 
and Lenz, 2005, Banks, 2009). However, the lipid composition and packing in the plasma 
membrane in addition to expression of multitudes of transport mechanism at BBB call for 
more stringent guidelines for drug-like molecules targeting the brain. The modification of 
Lipinski rule of 5 with more stringent parameters has been devised by Hitchcock and 
Pennington (2006), Table 1.1.1. 
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Table 1.1.1: Physicochemical property ranges. Suggested for increased CNS permeability. 
 
Property (Lipinski et al., 2001) (Hitchcock and Pennington, 
2006) 
MW ≤500 <500 
LogP ≤5 2-5 
HBA ≤10 - 
HBD ≤5 <3 
TPSA - <90 
 
Alkylated HPO uptake into the brain by membrane diffusion has been shown to increase 
as the alkyl group is getting longer, due to increase in lipophilicity. By contrast, addition of 
hydroxyl group into HPO molecules lower the lipophilicity and their entry into the brain is 
almost entirely abolished in comparison to their non-hydroxylated derivatives (Habgood et 
al., 1999). Nevertheless, it is important to highlight that breaking one of the suggested cut-
offs point in these guidelines would not necessarily lead to unsuccessful brain permeation 
by passive membrane diffusion.  
 
 Transporter systems 
Due to the presence of complex tight junction that form continuous belt along the perimeter 
of BCEC, the paracellular diffusion of small molecules through the intercellular space is 
completely absent. Furthermore, passive membrane diffusion for hydrophilic molecules is 
very limited due to the lipidic nature of biological membranes. Because of these reasons, 
multitude of different transport systems are expressed at the BBB to assist with nutrients 
uptake and metabolites removal (carrier-mediated uptake). Additionally, a specific 
transport system with broad substrate specificity is aimed for preventing the entry of 
xenobiotics, toxins and potentially harmful molecules into the brain (efflux pump) (Zlokovic, 
2008, Abbott et al., 2010, Pardridge, 2012). Utilization of these carrier systems expressed 
at the BBB might be an attractive strategy for improve delivery of therapeutics such as iron 
chelators that would otherwise have minimal access to the CNS (Pardridge, 2012, Lee et 
al., 2001, Qin et al., 2010). 
 
Carrier mediated transport (CMT). The brain requires many hydrophilic biomolecules as 
nutrients to support normal biochemical and physiological functions. Access of these 
molecules to the brain from blood circulation via paracellular route are completely absent, 
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and therefore is entirely rely on carrier-mediated transport. BBB express many specialise 
carriers to transport these biomolecules which include glucose, amino acids, nucleotides 
and choline (Lee et al., 2001, Pardridge, 2012, Abbott et al., 2010). Mechanisms of CMT 
could be passive (uniporter) or secondary-active (symporter and antiporter). Many drugs 
are known to take the advantage of these CMT to get into the brain. These include L-
DOPA, valproic acid, gabapentin, lidocaine and morphine glucuronide (Begley, 2004, 
Tamai and Tsuji, 2000, Anderson, 1996). 
 
One of the CMT at BBB that has successfully been employed for drug delivery is the large 
neutral amino acid transporter 1 (LAT1). LAT1 is an amino acid exchanger (antiporter) 
expressed on the apical (blood side) and basolateral (brain side) of BCEC. This transporter 
recognises and transport for large L-α-amino acids such as tyrosine, phenylalanine and 
leucine (Ylikangas et al., 2014, Pavan et al., 2008, Abbott et al., 2010). Similarly, drugs 
that are transported by LAT1 such as L-DOPA (Gomes and Soares-da-Silva, 1999), 
melphalan (Cornford et al., 1992) and 4-chlorokynurenine (Hokari et al., 1996) are L-α-
amino acids derivatives which resembles their natural substrates. On the contrary, 
gabapentin does not show structural similarity with L-α-amino, however, its cyclic structure 
and restricted conformation bring the amino and carboxy groups in close proximity 
allowing recognition and transport by LAT1 (Pardridge, 2012). Other CMTs have also been 
suggested as facilitators of brain-directed drug delivery (Pardridge, 2012, Begley, 2004, 
Tamai and Tsuji, 2000, DiNunzio and Williams, 2008). A good example in this respect is 
the glucose transporters (GLUTs) at BBB. Because brain neurons are unable to 
synthesize or store glucose, they are fully dependent on glucose transport across the BBB, 
which is facilitated by glucose transporters. In mammalian brain, GLUT1 and GLUT3 are 
the predominant GLUTs responsible for glucose transport (McEwen and Reagan, 2004). 
GLUT1 is highly expressed in the brain capillary endothelial cells and is responsible for 
transporting glucose from blood into the extracellular space of the brain (Qutub and Hunt, 
2005). GLUT3 is the major neuronal GLUT and helps transport glucose from the 
extracellular space into the neurons (Dwyer et al., 2002). In addition, GLUT2 is expressed 
in astrocytes of the brain. The GLUT1 is located in the membrane of brain capillary 
endothelial cells composing the BBB (Choeiri et al., 2002). Furthermore, the glucose 
consumption of the brain amounts to about 30% of the total body glucose consumption 
(Dick et al., 1984). This high level of cerebral glucose uptake suggests that the facilitative 
transporter by GLUTs might be a useful carrier for efficient and selective glucose-targeted 
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drug delivery to the brain. Glucose analogues are theoretically good candidates for drug 
transport through the BBB (Qin et al., 2010).  
 
Currently, there are no available clinical drugs that target GLUT transporter at BBB. The 
idea of conjugating CNS-targeted drugs with glucose is based on the observation that 
GLUT1 transporters are highly expressed on brain capillary endothelial cells, increasing 
the chances of glucose-conjugated drugs to cross the BBB via GLUT1 transporters. 
However, due to the widespread expression of other isoforms of GLUTs, severe side 
effects might arise since the glucose-conjugated drugs can be distributed all over the body.  
Potential side effects can be minimised when GLUT1 is selected as a targeted transporter, 
taking advantage of different regulation of GLUT1 in comparison with other GLUTs. 
GLUT1 is a non-insulin dependent glucose transporter in which it is continuously 
expressed on brain capillary endothelial cell membrane regardless of the blood insulin 
level (Gould and Holman, 1993). Other types of GLUTs are transiently stored in 
cytoplasmic vesicles and expressed only on cell membrane upon rising of blood insulin 
level after food intake. Therefore, side effects could be set to minimum if glucose-
conjugated drugs are taken during low blood insulin level for example in between meals 
or patients required to fast prior to drugs intake (Calvaresi and Hergenrother, 2013). In 
previous studies, different glycoconjugates used as candidates for the treatment of CNS 
diseases have been synthesized, which could increase the BBB permeability by carrier-
mediated transport, such as 7-chlorokynurenic acid (Bonina et al., 2000b), dopamine 
(Francesco et al., 2003), glycosyl derivatives of ibuprofen (Chen et al., 2009).  
 
Efflux-pump. BBB is armed with efflux pumps to export potentially toxic molecules out 
from the brain. Efflux pump exclusively requires ATP regardless of the concentration 
gradient of the molecules between extracellular (blood) and intracellular (cytoplasm) 
space. Notable examples of efflux pumps that are express at BBB are P-glycoprotein (P-
gp), breast cancer resistance protein (BCRP) and the multidrug resistance-associated 
proteins (MRP) (DiNunzio and Williams, 2008, Löscher and Potschka, 2005). These efflux 
pumps have broad substrate specificity but they share one common characteristic, that is 
lipophilic molecules as their primary substrates (Rautio et al., 2008a, Jong and Huang, 
2005). Therefore, although having the range of optimum lipophilicity for drug molecules 
appear to be important for passive membrane diffusion at BBB, it does not confirm 
successful brain penetration. Co-administration of drug molecule that is a substrate for 
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efflux-pump with efflux pump inhibitor have been shown to effective to increase brain 
uptake in in vitro and in vivo model (Hoosain et al., 2015, Amin, 2013). However, 
translation into the clinic was unsuccessful due to the effective dose for efflux-pump 
inhibitor to allow brain penetration of efflux-pump substrate, is associated with toxicity 
(Amin, 2013). Recognising contribution of efflux pumps in brain uptake at the early stage 
of drug discovery and development is important to avoid failure or inefficient brain 
permeability in the later clinical stage. Clinical example of drug that has low brain 
permeability due to efflux pump is the antiretroviral, zidovudine for AIDS treatment (Pan 
et al., 2007, Ene et al., 2011, Fox et al., 2002). Although zidovudine helps to slow down 
HIV replication and thus delay disease progression, it does not effectively reduce 
neurological symptoms associated with HIV virus. It was later found out that zidovudine is 
a substrate for BCRP efflux pump that was discovered in 1998 (Pan et al., 2008, Ni et al., 
2010). 
 
Having said this, increase in lipophilicity of the novel CP20 derivatives with chiral 
substituent containing -OH functional group (cLogP=-0.496 to 1.130) may increase brain 
uptake compare to CP20 (cLogP=-0.903) as described in Section 1.1.7. However, this 
may at the same time increase the potential of the compounds to be a substrate for efflux 
pumps which counteract the increase partition in cell membrane (Banks, 2009). 
Additionally, conjugating CP20 derivatives with molecules that are known to be carried by 
specific transporters at BBB may also be one of the strategy to circumvent BBB. The 
glucose conjugated compound was very likely to exhibit increase brain uptake due to 
possible interaction of glucose moiety with GLUT that facilitated uptake into the brain 
(Rautio et al., 2008b, Devraj et al., 2011).  
 
 General hypothesis and aims 
Accumulating evidence has shown that loss of dopaminergic neurones in the substantia 
nigra pars compacta in Parkinson’s disease (PD) patients are exacerbated by the 
presence of excess iron which contribute to the generation of reactive oxygen species 
(ROS), leading to oxidative stress and eventually, cell death (Mochizuki and Yasuda, 
2012, Ayton et al., 2014). 
Deferiprone (CP20) is the only orally active 3-hydroxy-4-pyridinone (HPO) iron chelator 
used in clinic, mainly to treat Thalassemia, sickle cell anaemia and Friedrich’s ataxia. 
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CP20 crosses the blood-brain barrier (BBB), and is effective in improving motor symptoms 
in PD patients (Mounsey and Teismann, 2012, Abbruzzese et al., 2011). However, high 
dose of CP20 need to be administered due to low oral bioavailability as a result of 
extensive glucuronidation in the liver (Singh et al., 1992). Additionally, CP20 can cause 
severe side effects due to the iron chelation property such as agranulocytosis and 
cytopenia (Henter and Karlen, 2007). As a potential future treatment for PD patients and 
to outweigh the therapeutic ability over side effects, novel iron chelators have been 
developed to overcome this problem. 
A series of novel bidentate HPO iron chelators synthesised base on CP20 structure was 
designed to resist glucuronidation in the liver by adding chiral hydroxyalkyl group but 
maintain the affinity towards iron at least comparable to CP20 (Hider et al., 2011). Despite 
structural alteration, the novel HPOs still exhibit physicochemical properties that favour 
brain penetration.   
 
It is hypothesised that the novel HPO iron chelators based on the CP20 structure are able 
to cross the BBB and show neuroprotection in PD.  
 
The aims of these studies were to investigate whether the novel iron chelators can cross 
the BBB and are protective against dopaminergic neurons from toxin-induced cell death. 
Specifically, these studies had the following objectives: 
 
a) The determination of the BBB permeability of novel HPO bidentate iron chelators 
by using in situ brain perfusion technique in rats. 
b) Determination of the neuroprotective properties of the novel iron chelators against 
Parkinson’s disease (PD)-related toxins in vitro using neuroblastoma cell line (SH-
SY5Y). 
c) The evaluation of the pharmacokinetic distribution of selected novel iron chelators 
upon intraperitoneal (i.p.) injection in plasma and brain to determine dose and 
frequency for in vivo studies. 
d) The evaluation of the neuroprotective effect of selected novel iron chelators in vivo 
using the 6-hydroxydopamine (6-OHDA) rat model of PD. 
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2 Materials and Methods 
In order to test the hypothesis that the novel HPO iron chelators based on the CP20 
structure are able to cross the BBB and show neuroprotection in PD the following studies 
were performed: 
▪ Six novel HPO bidentate iron chelators (CN116, CN118, CN126, CN128, CN226 and 
CN228) were evaluated for brain penetration by using in situ brain perfusion in male 
Wistar rat. In addition, CP84 and its glucose conjugate (FCF132) were also evaluated 
to determine whether transport via the glucose transporter (GLUT) would enhance 
brain delivery. The brain permeability results were compared with the parent 
molecule, CP20. This study addressed the first aim in order to determine the BBB 
permeability of novel HPO bidentate iron chelators. 
▪ The novel HPO bidentate iron chelators which crossed the BBB (CP84, CN116, 
CN118, CN126, CN128, CN226 and CN228) were then evaluated for thir ability to 
protect SH-SY5Y neuroblastoma cell lines against toxins that are relevant to the 
mechanism of induction of cell death in PD (H2O2, 6-OHDA and Fe3+). The cell viability 
was assessed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay.  This addressed the second aim determine the neuroprotective 
properties of the novel iron chelators against Parkinson’s disease (PD)-related toxins 
in vitro, 
▪ Selected novel HPO bidentate iron chelators that showed brain permeation in situ and 
neuroprotective in vitro (CP84, CN128 and CN226) were then assessed for 
distribution in plasma and brain of male Wistar rat after an i.p. injection. CP20 was 
used as a reference drug in this study. A validated HPLC assay was used to quantify 
the concentration of HPO in plasma and brain.  This addressed the third aim to 
evaluate of the pharmacokinetic distribution of selected novel iron chelators upon 
intraperitoneal (i.p.) injection in plasma and brain to determine dose and frequency 
for in vivo studies. 
▪ Finally, selected novel HPO bidentate iron chelators that showed brain permeation in 
situ, neuroprotection in vitro and brain permeation in vivo were assessed for 
neuroprotective effect by i.p. injection on 6-OHDA striatal lesioned male Wistar rat. 
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The neuroprotective effect was compared to lesioned rat treated with CP20.This 
chapter describes in detail the methodologies that were used in these studies which 
includes method optimisation and validation for each results chapter.  This addressed 
the final aim to evaluate of the neuroprotective effect of selected novel iron chelators 
in vivo using the 6-hydroxydopamine (6-OHDA) rat model of PD. 
The material and methods required to perform these studies are described in this chapter. 
 
 Evaluation of the blood-brain barrier permeability of 
iron chelators using in situ brain perfusion 
 Introduction 
In situ brain perfusion technique involves direct insertion of cannula into the common 
carotid arteries that bring oxygenated blood and nutrients to the brain. The inserted 
cannula allows perfusion with oxygenated buffers (normal Ringer’s buffer) and studied 
compounds replacing the circulating blood. The jugular veins are severed, making the 
system open, and thus avoiding re-circulation of perfusate. This technique is used at the 
initial stage of drug discovery and development to determine the brain permeability of 
compounds of interest. The compounds are perfused into the brain in situ bypassing the 
systemic circulation, thus, avoiding systemic drug metabolism not only in the liver, but also 
in other metabolically active organs such as spleen and kidney that render the compound 
intact (Preston et al., 1995). Besides circumventing systemic metabolism, this technique 
also restricts peripheral distribution, making sure that the studied compound is primarily 
distributed to the brain (Smith, 2003). Having said this, metabolism in brain tissue, if any, 
is unavoidable. Although direct systemic injection of a drug of interest is considered as a 
‘gold standard’ in BBB permeability study, data derived from this technique need to be 
carefully interpreted and are not straightforward as it involves systemic metabolism and 
distribution to other tissues (Takasato et al., 1984, Bickel, 2005, Mensch et al., 2009). The 
perfusion was terminated during predominantly influx and unidirectional transports 
process at the BBB, allowing determination of both brain uptake and rate of brain uptake 
(Smith, 2003, Takasato et al., 1984). 
 
Total brain uptake and rate over time can be determined from the drug concentration in 
brain and perfusate at terminal time point. In addition, brain homogenate devoid of brain 
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capillary endothelial cells (BCEC) can be prepared from brain homogenate by differential 
density centrifugation using concentrated dextran, which has a density in between brain 
capillary endothelial cells and the rest of brain tissue. The so called ‘capillary depleted 
brain’ will correct for compound that adhere to endothelial cells and trapped intracellularly 
(Triguero et al., 1990).  
 
In situ brain perfusion was performed by a modified version of Preston et al. (1995).  
Detailed methodology is described below. 
 Animals   
Male Wistar rats weighing between 250-300 g (Harlan UK Ltd) were housed between 2-4 
rats per cage in the Biological Service Unit (BSU), King’s College London. Temperature 
and humidity were maintained at 21-24 ºC and 55-65% respectively with 12h light/dark 
cycle. The rats had accessed to standard food pellet and tap water ad libitum. The rats 
were allowed an acclimatisation period of at least one day after arrival at BSU before the 
perfusion experiment commence. The experiments were approved under Animal 
(Scientific Procedure Act) 1986 and conducted under project license number 70/0688. 
 
 Preparation of buffers 
 Normal Ringer’s solution 
The perfusion fluid was a normal Ringer’s solution (NRS), Table 2.2.1, containing bovine 
serum albumin (BSA; representing physiological concentration of plasma proteins) with 
traces of Evan’s blue for visualisation of vessels (Triguero et al., 1990). NRS was kept 
warm at 37 °C, and continuously bubbled with 5% CO2/95% O2 during in situ brain 
perfusion. The NRS was initially allowed to equilibrate with 5% CO2/95% O2 for at least 20 
minutes. The pH of the solution was evaluated after equilibrium and within the range of 
7.35 to 7.45. After equilibration with O2, NRS pH deviating from the aforementioned ranges 
was adjusted using 2 N NaOH or 2 N HCl. Prior to perfusion, oxygen equilibrated NRS 
was pumped into the in situ brain perfusion surgical set up by peristaltic pump (505S; 
Watson Marlow, UK), passing through all the connecting tubing to terminal polyethylene 
(PE) cannula. Prepared NRS (without glucose, BSA and Evan’s blue) was stored at 4 °C 
and used within 4 weeks of preparation. 
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Table 2.1.1: Chemical constituent of normal Ringer’s solution and their concentration. 




NaCl 6.90 118.0 
KCl 0.35 4.7 
CaCl2 0.37 2.5 
MgSO4 0.30 1.2 
NaHCO3 2.10 25.0 
KH2PO4 0.16 1.2 
HEPES 2.38 10.0 
Glucose* 1.80 10.0 
BSA* 40.00 - 
Evan’s blue* 0.0011 - 
*Glucose, BSA and Evan’s blue were added on the day of the experiment to avoid microbial growth. 
 
 Physiological buffer 
Physiological buffer solution (PhyBS), Table 2.2.2 (Triguero et al., 1990), was used during 
the brain homogenisation process to maintain the pH and physiological environment of 
brain tissue. PhyBS pH was adjusted using 2 N NaOH or 2 N HCl to be within the range 
of pH 7.35 to pH 7.45. 
 







NaCl 8.24 141.0 
KCl 0.30 4.0 
CaCl2.2H2O 0.41 2.8 
MgSO4.7H2O 0.25 1.0 
NaH2PO4.H2O 0.14 1.0 
HEPES 2.38 10.0 
Glucose* 1.80 10.0 
*Glucose was added on the day of the experiment to avoid microbial growth. 
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 In situ brain perfusion 
The perfusion set up is portrayed in Figure 2.1.1. This system was made ready before 
surgery by filling all connected tubing with oxygen equilibrated NRS. HPO and 
radiolabelled compounds were filled into two 20 mL syringes and secure on slow-drive 
Harvard Type 22 syringe pump (Harvard Apparatus, USA) and primed into the flowing 
NRS to make sure all air bubbles are removed. The connecting tubing was then clamped, 
and NRS was allowed to flow for another 2 minutes to wash out all traces of compounds. 
 
Figure 2.1.1: Schematic diagram of in situ brain perfusion set up. 
 
The in situ brain perfusion technique in this study involves perfusion of both hemispheres 
of the brain in the absence of the systemic circulation as a modification of the unilateral 
perfusion described by Takasato et al. (1984), and modified to bilateral perfusion by 
Preston et al. (1995). Rats were anaesthetised with 50 mg/kg ketamine (VetalarTMV; Pfizer, 
USA) and 0.2 mg/kg medetomidine (Domitor®; Orion Pharma, UK) intraperitoneally (i.p.), 
and maintained at 37 °C using a heating pad. Whilst in a supine position, rats were injected 
with 100,000 U/kg heparin (i.p.; Wockhardt UK Ltd, UK) to prevent blood clotting. Local 
anaesthetic, lignocaine/adrenaline (Norbrook, UK) was then injected subcutaneously (s.c.) 
at five multiple sites (total dose was 20 and 12.5 mg/kg) on the chest. 
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An incision was made posterior to the chest and going upward to the chin. Muscles that 
covered the trachea were slowly detached to the sides to expose the trachea. Carotid 
arteries were located beneath the muscle layers under trachea. The common carotid 
arteries were exposed and cleaned from fat tissues with forceps. Two pairs of surgical 
cotton threads were loosely ligated posterior and anterior to the exposed arteries.  
In all of the experiments, tubing made from silicone was used to reduce drug or protein 
binding in the tube lumen (Figure 2.1.2). NRS was passed through a heat exchanger, then 
a double chamber filter and bubble trap filled with polymer wool to the silicone tubing 
(internal diameter, ID=1 mm, outer diameter, OD=1.5 mm, length=420 mm; Altec, UK) 
connected to bevelled PE tubing cannula (ID=0.58 mm, OD=0.96 mm, length=20 mm; Carl 
Stuart UK Ltd., UK) through PE tubing fitting (ID=0.86 mm, OD=1.27 mm, length=10 mm; 
Carl Stuart UK Ltd., UK). 
 
 
Figure 2.1.2: The tubing and cannula for in situ brain perfusion. 
 
NRS was infused at 90% (1.44 mL/min) of the total flow rate (1.60 mL/min in total) to each 
brain hemisphere. The posterior ligation of the artery was tightened to halt blood flow and 
a small hole was made in each carotid artery with Vanna scissors. The PE cannulas 
connected to the NRS perfusion system were inserted into the hole for perfusate inflow 
and held in place by tightening the anterior ligature (Figure 2.1.3). The jugular veins on 
both sides were exposed and severed for perfusate drainage out from the brain just after 
the insertion of cannula. Brain was allowed to perfuse with NRS for at least one minute to 
wash out the blood.  




Figure 2.1.3: Step by step procedures of carotid artery cannulation. 
 
A) The neck area was exposed and injected with local anaesthetic, lignocaine and adrenaline (s.c.) 
B) An incision was made vertically on the neck C) The fats and muscles covering the neck was 
pulled away until the tissue covering the trachea is visible D) The tissue covering the trachea was 
pulled away with haemostat E) Carotid artery was located beneath the tissue covering the trachea. 
A pair of forceps were used to isolate the carotid artery from the tissue. The carotid artery was 
cleaned from fats and associated tissues F) A pair of cotton thread was loosely ligated on the 
anterior and posterior part of the artery G) The ventral ligation was tightened H) Small hole was 
made above the tightened posterior ligation with Vanna scissors I) A cannula with flowing NRS was 
slowly inserted into the pre-made hole J) The anterior ligation was tightened to hold the cannula in 
place K) The jugular vein on the ipsilateral side was cut-off to allow the perfused NRS to flow out. 
The same steps were repeated on the contralateral side of carotid artery. 
Compounds for study were filled into a 20 mL syringe powered by slow-drive syringe pump 
(22-5555, Harvard Apparatus, USA). The perfusion rate of slow drive syringe pump was 
10% (0.16 mL/min) of the overall flow rate (1.60 mL/min in total). Ninety percent of the 
perfusate came from the oxygenated/proteinaceous NRS to support normal brain 
physiology. Brain perfusion with compounds of interest began at least 3 minutes after both 
of the cannulas were inserted into right and left common carotid arteries in order to allow 
removal of blood from brain capillaries (Smith and Allen, 2003). The perfusion pressure 
was monitored constantly by a pressure transducer and fell between 30 mmHg to 50 
mmHg in this setup. Pressure deviating from this range may indicate improper perfusion. 
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 Measurement of pH, gases and ions in whole blood and perfusate 
In situ brain perfusion was performed for 5, 10, 20, 40 and 60 minutes to evaluate the 
physiological parameters of the perfused NRS to support normal brain function during long 
duration of perfusion, the perfusate was sampled before beginning of perfusion and after 
it has passed the brain and flow out through the jugular vein. Additionally, whole blood 
was also sampled from the anaesthetised rat before the start of the perfusion so that 
comparison can be made with the NRS perfusate. 
 
The arterial blood was sampled via tail ventral artery with 23G winged needle (Hospira, 
USA) connected to 1 mL syringe (Terumo, Japan) with 25G needle (Terumo, Japan) 
before start of perfusion. Rat jugular vein on the left side was made visible with a pair of 
forceps from surrounding muscle tissues and fats. Surgical cotton thread was loosely 
ligated anterior to the incision site. Isolated jugular vein was held in place with forceps and 
small incision was made on the vein with Vanna scissors. Bevelled PE cannula (internal 
diameter, ID=0.58 mm, outer diameter, OD=0.96 mm, length=20 mm; Carl Stuart UK Ltd., 
UK) connected to silicone tubing (ID=0.5 mm, OD=0.75 mm, length=120 mm; Altec, UK) 
was inserted and the cotton thread was tightened to secure the cannula in place. Flowing 
venous blood was collected into 1 mL syringe (Terumo, Japan) attached to 25G needle 
(Terumo, Japan).  
 
Additionally, the perfusion fluid (oxygenated NRS) was sampled from the tip of the 
perfusion cannula before carotid artery cannulation. After the perfusion started, venous 
perfusate was sampled from the cannulated jugular vein at 10, 20, 40 and 60 minutes. 
 
The collected whole blood and perfusate samples were immediately pipetted into a CG8+ 
cartridge (Abbott, USA) and analysed for O2, CO2, glucose, pH and physiological ions 
[Na+, K+, HCO3- and ionised Ca2+ (iCa2+)] level with an iSTAT portable blood analyser 
(Abbott, USA). Figure 2.1.4 shows the results obtained from whole blood and perfusate 
using iSTAT portable blood analyser.  
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Figure 2.1.4: pH, ions and blood gaseous in arterial and venous of whole blood (naïve rats) 
or perfusate (perfused rats).  
The whole blood and perfusate samples were analysed by iSTAT portable blood analyser using 
CG8+ cartridge  for simultaneous analysis of  pH, ions and blood gaseous (Graph a-h). Red bars 
denote data for whole blood and blue bars denote data for perfusate. The grey shaded area showed 
the normal physiogical range of pH, gases and ions in blood. Data are expressed as  mean+SEM  
(n=3-6 rats). $ p<0.05  (arterial blood vs venous blood; paired t-test, two-tailed); & p<0.05, &&& 
p<0.001  (arterial blood vs arterial perfusate; unpaired t-test, two-tailed);   * P<0.05, ** p<0.01, *** 
p<0.001 (arterial perfusate vs venous perfusate; one-way ANOVA followed by Holm-Šídák multiple 
comparison test);   # p<0.05, ## p<0.01, ### p<0.001 (venous blood vs venous perfusate; one-way 
ANOVA followed by Holm-Šídák multiple comparison test). 
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The pH between arterial and venous blood was not different from each other and was 
within the reported physiological range (Figure 2.1.4a; Subramanian et al., 2013, Guyenet 
et al., 2005). Arterial perfusate pH was within the physiological pH although the pH was 
slightly higher. In contrast to the venous blood, pH of venous perfusate dropped at all 
perfusion time end-point, with the average pH was 0.1 unit lower than the reported 
physiological range (physiological range pH=7.20-7.50; Subramanian et al., 2013, 
Guyenet et al., 2005).  
 
Na+, ionised Ca2+ (iCa2+) and K+ concentration in whole blood fall within the physiological 
range (Figure 2.1.4b, c & d; Giknis and Clifford, 2008, Hemmingsen et al., 1998). There 
was no different in Na+, iCa2+ and K+ level between arterial and venous blood. Similarly, 
no different was observed in Na+, iCa2+ and K+ level between arterial blood and arterial 
perfusate. Comparison between venous blood and venous perfusate showed no different 
in iCa2+ level. In contrast, Na+ and K+ level in venous perfusate were higher than venous 
blood, although they still fall within the reported physiological range (Giknis and Clifford, 
2008, Hemmingsen et al., 1998). 
 
HCO3- level in arterial and venous blood were within reported physiological pH (Figure 
2.1.4e; Giknis and Clifford, 2008). However, HCO3- showed unexpected lower 
concentration (2-fold lower) in arterial perfusate although during preparation of the NRS 
perfusion fluid, NaHCO3 salt amounting to 25 mM that mimics physiological condition was 
added. One possible explanation for this observation is that continuous and extensive 
oxygenation of the perfusion fluid caused displacement of CO2 in the solution, thus the 
reaction showed in Equation 2.1.1 move to the left (Swietach et al., 2010). 
 
 𝐻2𝑂 + 𝐶𝑂2  ↔ 𝐻2𝐶𝑂3 ↔ 𝐻𝐶𝑂3
−  + 𝐻+    Equation 2.1.1 
 
Similar observation has been reported in hyperventilated rat whereby the HCO3- level in 
blood dropped 2-fold to 11.5 mmol/L (Weyne et al., 1970). As the reaction shifted to the 
left, the bicarbonate buffering system was less able to maintain the perfusion fluid pH 
within the physiological range as described above. Thus, addition of 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) into the perfusion fluid helped to 
maintain the pH (Choi and Zheng, 2009). 
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Glucose concentration in whole blood was higher (18-20 mmol/L) than the reported 
physiological range (3.9-11.6 mmol/L; Figure 2.1.4f; Giknis and Clifford, 2008, 
Subramanian et al., 2013). However, this is expected as rats anaesthetised with general 
anaesthesia and muscle relaxant such as ketamine and xylazine have been shown to 
exhibit higher level of blood glucose up to 19.4 mmol/L (Brăslaşu et al., 2007, Saha et al., 
2005). Therefore, the accepted physiological range became widened in this study to 
include range of blood glucose in anaesthtised rats (3.9-20 mmol/L). Arterial and venous 
perfusate level were within physiological range correspond to the 10 mM glucose added 
into the perfusion fluid.  
 
O2 partial pressure (PO2) in arterial blood was within physiological range (Figure 2.1.4g; 
Giknis and Clifford, 2008). Venous blood PO2 dropped 1.7-fold as would be expected for 
jugular venous blood (Duong et al., 2001). Arterial perfusate PO2 was 2.4-fold higher than 
arterial blood PO2 as the NRS perfusion fluid was continously bubble with 95% O2/5% 
CO2. Similar observation has been reported where hyperventilation in living rats caused 
1.3-fold increase in arterial PO2 (Duong et al., 2001).The continous and extensive 
oxygenation of the NRS was important to supply the perfused brain with sufficient O2 to 
support brain metabolism. Venous perfusate PO2 was 2.4-fold higher than venous blood 
PO2. However, venous perfusate PO2 was 1.7-fold lower than arterial perfusate PO2 which 
corresponds to venous PO2 dropped in whole blood. This suggest that the brain was 
metabolically active as in living rat when perfused for up to 60 minutes.  
 
CO2 partial pressure (PCO2) in whole blood was within physiological range. PCO2 in 
venous blood increase by 1.2-fold as reported (Figure 2.1.4h; Dauchy et al., 2000). 
Arterial perfusate CO2 was 2.4-fold lower than arterial blood PCO2 as should be expected 
for continuously oxygenated perfusate (Duong et al., 2001, Weyne et al., 1970). Venous 
perfusate PCO2 was 1.3-fold lower than venous blood PCO2. However, venous perfusate 
PCO2 was increase by 2.2-fold compared to arterial perfusate PCO2. This suggest that the 
brain actively remove metabolic waste for up to 60 minute perfusion. The absence of red 
blood cells (RBC) in the perfusate might explain the higher PCO2 in venous perfusate as 
carbonic anhydrous in RBC helps in reducing the level of post-capillary CO2. The higher 
PCO2 in venous perfusate might also explain the slight dropped in pH in venous perfusate 
as incresased soluble CO2 in solution contributed to decrease in pH (Motais et al., 1989). 
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The concentration of dissolved O2 and CO2 in blood and perfusate were calculated by 
multiplying the PO2 and PCO2 with 0.0031 mL O2/mmHg O2/dL and 0.067 mL CO2/mmHg 
CO2/dL respectively as described by Henry’s Law (Bacher, 2005). The difference of O2 
and CO2 concentration in arterial and venous samples were calculated. Arterial-venous 
(A-V) difference of soluble O2 in whole blood and perfusate were within the physiological 
range (Figure 2.1.5). Similarly, venous-arterial (V-A) difference of soluble CO2 in whole 
blood was also within the reported physiological range (Giknis and Clifford, 2008, Duong 
et al., 2001). 
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Figure 2.1.5: Arterial-venous O2 (A-V) and venous-arterial (V-A) CO2 diferences in rats. 
 
a) The O2 concentration difference between arterial and venous blood/perfusate in naïve and 
perfused rats. b) The CO2 concentration difference between venous and arterial blood/perfusate in 
naïve and  perfused rats. The grey shaded area showed the normal physiogical range. Data are 
expressed as  mean+SEM  (n=3-6 rats).* P<0.05, ** P<0.01 (naïve rat vs perfused rat; one-way 
ANOVA followed by Holm-Šídák multiple comparison test). 
 
Physiologically reported arterial-venous difference of glucose was very low (0.06-1.11 
mmol/L (Somogyi, 1948). Thus, negative A-V values can easily be obtained due to slight 
analytical error (Figure 2.1.6). Nevertheless, the positive A-V of glucose obtained in this 
study was within the reported physiological range. This observation suggested that the 
brain was metabolically active up to 60-minute perfusion. 




















































Figure 2.1.6: Arterial-venous (A-V) glucose diference in rats. 
Glucose concentration difference between arterial and venous blood/perfusate in naïve and 
perfused rats. The grey shaded area showed the normal physiogical range. Data are expressed as  
mean+SEM  (n=3-6 rats). *  P<0.05 (naïve rat vs perfused rat; one-way ANOVA followed by Holm-
Šídák multiple comparison test). 
 
In summary, the pH, electrolytes and blood gases in the arterial perfusate generally agreed 
with the accepted physiological range in whole blood. Although some parameters showed 
deviation from physiological range, this is expected and explainable as the perfusion fluid 
was continously and extensively gas with O2, and lacked RBC that help buffering pH and 
ion levels.  
 
 Validation of in situ brain perfusion 
It has been shown in previous section (Section 2.1.5) that the NRS perfusate physiological 
parameters were within the blood physiological range for up to 60-minutes perfusion. In 
this section, details of the experiment conducted to determine the linearity of HPO brain 
uptake for up to 60-minute perfusion using CP20 as the prototype HPO was described. 
14C-sucrose and 3H-O-methyl-D-glucose (3H-OMG) were simultaneously measured to 
determine the integrity and functionality of BBB. 
 
In situ brain perfusion was validated by using deferiprone (CP20, MW=139.15 g/mol; 
Sigma-Aldrich, USA) as a model drug of HPO bidentate iron chelators, 3H-O-methyl-D-
glucose (3H-OMG, MW=194.2 g/mol; Perkin Elmer, USA) and 14C-sucrose (MW=342.3 
g/mol; Perkin Elmer, USA). CP20 crosses the BBB through passive diffusion and was used 
as prototype drug to evaluate the brain penetration of novel HPO (Hider et al., 2011, 
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Habgood et al., 1999). 3H-OMG was transported across the BBB via GLUT-1 transporter 
(Reyes et al., 2002). 14C-sucrose was used as a vascular space marker and negative 
control since it does not crossed BBB (Ennis and Betz, 1986). 
 
CP20 (500 µM), 3H-OMG [(296 kBq/rat (8 µCi/rat)] and 14C-sucrose [185 kBq/rat (5 
µCi/rat)] in NRS were filled in a 20 mL syringe. The specific activity and amount of 3H-
OMG and 14C-sucrose were summarised in Table 2.1.3.  The carotid arteries were isolated 
as described earlier in Section 2.1.4.  
 















3H-OMG 80 >97 194.2 0.100 
14C-sucrose 0.432 >97 342.3 12 
 
These compounds were perfused simultaneously to the brain for 5, 10, 20, 40 and 60 
minutes. At each of the perfusion time point, the perfusion was stopped and the head was 
decapitated. 
 
 Preparation of in situ brain perfusion samples for quantification 
analysis 
At the end of perfusion, the rats were decapitated and the brain was removed immediately 
for sample processing. Additionally, sample of flowing perfusate was taken from the end 
of the PE cannula. Brain hemispheres were cleaned with cotton bud moistened with 
PhyBS to remove pial layer followed by dissection to remove the cerebellum and choroid 
plexus. Cerebellum is mainly supplied by a vertebral artery and therefore was not included 
in the brain uptake measurement (Yao et al., 1990, Preston et al., 1995). Additionally, 
choroid plexus, a highly vascularise brain structure found at the lateral, third and fourth 
ventricles was also removed because of the leaky capillaries in this region (Liddelow, 
2015, Preston et al., 1995). The brain was homogenised in PhyBS. 14C-sucrose perfused 
along with 3H-OMG and CP20 work as a vascular marker so that 3H-OMG and CP20 in 
capillary lumen leaked during the homogenisation process can be estimated and corrected 
(Triguero et al., 1990, Preston et al., 1995). Processed whole brain homogenate represent 
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the uptake of 3H-OMG and CP20 in BCEC and brain parenchyma. As BCEC is the barrier 
component of BBB, the uptake of 3H-OMG and CP20 in BCEC and brain parenchyma 
must be differentiated. Differential centrifugation with concentrated dextran that has a 
density in between BCEC and brain parenchyma helps to physically separate these two 
compartments, thus allowing measurement of 3H-OMG and CP20 in brain parenchyma 
only (Triguero et al., 1990). This section explained in detail the method used in preparation 
of the samples for quantification analysis. 
 
The brain was weighed and homogenise in PhyBS [1:1 (w/v) dilutions, ten strokes 
homogenisation in a Potter-Elvehjem borosilicate glass homogeniser, 150 mm x 10 mL; 
Jencons, England]. Sequentially, the same volume of 30% (w/v) dextran [(final 
concentration 15% (w/v)] was added and briefly homogenised for four strokes with the 
homogeniser producing whole brain homogenate. Total dilution of brain at this point was 
1:3 (w/v). 
 
 Sample preparation for 3H-OMG and 14C-sucrose measurement 
i) Perfusate 
Perfusate sample (100 µL) taken from the end of polyethylene cannula upon termination 
of in situ brain perfusion was pipetted into 7 mL scintillation vial. Tissue solubiliser (0.5 
mL, Soluene; Canberra-Packard, UK) was added and mix with a mixer (Vortex-Genie2; 
Scientific Industries, USA). The samples were incubated at room temperature for 24 h. 
Five millilitre of scintillation cocktail (Ultima Gold XR; Perkin Elmer, USA) was added, 
mixed with a mixer and incubated for 30 minutes before analysis by liquid scintillation 
spectroscopy (LSS) counter. Vehicle (NRS) was processed the same way as a blank. 
Samples preparation was performed in duplicate.  
ii) Whole brain fraction 
Five hundred microliters of whole brain homogenate were pipetted into a 7 mL scintillation 
vial. Tissue solubiliser (0.5 mL) was added and mixed with a mixer. The samples were 
incubated at room temperature for 24 h to allow tissue solubilisation. Scintillation cocktail 
(5 mL) was added, vortex and incubated for 30 minutes before analysis by LSS counter. 
Vehicle (PhyBS and dextran mixture) was processed in the same way forming blank 
controls. Sample preparation was performed in duplicate. 
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iii) Capillary depleted brain fraction 
Seven hundred microliters of whole brain homogenate were pipetted into 1.5 mL 
microcentrifuge tube and spun at 5400 g for 20 minutes at 4 ºC (Triguero et al., 1990). 
Three layers of separation were formed upon centrifugation (Figure 2.1.7).  
 
Figure 2.1.7: Illustration of capillary depleted brain preparation.  
First layer from the top was brain parenchyma, second layer was mixture of physiological buffer 
and dextran, and third layer was capillary rich brain tissue pellet. Capillary depleted brain 
parenchyma (1st layer) was carefully loosened by small spatula from the microcentrifuge wall before 
decanted into other microcentrifuge tube together with the 2nd layer and subsequently vortexed to 
evenly distribute the supernatant. PhyBS= physiological buffer saline; EC=endothelial cells. 
 
Tissue solubiliser (0.5 mL) was added to 500 µL of capillary depleted brain homogenate 
and mixed by a mixer. The samples were incubated at room temperature for 24 h. Five 
millilitre of scintillation cocktail was added, vortexed and incubated for 30 minutes before 
analysis by LSS counter (Figure 2.1.8). Vehicle (PhyBS and dextran mixture) was 
processed in the same way as blank controls. 




Figure 2.1.8: Sample preparation for LSS analysis. 
 
 Sample preparation for HPO iron chelators measurement 
i) Perfusate 
Perfusate sample (300 µL) taken from the end of polyethylene cannula upon termination 
of in situ brain perfusion was diluted 1:4 (v/v) with NRS. Three hundred microliter of diluted 
perfusate was pipetted into 1.5 mL microcentrifuge tube and 30 µL of trifluoroacetic acid 
(TFA; Sigma-Aldrich, USA) was added to denature the proteins. After a brief mixed with a 
mixer, the samples were centrifuged at 20800 g for 45 minutes to precipitate the protein. 
One hundred microliters of supernatant were taken and pipetted into 0.3 mL conical crimp 
vial (Kinesis, UK), seal with 8 mm polytetrafluoroethylene (PTFE) crimp cap (Kinesis, UK) 
sealed with a crimper. Thirty microliters was injected into high performance liquid 
chromatography (HPLC) system (Figure 2.1.9). Samples preparation was performed in 
duplicate. 
ii) Whole brain fraction 
Five hundred microliters of whole brain homogenate were pipetted into 1.5 mL 
microcentrifuge tube and 50 µL of TFA was added to denature the proteins. After a brief 
mixed with a mixer, the samples were centrifuged at 20800 g for 45 minutes to precipitate 
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the protein. One hundred microliters of supernatant were taken and pipetted into HPLC 
vial and seal with crimper. Samples preparation was performed in duplicate. 
iii) Capillary depleted brain fraction 
Capillary depleted brain was prepared as described in Section 2.1.6.a.iii. Capillary 
depleted brain homogenate (500 uL) was pipetted into 1.5 mL microcentrifuge tube and 
50 µL of TFA was added to denature proteins. After a brief mixed by a mixer, the samples 
were centrifuged at 20800 g for 45 minutes to precipitate the protein. One hundred 
microliters of supernatant were taken and pipetted into 0.3 mL conical HPLC vial. Samples 
preparation was performed in duplicate.  
 
Figure 2.1.9: Sample preparation for HPLC analysis by gradient reversed-phase ion-pair 
method. 
 
 Validation of capillary depleted brain preparation 
Alkaline phosphatase is a water-soluble enzyme abundantly present in brain capillary 
endothelial cells but not in brain parenchyma. Therefore, alkaline phosphatase enzyme 
activity was assayed in capillary-depleted brain parenchyma and capillary enriched pellet 
to asses for effective separation (Triguero et al., 1990, Williams et al. 1980). p-nitrophenyl 
phosphate (pNPP) was used as a probe substrate in the reaction. Alkaline phosphatase 
catalysed dephosphorylation of pNPP to p-nitrophenol (pNP), a product that turn yellow in 
alkaline condition and shows maximal absorption at 405 nm (Figure 2.1.10).  
 





Figure 2.1.10: Conversion of p-nitrophenyl phosphate, a probe substrate for alkaline 
phosphatase to formed yellowish hue product in alkaline condition, p-nitrophenol, which 
has maximal absorption at 405 nm.  
 
The amount of pNP formation is proportional to the amount of alkaline phosphatase 
present in the brain homogenate, and therefore the activity of the enzyme can be 
calculated.  
 
 Determination of protein concentration 
Prior to alkaline phosphatase assay, protein concentration of capillary depleted brain and 
capillary enriched tissues were determined with a commercial Pierce™ bicinchoninic acid 
(BCA) Protein Assay Kit (Thermo Fisher, UK). A set of known concentrations of bovine 
serum albumin (BSA) in 0.9 % NaCl were prepared and the absorbance of each sample 
was read on a microplate reader (540 nm). A standard curve of absorbance against BSA 
concentration was constructed just prior to measurements of samples (Figure 2.1.11). 
Capillary depleted brain and capillary enriched tissues (25 µL) were pipetted into a 96-well 
microplate. Reaction reagent (200 µL) composed of reagent A and reagent B at 50 to 1 
ratio was added to each well and the plate was mix thoroughly on a plate shaker for 30 
seconds. The plate was covered and incubated at 37 °C for 30 minutes and the 
absorbance was measured at 540 nm on a plate reader. The amount of protein in brain 
samples was calculated based on linear equation derived from BSA standard curve. 
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Figure 2.1.11: Typical BSA standard curve obtained from BCA protein assay.  
Data analysed by least-square regression analysis (GraphPad Prism 7 Software). 
 
 Alkaline phosphatase assay 
Reaction mixture (500 µL) contained 50 mM MgCl2, 5 mM CaCl2, 100 mM KCl, 100 mM 
Tris (pH 9) and 5 mM pNPP. The reaction was initiated by adding 50 µL of capillary 
depleted brain or capillary enriched tissues (0.5 mg/mL final concentration) and incubated 
at 37 ºC for 30 minutes. At the end of the incubation time, the reaction was terminated with 
500 µL NaOH (1 M) and put on ice for 10 minutes. The absorbance was taken at 405 nm 
in a final volume of 300 µL against a blank (reaction mixture with capillary depleted 
brain/capillary rich fraction was replaced with water).  
The concentration of pNP formed in the reaction mixture was determined by substituting 
the absorbance in the linear equation obtained from pNP standard curve (Figure 2.1.12) 
constructed from absorbance reading at 405 nm of pNP concentration between 0.04 to 
0.7 mM. 
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Figure 2.1.12: Typical pNP standard curve obtained from alkaline phosphatase enzyme 
assay.  
Data analysed by least-square regression analysis (GraphPad Prism 7 Software). 
 
The alkaline phosphatase specific activity was calculated as followed: 
𝐴𝑃 (𝑛𝑚𝑜𝑙/𝑚𝑖𝑛/𝑔) =
𝑝𝑁𝑃  (𝑢𝑀)
𝑡 (min) X protein (mg/mL)
 𝑋 1000    Equation 2.2.2 
Alkaline phosphatase specific activity in capillary enriched pellet was greater than capillary 
depleted brain by 37-fold (Figure 2.1.13). The percentage purity of capillary separation 
from brain homogenate was 96.68 % based on alkaline phosphatase specific activity, thus 
confirming the separation using dextran density differential centrifugation (Moos and 












































Figure 2.1.13: Alkaline 
phosphatase specific activity in 
capillary depleted brain (Cd) and 
capillary enriched pellet (Cap). 
Individual brain was taken from in situ 
brain perfused rats. Capillary enriched 
pellet (Cap) shows higher alkaline 
phospatase activity compared to 
capillary depleted brain (Cd). Data are 
expressed as mean+SEM (n=6 rats). 
*** P<0.001 (paired t-test, one-tailed). 
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 Quantification analysis of in situ brain perfusion samples 
Samples prepared after in situ brain perfusion were analysed by liquid scintillation 
spectroscopy (LSS) counter and high-performance liquid chromatography (HPLC) to 
quantify HPO and radiolabelled compounds.  
 
 Liquid-scintillation spectroscopy (LSS) 
3H-OMG and 14C-sucrose (Perkin Elmer®, USA) activity were counted on a LSS counter 
(LKB Wallac 1219 Rackbeta, Wallac, USA). The LSS counter was pre-programmed in the 
computer memory to correct automatically the preparation errors for newly quenched 
samples. The radioactivity was expressed as disintegration per minute (DPM).  
 
 High-performance liquid chromatograpy (HPLC) 
i) Calibration curve 
Standard solutions of HPOs ranging from 5 to 1000 µM were prepared by serial dilution 
from a 5000 µM stock dissolved in HPLC water. 
 
ii) Quantification of hydroxypyridinones (HPOs) by HPLC  
HPOs concentrations were evaluated by a gradient ion-pair HPLC method. The 
quantification method was provided by Dr Sukhvinder Bansal from Institute of 
Pharmaceutical Science, King’s College London. Two mobile phase systems compose of 
10% (v/v) acetonitrile in water (mobile phase A) and 90% (v/v) acetonitrile in water (mobile 
phase B) with 1 g/L pentadecafluorooctanoic acid as the ion-pair reagent in each mobile 
phase were used to separate the HPOs. 
The quantification was performed on an Ultimate 3000 Standard LC Systems equipped 
with quaternary pump delivery system (LPG-3400SD), autosampler (WPS-3000(T)SL 
Analytical) and multi-wavelength detector (3000 VWD). 
Thirty microliters (30 µL) of each sample was injected into Poroshell 120 EC-C18 
reversed-phase column, 2.7 µm particle size, 2.1 x 50 mm diameter and length 
manufactured by Agilent (Cat no. 699775-902). The pump flow rate was set at 0.2 mL/min 
and HPO separation was obtained with a mobile phase B gradient starting at 10% B, rising 
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to 90% over 10mins, held for 3 mins and falling back to 10% over 2 mins (Figure 2.1.14). 
The total running time was 25 minutes including equilibration time for the column at 10 % 
B 10 minutes before the next injection. HPOs eluted from the column were detected at 
280 nm wavelength.  
 
Figure 2.1.14: HPLC gradient method for a successful separation of HPOs. Mobile phase B 
contained 90 % (v/v) acetonitrile in water with 1 g/L pentadecafluorooctanoic and 0.01 % (v/v) 
formic acid. 
 
The peak integrations and data analysis were performed using Chromeleon 6.8 
Chromatography Data System (Figure 2.1.15). The peak height (H) signal of 
concentration-known HPO chromatogram was used to construct the calibration curve 
(Figure 2.1.16). The peak height (H) signal of HPO chromatogram for in perfusate, brain 
homogenate and capillary depleted brain was multiplied with the dilution factor (Table 
2.1.4). The corrected value was converted to concentration in µM based on the 
constructed calibration curve.   
 





Brain homogenate 4.4 
Capillary depleted brain 4.4 
 
  CHAPTER 2: MATERIALS AND METHODS 
74 
 




1 0 0 0
1 5 0 0
2 0 0 0















a ) b )
c ) d )




1 0 0 0
1 5 0 0
2 0 0 0



















1 0 0 0
1 5 0 0
2 0 0 0



















1 0 0 0
1 5 0 0
2 0 0 0
















Figure 2.1.15: Representative chromatogram for CP20. 
 
a) 500 µM standard b) brain homogenate c) capillary depleted brain and d) perfusion fluid from 
rat perfused with 500 µM CP20 for 20 minutes. CP20 retention time was ~8.3 minute. m.AU: mili-
absorption unit. 
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Figure 2.1.16: Representative calibration curve for CP20 prepared in HPLC water.  
m.AU: mili-absorption unit. Data was analysed by least-square linear regression analysis 
(GraphPad Prism 7 Software). 
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iii) Recovery study for HPOs 
Recovery studies of HPOs from brain tissues and perfusion fluid was performed since the 
standard calibration curve was prepared in HPLC water. HPOs working stock (450 µM) 
were prepared in water. The working stock was spiked into HPLC water, pooled brain 
homogenate or perfusate in triplicate at 1:14 (v/v) dilution (final = 30 µM). TFA was added 
so that its final concentration in the solution was 10% (v/v). All of the samples were mixed 
and centrifuged at 20800 g for 45 minutes. The supernatant was taken and analysed by 
HPLC as described in Section 2.1.7a ii. Percentage recovery was calculated as showed 




 𝑋 100    Equation 2.1.3 
Where HBr is the peak height of HPO chromatogram in brain homogenate, HPf is the peak 
height of HPO chromatogram in perfusion fluid and Hwater peak height of HPO 
chromatogram in water. 
The sample extraction step was a crucial part in HPLC analysis of biological samples to 
precipitate proteins and release HPO from the association of biological matrices protein 
and lipid into the solution (Alshammari et al., 2015).  CP20, FCF132, CN116 and CN118 
in perfusion fluid and brain samples showed between 88-100% recovery (Table 2.1.5). 
CN126 and CN128 were showed 80-86 % recovery from perfusate and 64-70% from brain. 
CP84, CN226 and CN228 showed the least recovery among all of the HPOs tested (61-
65% recovered). As showed in Table 2.1.5, recovery from perfusion fluid was equal to or 
higher than recovery from brain homogenate. The percentage recovery for all of the HPOs 
were corrected when the peak height signal of HPO chromatograms was converted to 
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Table 2.1.5: Percentage (%) recovery of HPOs extracted with 10% (v/v) TFA from spiked 
perfusion fluid and brain homogenate. 
HPOs 
% Recovery 
Perfusion fluid Brain 
CP20 95.3±2.8 87.7±1.2 
CP84 68.7±4.6 62.0±12.7 
FCF132 104.0±3.5 104.7±3.3 
CN116 104.7±0.9 102.3±0.9 
CN118 94.0±3.6 95.3±0.3 
CN126 79.7±2.3 64.3±3.2 
CN128 85.6±5.8 70.7±4.2 
CN226 65.0±4.0 50.7±2.3 
CN228 60.7±3.7 50.7±0.7 
Data are expressed as mean±SEM (n=3 independent samples). 
 
 Determination of unbound HPO in brain, plasma and perfusion 
fluid 
The NRS perfusion fluid contained the physiological concentration of bovine serum 
albumin (40 g/L BSA; Section 2.1.3). Therefore, it is imperative to determine the extent of 
HPO binding to BSA as only unbound HPO would be able to cross the BBB (Hammarlund-
Udenaes et al., 2008, Friden et al., 2007). In addition, HPO binding in brain tissue was 
also evaluated.  
The method reported by Summerfield et al. (2007) was followed to determine the fraction 
of HPO unbound in brain, plasma and perfusion fluid. Evaluation of unbound HPO was 
performed in a separate in vitro experiment, as the bound HPO releases during sample 
processing and extraction with TFA due to protein denaturation (Section 2.1.7).  3H-OMG 
and 14C-sucrose has been reported to not significantly bind to plasma protein at low 
concentrations (Mereish et al., 1982, Chinachoti and Steinberg, 1988). Brain from control 
rats were used to prepare a whole brain homogenate at 1:3, 1:7 and 1:15 (w/v) dilutions. 
Degree of dilutions did not affect the degree of HPOs binding to protein; therefore, brain 
diluted 1:3 (w/v) was used for all experiments (Table 2.1.6). 
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Table 2.1.6: Effects of brain homogenate dilution on the detection of free, unbound CP20 in 
brain tissue 






CP20 was spiked into a diluted pooled brain homogenate. Data are expressed as mean±SEM (n= 
3 tubes). Statistical analysis using one way ANOVA showed no significant different. 
 
Blood was collected from control rats by cardiac puncture with 21G needle attached to 5 
mL syringe. The collected whole blood was transferred into heparinised tube and spun at 
5400 g for 20 minutes; the supernatant which is the plasma was isolated and kept frozen 
until use. Perfusion fluid was prepared by supplementing NRS with 10 mM glucose and 
40 g/L BSA as described in Section 2.1.3. HPO stock solution (1800 µM) was spiked into 
whole brain homogenate, plasma, perfusion fluid and distilled H2O (as a control) in a ratio 
of 1:10 to give a final HPO concentration of 180 µM. The tubes were mixed with vortex 
mixer and incubated in a shaking water bath at 37 °C for 20 minutes before transferred 
into Vivaspin® tubes (2 kDa MWCO; GE Healthcare Life Sciences, UK). Vivaspin® tubes 
were spun at 3000 g for 20 minutes and the filtrate collected at the bottom collector of 
Vivaspin® tube was analysed by HPLC. The percentage of HPO unbound to protein in 




 𝑋 100   Equation 2.1.4 
Where Cf = concentration of HPO in filtrate (µM) and Cc = concentration of HPO for control (µM). 
The extent of unbound HPO in perfusion fluid was compared with pooled rat plasma as 
showed in Figure 2.1.17. There was no difference between plasma and perfusion fluid 
unbound concentration for all of the HPOs tested. Indeed, it has generally been accepted 
that plasma albumin primarily governs the binding of drug in blood circulation (Gurevich, 
2013, Weiss et al., 2006, Smith et al., 2010, Bohnert and Gan, 2013). This justifies the 
addition of physiological concentration of BSA (40 g/L) into the normal Ringer’s solution 
for brain perfusion to mimic in vivo plasma content (Table 2.1.1). FCF132, CN116 and 
CN118 showed no or limited binding in plasma and perfusion fluid (86–100% unbound 
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concentration). CP84, CN126, CN128 and CN228 were between 54–69% unbound in 
plasma and perfusion fluid.  CN228 and CP20 have 50% or less in unbound state in 
plasma and perfusion fluid with CP20 in perfusion fluid showed the least unbound (45%). 
For all of the HPOs evaluated, percentage unbound in perfusion fluid was always less than 
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Figure 2.1.17: Percentage of free-unbound HPOs in perfusate, plasma and brain 
homogenate. 
HPO were spiked into pooled diluted [1:3 (w/v) dilution] brain homogenate. Data are expressed as 
mean+SEM. n=3 different determinations. No significant different P> 0.05 (plasma vs perfusion 
fluid; unpaired t-test, two-tailed),** P< 0.01, *** P< 0.001 (perfusion fluid vs brain; unpaired t-test, 
two-tailed). 
 
CP20, FCF132 and CN116 showed 100% unbound in the brain (Figure 2.1.17). CP84, 
CN118, CN128, CN226 and CN228 were moderately unbound in brain (62–68%). CN126 
showed the least unbound among all other HPO in the brain (57%). As opposed to drug 
binding to albumin in blood, drug binding in brain is primarily governed by the lipid 
constituent of brain tissues. This is because, brain has a lower composition of protein (8% 
vs 18%) and higher lipid composition than blood (11% vs 0.7%; Jeffrey and Summerfield, 
2007). CP20, CN116 and CN226 unbound concentration in brain was higher by 2-fold, 
1.2-fold and 1.4-fold respectively than perfusion fluid. In contrast, CN118 unbound in brain 
was 1.3-fold lower than in perfusion fluid. Other HPO (CP84, FCF132, CN126, CN128 and 
CN228) showed the same degree of binding in perfusion fluid and brain. The fraction of 
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HPO unbound was taken into account during brain uptake calculation as was described in 
Section 2.1.10.  
 
In order to see any relationship between free, unbound HPO with lipophilicity (cLogP), 
regression analysis was performed on the unbound HPO against cLogP plot. The 
percentage unbound HPO in plasma, perfusion fluid and brain homogenate were less as 
the lipophilicity constant (cLogP) increased (Figure 2.1.18).  
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Figure 2.1.18: Relationship between free unbound HPO with HPO cLogP. 
Unbound HPO were plotted against HPO lipophilicity (cLogP). Black circle (○) represents unbound 
HPO in graphs a) pooled plasma, b) perfusion fluid and c) pooled brain homogenate. Black dotted 
line (…) represents best-fit line for regression analysed on compounds represented by black circle 
(○) in graph a), b) and c).  HPO cLogP were obtained using a ChemDraw Software version 15.1. 
Data are expressed as mean±SEM (n=3 tubes). Significant difference for linear regression analysis 
was set at P<0.05. Co-efficient of variation (r2), degree of freedom (df; 25) and P values were calculated 
using linear-regression analysis (GraphPad Prism 7 Software). 
 
The relationship was strongest in the brain followed by plasma while perfusion fluid 
showed the weakest relationship with cLogP. In plasma and perfusion fluid, unbound 
CP20 was the outlier that contributed to a weaker relationship with cLogP. cLogP has been 
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shown to be the dominant factor in determining the brain tissue binding due to its higher 
lipid content than blood (Wan et al., 2007, Jeffrey and Summerfield, 2007). 
 
In summary, it can be concluded that there was a significant inverse relationship between 
the degree of HPO cLogP and unbound HPO in plasma, perfusion fluid and brain 
homogenate that was going to influence the total uptake of HPO into the brain. 
 
 Brain uptake calculation 
 3H-OMG and 14C-sucrose 
Disintegration per minute (DPM) was taken to show the rate of radioactive decay. Total 
brain uptake (Rtotal) of 14C-sucrose and 3H-OMG was calculated by finding a ratio between 
concentration in whole brain (CBr) or capillary depleted brain (CCd) (DPM/g) and 
concentration in perfusate, CPf (DPM/mL), Equation 2.1.5. 
 𝑅𝐵𝑟,𝑡𝑜𝑡𝑎𝑙 𝑜𝑟 𝑅𝐶𝑑,𝑡𝑜𝑡𝑎𝑙 (𝑚𝐿/𝑔) =
𝐶𝐵𝑟 𝑜𝑟 𝐶𝐶𝑑 (𝐷𝑃𝑀/𝑔)
𝐶𝑃𝑓 (𝐷𝑃𝑀/𝑚𝐿)
   Equation 2.1.5 




  Equation 2.1.6 
Rsucrose were subtracted from RBr,total and RCd,total to give a net brain uptake, RBr or RCd, 
Equation 2.1.7. 
𝑅𝐵𝑟 𝑜𝑟 𝑅𝐶𝑑(𝑚𝐿/𝑔) = 𝑅𝐵𝑟,   𝑡𝑜𝑡𝑎𝑙 𝑜𝑟 𝑅𝐶𝑑,   𝑡𝑜𝑡𝑎𝑙 − 𝑅𝑠𝑢𝑐𝑟𝑜𝑠𝑒  Equation 2.1.7 
The rate of brain uptake Kin, was calculated only for capillary depleted brain dividing with 
total perfusion time in minute (t), Equation 2.1.8. 
 𝐾𝑖𝑛,𝐶𝑑 (𝑚𝐿/𝑔/𝑚𝑖𝑛) =
𝑅𝐶𝑑 (𝑚𝐿/𝑔)
𝑡 (𝑚𝑖𝑛)
   Equation 2.1.8 
Figure 2.1.19 showed the example of brain uptake calculation for 3H-OMG. 











HPO percentage unbound in perfusion fluid and brain was determined in vitro as described 
in Section 2.1.10. Total brain uptake (RBr, total and RCd, total) was calculated by finding a ratio 
between concentration in whole brain (CBr) or capillary depleted brain (CCd) (nmol/g) and 
concentration in perfusate (CPf) (nmol/mL). 
𝑅𝐵𝑟,   𝑡𝑜𝑡𝑎𝑙 𝑜𝑟 𝑅𝐶𝑑,   𝑡𝑜𝑡𝑎𝑙 (𝑚𝐿/𝑔) =
𝐶𝐵𝑟 𝑜𝑟  𝐶𝐶𝑑 (𝑛𝑚𝑜𝑙/𝑔)
𝐶𝑃𝑓 (𝑛𝑚𝑜𝑙/𝑚𝐿)
   Equation 2.1.9 
Rsucrose were subtracted from RBr,total and RCd,total to give a net brain uptake, RBr or RCd, as 
described in Equation 2.1.7. 
HPO concentration in perfusion fluid were corrected for percentage unbound as only free 
HPO were able to cross the BBB. Net brain uptake corrected for HPO unbound in 
perfusate (RBr,u and RCd,u) was calculated by dividing with  percentage HPO unbound in 
perfusate (Pfu).   
𝑅𝐵𝑟,𝑢  𝑜𝑟 𝑅𝐶𝑑,𝑢 (𝑚𝐿/𝑔) =
𝑅𝐵𝑟 𝑜𝑟  𝑅𝐶𝑑 (𝑚𝐿/𝑔)
𝑃𝑓𝑢 
   Equation 2.1.10 
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RBr,u and RCd,u described the transport properties at BBB and brain affinity towards HPO. 
RCd,u was used to calculate the rate of brain uptake, Kin,Cd,u by dividing with the total 
perfusion time in minute (t) as described by Equation 2.1.11. 
𝐾𝑖𝑛,𝐶𝑑,𝑢 (𝑚𝐿/𝑔/𝑚𝑖𝑛) =
𝑅𝐶𝑑,   𝑢 (𝑚𝐿/𝑔)
𝑡 (𝑚𝑖𝑛)
     Equation 2.1.11 
Additionally, both HPO concentration in perfusate and capillary depleted brain were 
corrected for percentage unbound and described as RCd,uu (Equation 2.1.12). 
𝑅𝐶𝑑,𝑢𝑢 (𝑚𝐿/𝑔) =  𝑅𝐶𝑑  𝑋 
𝐵𝑟𝑢 
𝑃𝑓𝑢 
     Equation 2.1.12 
RCd, uu was used to describe the extent of distribution of unbound HPO in brain tissue. RCd, 
uu was used to calculate the rate of brain uptake, Kin,cd,uu by dividing with the total perfusion 
time in minute (t) as described by Equation 2.1.13.  
𝐾𝑖𝑛,𝐶𝑑,𝑢𝑢 (𝑚𝐿/𝑔/𝑚𝑖𝑛) =
𝑅𝐶𝑑,   𝑢𝑢 (𝑚𝐿/𝑔)
𝑡 (𝑚𝑖𝑛)
   Equation 2.1.13 
The concepts of these brain uptake parameters are explained in more detailed in the 
following Section (Section 2.1.11). Figure 2.1.20 showed the example of brain uptake 
calculation for CP20. 











 Concepts and description of brain uptake parameters 
Two main brain uptake parameters arises from the brain uptake calculation for HPO 
(Section 2.1.11) namely brain uptake from unbound compound in perfusate, in whole 
brain (RBr,u) and in capillary depleted brain (RCd,u). RBr,u includes total brain uptake in brain 
capillary endothelial cells (BCEC) and brain parenchyma. RCd,u is total brain uptake in brain 
parenchyma only since BCEC was removed through differential centrifugation with 15% 
(w/v) dextran (Section 2.1.7). Differences between RBr,u and RCd,u showed the degree of 
trapping of compound in BCEC (Triguero et al., 1990). Compounds trapped in BCEC were 
not considered as to have crossed the BBB since BCEC is the component of the BBB 
itself. Therefore, it was important to evaluate this phenomenon to avoid false positive 
results. 
 
RCd,u describes the transport properties at BBB and the affinity of brain for HPO (Loryan et 
al., 2016, Hammarlund-Udenaes et al., 2008, Friden et al., 2007). Correction for HPO 
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unbound in both perfusate and in capillary depleted brain give rise to another parameter, 
RCd,uu that is independent of binding to protein and lipid. This parameter describes the 
distribution of unbound HPO in brain tissue at the terminal perfusion time point. Therefore, 
this parameter is useful in describing the level of pharmacologically unbound (presumed 
to be active) HPO in brain tissue (Loryan et al., 2016, Hammarlund-Udenaes et al., 2008, 
Friden et al., 2007). In summary, RCd,u and RCd,uu parameters were used in this thesis to 
describe the brain uptake at the BBB and to calculate the rate of brain uptake (Kin,Cd,u and 
Kin,Cd,uu). 
 
 Patlak plot 
RBr, u total and RCd, u total was plotted against multiple terminal perfusion times to determine 
the linearity of brain uptake as described by Patlak (Patlak et al., 1983, Patlak and 
Blasberg, 1985). Linear regression analysis was performed on the linear portion of the 
points and the linear equation, y = mx + C was expressed as: 
  𝑅𝑡 = 𝐾𝑖𝑛 (𝑡) + 𝑉𝑉𝑎𝑠   Equation 2.1.13 
Where Rt is the total brain uptake at time t, Kin is the unidirectional rate constant, t is the 
perfusion time and Vvas is the vascular luminal space of brain capillaries. Figure 2.1.21 
showed a Patlak plot for CP20. CP20 showed a linear brain uptake up to 60-minute 
perfusion. Linear regression analysis using all the point gives a linear equation y = 1.265x 
+ 2.819. This showed that Kin and vascular space expressed respectively as 
mass/volume/time and volume/mass were 12.65 µL/min/g and 0.028 mL/g. 
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Figure 2.1.21: Example of Patlak plot for CP20 in rat brain. 
Each point represents RCd, u for CP20 plotted against respective terminal perfusion time. The data 
was not corrected for Rsucrose. Each point represents the mean±SEM (n=3-10 rats). Data was 
analysed by least square regression analysis (GraphPad Prism 7 Software). Degrees of freedom 
(Df; n-2) = 26. 
 
 Linearity of brain uptake 
It is important to determine the linearity of brain uptake especially for HPO since the rate 
of brain uptake can only be reliably measured before HPO reaching the steady-state (SS) 
concentration in the brain. RBr,u,total and RCd,u,total for 5, 10, 20, 40 and 60 minutes were 
plotted as a Patlak plot as showed in Figure 2.1.22. Both brain uptake profiles are not 
significantly different from each other, which indicate no significant trapping of HPO in the 
BCEC (Triguero et al., 1990). RCd,u showed brain uptake beyond the BBB, and thus was 
explained further in the following paragraph. 
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Figure 2.1.22: Patlak plot for 3H-OMG, CP20 and 14C-sucrose in rat brain. 
a) RBr,u,total for 3H-OMG, CP20 and 14C-sucrose was plotted against multiple perfusion times. b) RCd, 
u,total for 3H-OMG, CP20 and 14C-sucrose was plotted against multiple perfusion times. Blue square 
(□) represents brain uptake for 3H-OMG. Red circle (○) represents brain uptake for CP20. Green 
triangle (∆) represents brain uptake for 14C-sucrose. Data are expressed as  mean±SEM  (n=3-18 
rats). The blue line represent best-fit of data at multiple perfusion time (5, 10 and 20 minutes) while 
the red and green lines represent best-fit of data at multiple perfusion time (5, 10, 20, 40 and 60 
minutes) analysed by linear regression analysis (GraphPad  Prism 7 Software). The dotted blue 
line represent the best-fit of data at multiple perfusion time analysed by non-linear fit analysis 
(competitive inhibition, GraphPad  Prism 7 Software). 
 14C-sucrose 
The range of vascular space values during 5 to 60 minutes in situ brain perfusion were 
between 0.01-0.02 mL/g. This correspond with previously reported studies which showed 
14C-sucrose vascular space fell between 0.01-0.04 mL/g (Triguero et al., 1990, Zlokovic 
et al., 1994, Pardridge et al., 1990).14C-sucrose was used as a negative control to confirm 
the integrity of the BBB because of it hydrophilicity and the lack of specific carrier at the 
BBB which render it to confine only in the vascular space (Ennis and Betz, 1986). 
Additionally, 14C-sucrose was also employed as a vascular space marker to differentiate 
between brain capillary lumen space and brain parenchyma space after brain 
homogenisation take place (Triguero et al., 1990, Lockman et al., 2003). Selection of 
vascular space marker with suitable molecular weight is important to represent the 
vascular space of co-administered HPO. 14C-sucrose has a molecular weight of 342.3 
g/mol. The molecular weight falls within the range of tested compounds [3H-OMG (194 
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g/mol) and hydroxypyridinones (139 to 363 g/mol)] making 14C-sucrose appropriate as a 
vascular space marker in this study. 
 
 3H-OMG 
3H-OMG showed a linear uptake up to 20-minutes perfusion before reaching plateau 
afterwards. Maximum 3H-OMG accumulated uptake was approximately 29% of the 
concentration perfused (Figure 2.1.22b). 3H-OMG is a substrate for glucose transporter 
(GLUT1) and was employed as a positive control and as a functional indicator of intact 
BBB in respect of carrier-mediated transporter. As with the 14C-sucrose, 3H-OMG is a 
hydrophilic compound which would not crossed the BBB. However, GLUT1 carrier was 
expressed at the BBB to transport glucose from blood to brain down the concentration 
gradient (Reyes et al., 2002). 3H-OMG is a non-metabolised derivative of glucose, thus 
make it suitable for quantification for brain uptake via GLUT1 transporter (Jay et al., 1990). 
 
 CP20 
Since the novel HPO were designed based on CP20 structure, it was used as a model of 
HPO brain uptake. CP20 uptake was linear for up to 60-minutes perfusion time. Maximum 
accumulated brain uptake at the terminal time point (60 minutes) was approximately 80% 
of the concentration perfused (Figure 2.1.22b). CP20 showed increase accumulation in 
the brain over the perfusion time (5 to 60 minutes) confirming the linearity of the brain 
uptake for reliable determination of Kin. CP20 has been previously reported to penetrate 
the brain (Fredenburg et al., 1996, Roy et al., 2010).  Indeed, a ground-breaking pilot 
clinical study in Parkinson’s disease patients that were administered with 30 mg/kg/day 
for 36 months attenuates disease symptoms and analysis with T* MRI showed a reduction 
of iron in basal ganglia, demonstrating that deferiprone entered the brain to chelate and 
re-distributed iron (Abbruzzese et al., 2011). 
 
Regression analysis performed on 3H-OMG and CP20 Patlak plot revealed that the rate 
of uptake in the capillary depleted brain were 10.2 and 12.7 µL/min/g respectively (Table 
2.1.7). The vascular space (Vvas) obtained from the y-intercept of least-square linear 
regression analysis for 3H-OMG and CP20 agreed with the published data (Roy et al., 
2010, Triguero et al., 1990, Zlokovic et al., 1994, Pardridge et al., 1990).  
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Table 2.1.7:Rate of brain uptake in capillary depleted brain for 3H-OMG and CP20, and the 
respective brain vascular space derived from linear regression analysis on Patlak plot 
(Figure 2.23b). 
 14C-sucrose 3H-OMG CP20 
Kin,Cd,u (µL/min/g) 0.2±0.1 10.2±1.9 12.7±1.8 
Vvas (mL/g) 0.01±0.38 0.03±0.06 0.03±0.02 
Vvas (%) 1.0 3.0 3.0 
r2 0.0671 0.5835 0.6653 
p 0.1216 < 0.0001 < 0.0001 
df (n-2) 35 20 26 
Least-square linear regression analysis was performed on the linear portion of Patlak plot in Figure 
2.2.22b. Linear portion for 3H-OMG was from 5 to 20 minutes perfusion. Linear portion for CP20 
and 14C-sucrose was from 5 to 60 minutes perfusion.  14C-sucrose Kin,Cd,u showed rate of distribution 
in brain capillary lumen rather than brain uptake. Data are expressed as  mean±SEM  (n=22-37 
rats). p< 0.001 compared to CP20 (one-way ANOVA followed by Tukey’s multiple comparison test). 
Significant difference for linear regression analysis was set at  P<0.05. Co-efficient of variation (r2), 
degree of freedom (df: n-2) and p values were calculated using linear-regression analysis 
(GraphPad  Prism 7 Software). 
 
Base on multiple times point uptake presented in Figure 2.1.22b, 20 minutes was selected 
as the terminal perfusion time point for other novel HPO iron chelators. This is because, 
at 20 minutes, the brain uptake was still in the linear portion for a reliable estimation of Kin. 
Furthermore, HPO accumulated in the brain at 20-minute time point give enough 
sensitivity to be detected by HPLC-UV analysis. What most important is the vascular 
space showed by 14C-sucrose and uptake of 3H-OMG at 20 minutes strongly suggest that 
the BBB was physiologically intact and functional. 
 
RCd, u, total for 20-minutes perfusion for 3H-OMG, CP20 and 14C-sucrose depicted in Figure 
2.1.22b was extracted and plotted into bar graph as shown in Figure 2.1.23. The Rsucrose 
that represent the capillary space was subtracted from 3H-OMG and CP20 RCd, u, total. 
*** *** 
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Figure 2.1.23:  Brain uptake at 20-minutes perfusion time for 3H-OMG and CP20 in capillary 
depleted brain before (RCd,u,total)  and after (RCd,u) correction with 14C-sucrose vascular space. 
Striped bar graphs depict brain uptake that was corrected for 14C-sucrose vascular space. Data are 
expressed as  mean±SEM  (n=10-18 rats). ** P< 0.01, *** P< 0.001 compared to CP20 (corrected) 
(one-way ANOVA followed by Dunnett’s test).  
 
The initial rate of uptake (Kin,Cd,u) for 20 minutes was calculated as described in Section 
2.1.11. The Kin,Cd,u obtained from 20-minute perfusion showed no different from the results 
obtained from linear regression analysis of Patlak plot (Table 2.1.8). This strongly 
suggests that the methods and analysis used in this study were validated where the Rsucrose 
value reflecting the vascular space (Vvas) for CP20 derived from Patlak plot. 
 
Table 2.1.8: Comparison between Kin,Cd,u for 3H-OMG and CP20 calculated by single-time 




Patlak plot 10.2±1.9 12.7±1.8 
Single-time point 10.7±1.0 10.7±1.2 
Data are expressed as  mean±SEM  (n=10-36 rats). Statistical analysis using showed no significant 
different, p> 0.05 (unpaired t-test,two-tailed). 
 
To summarise, in situ brain perfusion was validated prior to brain permeability evaluation 
of novel HPO. These include measurement of pH, gas and ions in whole blood and 
perfusate in rats. After in situ brain perfusion, brain was taken out and the blood capillary 
associated with brain tissues was separated by density centrifugation with 15% (w/v) 
dextran. Following this, alkaline phosphatase specific activity was assessed in some of 
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the capillary depleted brain to confirm the success of separation. HPO that get into the 
brain after perfusion was extracted with 10 % (v/v) TFA. Recovery of HPO after extraction 
with TFA in brain and perfusate samples was measured with HPLC quantification method. 
Free-unbound concentration of HPO in perfusate and brain homogenate was evaluated in 
separate in vitro experiment whereby HPO were incubated with perfusate (NRS) or naïve 
rat brain homogenate followed by membrane-ultrafiltration. Results from this experiment 
were used to correct for unbound HPO in perfusate and brain. 
 
Experiment performed with CP20 at 5, 10, 20, 40 and 60 minutes showed linear uptake 
with tight and functional BBB (Figure 2.1.22). Following this, in situ brain perfusion were 
conducted in Male Wistar rats to evaluate permeability of novel HPO iron chelators using 
20 minutes as the optimum perfusion time due to linearity of brain uptake and adequate 
sensitivity for HPO measurement by HPLC-UV analysis.  
 
 Optimised and validated protocol for in situ brain perfusion  
This section explained the final protocol used for in situ brain perfusion for evaluation of 
novel HPO iron chelators, after optimisation and validation processes. Rats were 
anaesthetised with 50 mg/kg ketamine and 0.2 mg/kg medetomidine, i.p., and maintained 
at 37 °C using a heating pad (Figure 2.1.1). Whilst in a supine position, rats were injected 
with 100,000 U/kg heparin (i.p). Local anaesthetic, lignocaine/adrenaline was then injected 
subcutaneously (s.c.) at five multiple sites (total dose was 20 and 12.5 mg/kg) on the area 
of the chest. Common carotid arteries on the left and right sides were isolated one at a 
time. Two loose ligatures on the anterior and posterior part of each common carotid artery 
were added. Sequentially, jugular veins on both sides were isolated with a pair of forceps 
(Figure 2.1.2). Posterior loose ligature was tightened and a small incision with Vanna 
scissors was performed just above the tightened ligation. Cannula with flowing oxygenated 
NRS at 1.44 mL/min rate was inserted through the incision. At the same time, the jugular 
vein was severed to allow the drainage of the perfusate. The anterior ligature was 
tightened to secure the cannula in place. The NRS was allowed to perfuse for at least 
three minutes to wash out the blood. The same procedure was repeated for the 
contralateral common carotid artery.  
 
Infusion of novel HPO iron chelators was started when both common carotid arteries were 
cannulated with slow drive syringe pump that joined the main NRS circulation at 0.16 
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mL/min rate. The total flow rate that reach the end of the cannula was 1.6 mL/min. In situ 
brain perfusion with iron chelators were performed for 20 minutes after which the cannulas 
were removed from the arteries. Perfusate flowing out from the end of the cannulas were 
collected every time after completion of brain perfusion. Following this the rats were 
decapitated, and the brain was removed immediately for sample processing and analysis 
as described previously in Section 2.1.7 and Section 2.1.8. 
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 Determination of neurotoxins IC50 and HPO toxicity 
for neuroprotection studies using neuroblastoma 
cell lines (SH-SY5Y) 
 Introduction 
In vitro models of Parkinson’s disease (PD) are often used as a preliminary tool in the 
discovery of neuroprotection agents. The most utilised in vitro model of PD is the 
dopaminergic neuroblastoma cell line, SH-SY5Y (Xicoy et al., 2017). It is widely employed 
due to its catecholaminergic nature, which is relevant to the pathogenesis of PD in the 
general population of PD patients (Hasegawa et al., 2003, West et al., 1977). Historically, 
the SH-SY5Y cell line was derived from a third successive sub-clone (SH-SY → SH-SY5 
→ SH-SY5Y) of metastatic bone tumour biopsy (SK-SN-SH) of a 4-year old female with a 
neuroblastoma in 1973 (Kovalevich and Langford, 2013a). The SH-SY5Y cell line was 
preferred as an in vitro tool in neuroprotection study over neuronal primary culture such 
as primary mesencephalic cell or primary cortical neuron because of its ease of growing 
in the laboratory, stability for higher passage number and with limited contamination with 
glial cells (Xicoy et al., 2017). Furthermore, due to its wide acceptance and extensive use 
among the research community, comparison and reference with other similar types of work 
are possible.  
 
Typically, in the in vitro PD model for neuroprotection study using SH-SY5Y, cells were 
exposed to several different types of toxin to mimic the pathological event in vivo that lead 
to cell death. Each toxin is unique in terms of mechanism that causes the cell death. 
Therefore, selection of different types of toxins would give an insight into the way the 
neuroprotective agents work. The current study employed hydrogen peroxide (H2O2), 6-
hydroxydopamine (6-OHDA), MG132 and iron [ferric nitrolotriacetate (FeNTA)] as 
neurotoxins. This introduction section described the mechanism on how these neurotoxins 
cause cell death. 
 
 H2O2 
H2O2 is the most commonly used toxin to create oxidative stress in in vitro research. H2O2 
is a ubiquitous molecule that is continuously produced during mitochondria respiration 
(Giorgio et al., 2007). It is soluble in water and readily permeate biological membranes. In 
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the cell, H2O2 is produced either spontaneously or catalytically by superoxide dismutase 
(SOD) from the superoxide radical (O2●-) that is released specifically from the Complex I 
or Complex III of the mitochondria respiratory chain. This endogenous molecule is 
metabolised immediately after production by enzyme catalase, glutathione peroxidase 
(GPx) or peroxiredoxin to water and/or molecular oxygen (Rocha et al., 2015). H2O2 per 
se is mildly toxic relative to other neurotoxins, however, during oxidative stress, production 
of H2O2 increases as catalase fails to inactivate H2O2 efficiently due to saturation of the 
active site. In this situation, probability for H2O2 to react with endogenous iron via Fenton 
reaction also increases (Reaction 2.2.1). The Fenton reaction occurs spontaneously to 
produce highly reactive hydroxyl radical (OH●-). In the presence of O2●- that was 
concomitantly produced as a by-product of mitochondria respiration, Fe3+ is reduced to 
Fe2+ by Heber-Weiss reaction (Reaction 2.2.2). In this condition, a vicious cycle of OH●- 




                                 
→            𝑂𝐻 ⋅−  + 𝑂𝐻− + 𝐹𝑒3+            Reaction 2.2.1 
𝑂2
⋅− + 𝐹𝑒3+  
                                 
→           𝑂2 + 𝐹𝑒
2+     Reaction 2.2.2 
OH●- species primarily contributes to cell death by membrane lipid peroxidation that cause 
disintegration of cells and by interaction with DNA that interrupts the production of 
essential proteins. Loss of membrane integration disrupts the homeostatic balance of 
physiological ions. In the case of mitochondria as the production site of the OH●-, disruption 
of mitochondrial membrane induces releases of mitochondrial Ca2+ into cytoplasm that 
leads to activation of cell death. Similarly, the proximity of OH●- production to mitochondrial 
DNA might interfere with the expression of mitochondrial respiratory chain proteins that 
exacerbates oxidative stress (Chinnery and Hudson, 2013). Besides the production of 
OH●- from H2O2 degradation, H2O2 on its own stimulates activation of intracellular 
signalling pathways for cell death (Marinho et al., 2014). The combination of these cellular 
events eventually leads to cell death.  
 
 6-OHDA 
6-OHDA is a classical tool to model Parkinson’s disease pathology and was initially 
thought to be a non-endogenous metabolite of dopamine (Jellinger et al., 1995). 
Interestingly, it was later found in the brain and urine of Parkinsonian patients and is 
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believed to form by non-enzymatic hydroxylation of endogenous dopamine in the presence 
of Fe2+ and H2O2; Reaction 2.2.3 (Andrew et al., 1993, Curtius et al., 1974).  
 
𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 
           𝐻2𝑂2+ 𝐹𝑒
2+            
→                 6 − 𝑂𝐻𝐷𝐴    Reaction 2.2.3 
 
6-OHDA is a metabolite of dopamine that is toxic to the dopaminergic cells by two distinct 
but related mechanisms. The first mechanism directly generates ROS by auto-oxidation 
with O2 forming p-quinone and O2- (Reaction 2.2.4) or through enzymatic conversion by 
monoamine oxidase (MAO) forming H2O2 (Reaction 2.2.5) (Soto-Otero et al., 2000, Izumi 
et al., 2005).  
 
6 − 𝑂𝐻𝐷𝐴 
           𝑂2                    
→            𝑝 − 𝑞𝑢𝑖𝑛𝑜𝑛𝑒 + 𝑂2
⋅−     Reaction 2.2.4  
6 − 𝑂𝐻𝐷𝐴 
              𝑀𝐴𝑂             
→            𝐷𝑂𝑃𝐴𝐶 + 𝐻2𝑂2             Reaction 2.2.5 
 
The second mechanism is by direct inhibition of electron transport chain (ETC) in 
mitochondrial (Glinka and Youdim, 1995, Glinka et al., 1998). Extracellular toxicity occurs 
primarily by ROS generation through 6-OHDA metabolism, while intracellular toxicity 
occurs by both ROS generation and ETC inhibition. Preliminary step of intracellular toxicity 
relies on the expression of dopamine transporters (DAT) express on the axon terminal of 
dopaminergic neurons (Lehmensiek et al., 2006, Storch et al., 2004). Inside the neuron, 
6-OHDA either undergoes oxidative metabolism or directly inhibits Complex I and 
Complex IV of mitochondrial respiratory chain (Glinka and Youdim, 1995). Inhibition of the 
mitochondrial complexes generate more ROS that further exacerbates oxidative stress. 
Several studies revealed that p-quinone, an electrophile formed from 6-OHDA auto-
oxidation (Reaction 2.2.4) might be the primary species that confers 6-OHDA toxicity 
(Izumi et al., 2005, Villa et al., 2013). p-Quinone generated extracellularly can readily 
penetrate the cell membrane and exert toxicity by forming protein-adduct with intracellular 
proteins (Miyazaki et al., 2007). Furthermore, generation of p-quinone causes oxidative 
stress through depletion of GSH and ATP levels (Villa et al., 2013). 6-OHDA can also 
induce the release of iron bound to ferritin, which can induce the formation of dopamine 
toxic metabolite, 6-OHDA, in vivo; Reaction 2.2.3 (Jameson et al., 2004, Double et al., 
1998). Furthermore, 6-OHDA can also modulate several proteins for intracellular iron 
uptake such as Nedd4 family-interacting protein 1 (Ndfip1); an adaptor protein for the 
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Nedd4 family of ubiquitin ligases, hepcidin; an iron binding protein and divalent-metal 
transporter 1 (DMT1); an iron transporter that raised the level of intracellular iron (Jia et 
al., 2015, Xu et al., 2016). All these cellular events lead to decrease in cell protective 
mechanism which results in cellular degeneration (Glinka & Youdim, 1995).   
 
 MG132 
MG132 is a peptide-aldehyde that inhibits proteasomes enzymes complex responsible for 
intracellular protein degradation. As part of the ubiquitin-proteasomes system (UPS), this 
enzymes complex degrades intracellular proteins that are tagged with ubiquitin to smaller 
peptides for further degradation to amino acids and re-cycling for the synthesis of 
intracellular proteins. MG132 is relevant to model the pathogenesis of PD in vitro as mutant 
α-synuclein expressed in familial PD patients which tend to self-aggregate forming Lewy 
bodies also inhibit the proteasome (Kim et al., 2014). It has been shown that transfected 
cells overexpressing mutant α-synuclein were sensitised to cell death compared to non-
transfected cells after exposure to MG132 (Petrucelli et al., 2002). Inhibition of 
proteasomes enzymes complex initiate ROS productions presumably by decreasing the 
turnover rate of mitochondria and thus decreasing the capacity of electron transport chain 
(ETC) (Sullivan et al., 2004). Increase in ROS generates more misfolded protein by 
oxidation with some misfolded proteins forming fibrils that can increase mitochondria 
membrane permeability through pore formation. These can activate another pathway for 
ROS generations by releasing Ca2+ and cytochrome c to the cytosol (He and Lemasters, 
2002). Apart from ROS production, inhibition of the proteasome raises the level of 
intracellular proteins, most of which are important in intracellular signalling involving cell 
survival. One mechanism of MG132 that lead to cell death is by increasing the level of the 
short-lived tumour-suppressor protein, p53 which mediate apoptosis by decreasing its 
degradation (Nakaso et al., 2004). Besides tumour-suppressor proteins, other proteins 
involved in intracellular cell signalling such as transcription factors [e.g. nuclear factor-
kappa B (NF-kB)] and cell cycle protein [e.g. cyclin A] are also modulated which favour 
towards activation of cell death machineries (Guo and Peng, 2013). In summary, 
proteasomes inhibition caused accumulation of intracellular signalling proteins and 
generations of free-radicals that induce cell death. 
 
  CHAPTER 2: MATERIALS AND METHODS 
96 
 
This section described the method used to grow the SH-SY5Y cells and the determination 
of toxins and HPOs toxicity. 
 
 Human neuroblastoma cell lines (SH-SY5Y) 
Human neuroblastoma cell line (SH-SY5Y) was obtained from the European Collection of 
Cell Cultures (ECCC). The cells were arrived in dry ice and were grown in serum-
supplemented cell culture medium, complete-DMEM (Table 2.2.1) on the day of arrival. 
SH-SY5Y cells used in this study were initially at passage 18.  
 




Dulbecco's Modified Eagle Medium (DMEM) 500 Life Technologies, UK 
Fetal bovine serum (FBS) 50 Life Technologies, UK 
Penicillin-Streptomycin-Neomycin (PSN) 
antibiotic mixture [0.5% P, 0.5% S, 0.5% N in 
0.85% (w/v) saline] 
6 Life Technologies, UK 
 
To grow the cells, the cryovial containing cells suspension was thawed quickly in a water 
bath (Grant Instruments Ltd, UK) pre-set at 37 °C. Cell handling after this step was 
performed in sterile condition under a Grade II biosafety cabinet (Envair Ltd, UK). The 
commercially obtained SH-SY5Y cell suspension was slowly added into 10 mL complete-
DMEM in a Falcon tube followed by centrifugation (ThermoFisher, UK) at 200 g for 5 
minutes.  
 
Subsequently, supernatant was removed, and the cell pellet was reconstituted in 1 mL 
complete-DMEM. The cells suspension was briefly triturated and added to 25 cm2 (T25) 
flask coated with Nunclon Delta Surface (Nunc®; ThermoFisher, UK) containing 10 mL 
complete-DMEM followed by gentle shaking to distribute the cells. The cells were grown 
in an incubator (Panasonic Corporation, Japan) with humidified carbogen (5% CO2 and 
95% O2), and the cells were observed under an inverted optical light microscope (Nikon 
TMS) at 5X magnification the following day to confirm cell attachment to flask. Medium 
was replaced once or twice every week with fresh complete-DMEM.  
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 Sub-culturing SH-SY5Y 
When the cells have covered approximately 80% of the surface area of the T25 flask (i.e. 
reaching 80% confluence) by checking under the optical light microscope at 5X 
magnification (Figure 2.2.1), they were washed with 5 mL DPBS followed by 2 mL 0.05% 
trypsin-EDTA in phosphate buffer (Life Technologies, UK) for 6 minutes at 37 °C in CO2 
incubator. The cell suspension was centrifuged at 200 xg for 5 minutes. The cell pellet was 
re-suspended with 1 mL complete DMEM after the supernatant has been discarded. After 
a short trituration, the cells were passage into a 75 cm2 (T75) Nunc ® Nunclon Delta 
Surface flask (ThermoFisher, UK) containing 15 mL complete-DMEM.   
 
 
Figure 2.2.1:  SH-SY5Y cells grown at approximately 80% confluence (5X magnification). 
Upon reaching 80% confluence in T75 flask, the same steps of medium removal, cells 
trypsinisation and passaging were repeated, except that the 175 cm2 (T175) flask with 20 
mL complete-DMEM was used. After 2-3 passages, the cells grown in 175 cm2, they were 
ready for use in experiments. 
 
 Cells storage 
Some of the cells that were grown after receiving from commercial suppliers were stored 
in 1 mL cryovials (Starlab Group, UK) for future use. The storage of the cells maintained 
the lowest passage number relative to their sub-cultured counterparts. 
 
For storage, cells that reached 80% confluence in T175 flask were washed with 5 mL 
DPBS followed by 6 mL 0.05% trypsin-EDTA for 6 minutes at 37 °C. The cell suspension 
was centrifuged at 200 xg for 5 minutes. Cells number was counted as described in detail 
in Section 2.2.6 with improved Neubaeuer Brightline® 1mm deep haematocytometer 
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(Reichert Tecnologies, USA). The optimum cells number (3 X 106 cells/mL) was prepared 
in storage medium (40% DMEM, 40% FBS and 20% DMSO) and aliquoted (1 mL) to 
cryovials. The cryovials containing cells were frozen at -20 ºC (12 h), and finally stored at 
-70 ºC. 
 
 Growing cells from storage 
Two 1 mL cryovials containing cells were removed from the -70 ºC freezer and thawed 
quickly in a waterbath at 37 ºC. The cells were grown in T25 flask and sub-cultured to 
larger flask before use in experiments as described in Section 2.2.2 and Section 2.2.3. 
 Counting cells with hematocytometer 
SH-SY5Y cells grown in T175 flask were washed when the cells reached 80% confluence 
with 5 mL DPBS followed by incubation with 6 mL 0.05% trypsin for 5 minutes at 37 °C. 
The cell suspension was centrifuged at 200 xg for 5 minutes. The cell pellet was re-
suspended with 1 mL complete DMEM after the supernatant has been discarded. The 
cells suspension was diluted 1:49 (v/v) with 0.4% trypan blue solution prepared in 0.81% 
(w/v) NaCl and 0.06% (w/v) K2HPO4 (Sigma-Aldrich, UK). Two microliter of diluted cells-
trypan blue suspension was loading at the edge of a glass coverslip on a haemocytometer. 
Haemocytometer contains a grid of four identical squares on each corner with 16 smaller 
boxes with each square can occupy 0.0001 mL cell suspension. The average of cells from 
the four corner squares was taken and the cells number was calculated as the following: 
 
𝑪𝒆𝒍𝒍𝒔 𝒏𝒖𝒎𝒃𝒆𝒓 (𝒄𝒆𝒍𝒍𝒔 𝒎𝑳⁄ ) = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 4 𝑐𝑜𝑟𝑛𝑒𝑟 𝑏𝑜𝑥𝑒𝑠 ×  𝐷𝐹 × 104  Equation 2.2.1 
 
Figure 2.2.2: Example of cells number calculation with haemocytometer. 
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 Plating SH-SY5Y cells to 96-well plates 
Passage number (P) of SH-SY5Y used in this study were between P20 to P40. Whenever 
the cells show increase in the growth rate and resistance towards toxins, cells with lower 
passage number were used. Cells were diluted into several concentrations from the main 
cell suspension with complete-DMEM and were plated in a volume of 100 µL per well. The 
cells were allowed to attach to the surface of 96-well plate for at least 12 h after plating 
before use for experiment. The remaining stock of cells suspension was passaged to a 
new T175 cm2 for the next experiments.  
 
 
Figure 2.2.3:  Schematic diagram showing steps from cells thawing, growing in flask, 
counting and plating into 96-well plates. 
 
 Estimation of cell viability 
Cells viability was estimated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
(MTT) assay. The assay was based on the principle that viable cells could take up MTT 
intracellularly and reduce to insoluble purple formazan crystal by mitochondria reductase 
(van Meerloo et al., 2011). The formazan crystal was solubilised with dimethyl sulfoxide 
(DMSO) after the incubation medium removed and has a maximum absorption at 570 nm 








Figure 2.2.4:  Schematic diagram for conversion of mitochondria reductase substrate, MTT 
to purple formazan that has maximal absorption at 570 nm. 
MTT main stock solution (5.5 mg/mL) was prepared by dissolving in distilled water and 
was sonicated for 30 minutes, protected from light. The MTT main stock solution was 
sterile filtered using a 0.45 µm membrane with a 20 mL syringe under the biosafety 
cabinet. The filtered MTT main stock solution was aliquoted into microcentrifuge tubes and 
stored at -20 ˚C until use.  
 
On the day of the assay, the MTT stock solution was thawed in a water bath at 37 ˚C and 
MTT working stock solution (0.5 mg/mL), prepared in serum-free DMEM was added to the 
cells in 96-well plate. The plate was then incubated for 4h in CO2 incubator at 37 ˚C after 
incubation medium was removed. At the end of the incubation time, the culture medium 
with MTT was removed by quick inversion into a sink and slowly tapped into tissue to 
remove excess liquid (Morgan, 1998). DMSO (100 µL) was added into the 96-well, and 
lightly tapped to assist solubilisation. Absorbance at 570 nm was taken immediately and 
the percentage of viable cells calculated as follows: 
 
𝑉𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 (%) =
𝑇𝑟𝑒𝑎𝑡𝑒𝑑570𝑛𝑚−𝐵𝑙𝑎𝑛𝑘𝐷𝑀𝑆𝑂,570𝑛𝑚
𝐶𝑜𝑛𝑡𝑟𝑜𝑙570𝑛𝑚 − 𝐵𝑙𝑎𝑛𝑘𝐷𝑀𝑆𝑂,570𝑛𝑚
 𝑋 100   Equation 2.2.2 
The formation of formazan crystals as detected at 570 nm shows linear positive correlation 
with SH-SY5Y densities in the 96-well plates (Figure 2.2.5). Base on this observation, SH-
SY5Y density at 1X105 cells/mL was selected to be sufficient for toxicity and 
neuroprotection studies. The selected density was also widely reported by other literatures 
which makes comparison between studies feasible.  
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Figure 2.2.5: Linearity of MTT absorbance at 570 nm with different cell density. 
Data are expressed as  mean±SEM  (n=3).  Data was analysed by least-square regression analysis 
(GraphPad Prism 7 Software). Degrees of freedom (df) = 19. 




Selected neurotoxins were used to induce SH-SY5Y cells death. The death of SH-SY5Y 
cells mimicked the dying dopaminergic neurons, the pathological hallmark of Parkinson’s 
disease. Series of concentrations range were prepared for determination of concentration 
that caused 50% cell death (IC50) by MTT assay described in Section 2.2.8. The IC50 
concentration obtained were used in the neuroprotection studies.  
 
 Hydrogen peroxide (H2O2) 
Working stock solution (2000 µM) for H2O2 was prepared from the 30% (w/v) H2O2 main 
stock solution (Sigma-Aldrich, UK) in serum-free DMEM. A series of H2O2 concentrations 
ranging from 16-1000 µM were prepared in serum-free DMEM using the H2O2 working 
stock solution and were added (100 µL) into the 96-well plate containing 1x105 SH-SY5Y 
cells/mL. The cells were exposed to the various concentration of H2O2 (16-2000 µM) for 
20 h in a CO2 incubator. Cells incubated with serum-free DMEM were served as a control. 
After 20 h exposure to H2O2, the medium was removed and replaced with serum-free 
DMEM containing 0.5 mg/mL MTT and further incubated in the CO2 incubators for 4 h. At 
the end of the incubation, the medium was removed followed by cells lysis with 100% (v/v) 
DMSO and the absorbance was taken at 570 nm as described in Section 2.2.8. 
 
H2O2 started to show a concentration dependent reduction in cell viability at 125 µM and 
above (Figure 2.2.6). The IC50 value for H2O2 obtained by non-linear regression analysis 
was 222±33 µM which is within the range of reported values (Yeon and Kim, 2010, Ismail 
et al., 2012). 
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Figure 2.2.6: Cell death of SH-SY5Y cells following exposure to H2O2. 
SH-SY5Y cells were exposed to  H2O2 (16-2000 µM) for 20h. Cell viability was assesed by the MTT 
assay, where untreated cells was recorded as ~100% viable and served as a control. Data are 
expressed as  mean±SEM  (n=5). Non-linear regression analysis [log(toxin) vs. response -- Variable 
slope (four parameters)] was performed to calculate the IC50 (GraphPad Prism 7 Software). 
Degrees of freedom (df) = 42. * p <0.05, *** p <0.001 compared to control cells (one-way ANOVA 
followed by Dunnett’s test). 
 
 6-Hydroxydopamine (6-OHDA) 
Main stock solution (50 mM) for 6-OHDA (Sigma-Aldrich, UK) was prepared in 0.3% (w/v) 
ascorbic acid as sodium ascorbate (Sigma-Aldrich, UK) dissolved in serum-free DMEM. 
6-OHDA working stock solution (1000 µM) was prepared from the 6-OHDA main stock 
solution by 1:49 (v/v) dilution in serum-free DMEM. A series of 6-OHDA concentrations 
ranging from 4-250 µM were prepared in 0.006% (w/v) ascorbic acid in serum-free DMEM 
from the 6-OHDA working stock solution and were added (100 µL) into the 96-well plate 
containing 1x105 SH-SY5Y cells/mL. The cells were exposed to the various concentration 
of 6-OHDA (4-250 µM) for 20 h in a CO2 incubator. Cells incubated with 0.006% (w/v) 
ascorbic acid in serum-free DMEM was served as a control. After 20 h exposure to 6-
OHDA, the medium was removed and replaced with free-medium containing 0.5 mg/mL 
MTT and further incubated in the CO2 incubators for 4 h. At the end of the incubation, the 
medium removed followed by cells lysis with 100% (v/v) DMSO and the absorbance was 
taken at 570 nm as described in Section 2.2.8. 
 
6-OHDA showed a concentration dependent reduction in cell viability at 31 µM and above 
(Figure 2.2.7a). The IC50 value for 6-OHDA obtained by non-linear regression analysis 
was 39.5±5.8 µM which is within the range of reported values (Ryu et al., 2013, Storch et 
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al., 2000, Shi et al., 2013, Silva et al., 2016). The final concentration of ascorbic acid added 
into serum-free DMEM to reduce the rate of 6-OHDA oxidation was 0.006% (w/v) chosen 
based on the cell viability-ascorbic acid concentration response curve, which did not cause 
significant cell death (Figure 2.2.7b). Indeed, sodium ascorbate has been reported to 
induce apoptosis in neuroblastoma cell lines by interfering with iron uptake (Carosio et al., 
2007). In addition, report on protective effect of ascorbate on amyloid beta-exposed SH-
SY5Y cells used much lower concentration of ascorbate, 0.001% (w/v) than that was used 
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Figure 2.2.7: Cell death of SH-SY5Y cells following exposure to 6-OHDA and L-ascorbic acid. 
SH-SY5Y cells were exposed to  a) 6-OHDA (4-250 µM) and b) L-ascorbic acid [(0.0004-0.1% 
(w/v)] for 20 hours. Cell viability was assesed by the MTT assay, where a) cells treated with 0.006 
% (w/v) ascorbic acid b)  untreated cells were recorded as ~100% viable and served as controls. 
Arrowhead indicates the final L-ascorbic acid concentration chosen to protect 6-OHDA from rapid 
oxidation.  Data are expressed as  mean±SEM  a) n=4, b) n=5. Non-linear regression analysis 
[log(toxin) vs. response-variable slope (four parameters)] was performed to calculate the IC50 
(GraphPad Prism 7 Software). Degrees of freedom (df)= a) 36 and b) 26. ** p <0.05, *** p <0.001 
compared to control cells (one-way ANOVA followed by Dunnett’s test). 
 
 MG132 
MG132 main stock solution (1 mM) was prepared in 100% DMSO (Fisher Scientific, UK). 
MG132 working stock solution (10 µM) was prepared from the MG132 main stock solution 
by 1:9999 (v/v) dilution in serum-free DMEM. A series of MG132 concentrations ranging 
from 5 pM - 5 µM were prepared in 0.001% (v/v) DMSO in serum-free DMEM from the 
MG132 working stock solution and were added (100 µL) into the 96-well plate containing 
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1x105 SH-SY5Y cells/mL. The cells were exposed to the various concentration of MG132 
(5 pM -10 µM) for 20 h in a CO2 incubator. Cells incubated with 0.001% (w/v) DMSO in 
serum-free DMEM served as a control. After 20 h exposure to MG132, the medium was 
removed and replaced with free-medium containing 0.5 mg/mL MTT and further incubated 
in the CO2 incubators for 4 h. At the end of the incubation, the medium removed followed 
by cells lysis with 100% (v/v) DMSO and the absorbance was taken at 570 nm as 
described in Section 2.2.8. 
 
MG132 showed a concentration dependent reduction in cell viability at 0.0005 µM and 
above (Figure 2.2.8a). The IC50 value for MG132 obtained by non-linear regression 
analysis was 352±0.05 pM which is rather lower than the reported values. The reported 
IC50 values for MG132 were between 0.5 to 10 µM (Yamada et al., 2011, Nakaso et al., 
2004). The higher IC50 values in those reports probably due to the used of cells at higher 
passage number as they tend to be resistant toward toxins. Unfortunately, for most 
reported studies employing SH-SY5Y, details on the passage number used were not 
provided and therefore this is not conclusive. Another possible explanation was that, 
repeated freezing and thawing of MG132 main stock solution may contributed to the 
significant loss of MG132 potency due to the fact that MG132 is a small peptide. It is 
believed that small peptides are prone to misconfiguration after a freezing-thawing cycles 
which reduced its potency (Prasad et al., 2013, Turner et al., 2011). The final concentration 
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Figure 2.2.8: Cell death of SH-SY5Y cells following exposure to MG132. 
SH-SY5Y cells were exposed to  a) MG132 (5 pM – 10 µM) and b) DMSO [0.0001-50% (v/v)] for 
20 hours. Cell viability was assesed by the MTT assay, where a) cells treated with 0.001 % (v/v) 
DMSO  b)  untreated cells were recorded as ~100% viable and served as controls. Arrowhead 
indicates the final DMSO concentration chosen to not significantly cause cell death. Data are 
expressed as  mean±SEM  a) n=4 & b) n=3. Non-linear regression analysis [log(toxin) vs. response-
variable slope (four parameters)] was performed to calculate the IC50 (GraphPad Prism 7 Software). 
Degrees of freedom (df)= a) 33 & b) 24. ** p <0.05, *** p <0.001 compared to control cells (one-
way ANOVA followed by Dunnett’s test). 
 
 Ferric nitrolotriacetoacetate (FeNTA) 
Main stock solution (12.5 mM) for ferric nitrolotriacetoacetate (FeNTA) was prepared from 
a combination of FeNO3.9H2O (Sigma-Aldrich, UK) and sodium nitrilotriacaetace (NaNTA) 
(Santa Cruz Biotechnelogy, USA) in a 1 to 5 molar ratio (FeNTA 1:5) in 10 mM HEPES 
(Sigma-Aldrich, UK) according to a method described by Molina-Holgado et al. (2008). 
The pH of the main stock solution was adjusted to pH 7.4 with 5 M NaOH and sterile 
filtered (0.45 µm filter; ThermoFisher, UK) under the biosafety cabinet.  The working stock 
solution for FeNTA (1:5; 5000 µM) was prepared in serum-free DMEM from the main stock 
solution. A series of FeNTA (1:5) concentrations ranging from 40-2500 µM were prepared 
in in serum-free DMEM from the FeNTA (1:5) working stock solution and were added (100 
µL) into the 96-well plate containing 1x105 SH-SY5Y cells/mL. The cells were exposed to 
the various concentration of FeNTA (1:5) (40-5000 µM) for 20 h in a CO2 incubator. Cells 
incubated with serum-free DMEM was served as a control. After 20 h exposure to FeNTA 
(1:5) the medium was removed and replaced with serum-free DMEM containing 0.5 
mg/mL MTT and further incubated in the CO2 incubators for 4 h. At the end of the 
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incubation, the medium removed followed by cells lysis with 100% (v/v) DMSO and the 
absorbance was taken at 570 nm as described in Section 2.2.8.  
 
FeNTA (1:5) showed a concentration dependent reduction in cell viability at 1250 µM and 
above (Figure 2.2.9a). SH-SY5Y is relatively resistance towards FeNTA (1:5) compared 
to other neurotoxins used in this study with an IC50 value obtained by non-linear regression 
analysis was 1082±125 µM. No reported IC50 values available for FeNTA (1:5) with SH-
SY5Y cells. IC50 for FeNTA (1:5) on primary cells of mouse cortical neurons was low, 10 
µM, relative to the IC50 obtained in this study (Molina-Holgado et al., 2008). In the same 
report, SH-SY5Y was also employed, however, FeNTA was not used as a toxin for SH-
SY5Y cells probably because of its marked resistance towards cell death. Furthermore, 
IC50 for NaNTA derived from exposure of comparable NaNTA concentration over Fe3+ 
concentration (5 to 1 ratio) showed approximately 5-fold the IC50 of FeNTA (1:5) (Figure 
2.2.9b). It can be concluded that the IC50 value from FeNTA was primarily due to the NTA 
toxicity rather than Fe3+ itself. NTA is a tripodal chelator for Fe3+ that requires 3 molecules 
of NTA to act as a bidentate chelator to completely chelate 1 molecule of iron (Gabričević 
and Crumbliss, 2003). It is possible that the interaction of NTA as a ligand for Fe3+ is so 
strong that Fe3+ was not available for chemical reactions. Alternatively, due to the excess 
molecules of NTA, availability of Fe3+ was limited due to efficient chelation. Fe(NO)3 on its 
own did not kill the cells because of precipitation to form inactive Fe(OH)3 at physiological 
pH which limit the use by its own in this study (Figure 2.2.9c).  
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Figure 2.2.9: Cell death of SH-SY5Y cells following exposure to FeNTA (1:5). 
SH-SY5Y cells were exposed to  a) FeNTA (1:5) (40 - 5000 µM), b) NaNTA (20 - 25000 µM) & c) 
FeNO3 (4 - 5000 µM) for 20 hours. Cell viability was assesed by the MTT assay, where untreated 
cells was recorded as ~100% viable and served as a control. Data are expressed as  mean±SEM  
a) n=4 , b) & c) n=3. Non-linear regression analysis [log(toxin) vs. response-variable slope (four 
parameters)] was performed to calculate the IC50 (GraphPad Prism 7 Software). Degrees of 
freedom (df) = a) 33 & b) 24. *** p <0.001 compared to control cells (one-way ANOVA followed by 
Dunnett’s test). 
 
In an attempt to lower the NTA concentration for every mole of Fe3+, FeNTA was prepared 
as above, however by a combination of 1 to 3 molar ratio of FeNO3.9H2O and NaNTA as 
reported by Iqbal et al. (2003). Several concentrations of FeNTA (1:3) were prepared and 
exposed to SH-SY5Y cells as described above. After 20 h exposure with FeNTA, the 
medium was removed and replaced with serum-free DMEM containing 0.5 mg/mL MTT 
and further incubated in the CO2 incubators for 4 h. At the end of the incubation, the 
medium was removed followed by cells lysis with 100% (v/v) DMSO and the absorbance 
was taken at 570 nm as described in Section 2.2.8.  
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FeNTA (1:3) showed a concentration dependent reduction in cell viability at 625 µM and 
above (Figure 2.2.10a). The IC50 value for FeNTA (1:3) obtained by non-linear regression 
analysis was 457±32 µM. At this FeNTA (1:3) concentration, the equivalent NTA 
concentration is 1371 µM. The IC50 value derived from cell viability-NTA concentration 
response curve for each equivalent concentration of FeNTA (1:3) was 6383±308 µM with 
reduction of cells viability started at 3750 µM and above (Figure 2.2.10b). Exposure of 
500 µM FeNTA (1:3) on hepatoma cell lines, HepG2, only killed approximately 20% of the 
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Figure 2.2.10: Cell death of SH-SY5Y cells following exposure to FeNTA (1:3). 
SH-SY5Y cells were exposed to  a) FeNTA (1:3) (4-5000 µM) and b) NaNTA (12-15000 µM) for 20 
hours. Cell viability was assesed by the MTT assay, where untreated cells was recorded as ~100% 
viable and served as a control. Arrowhead indicates the final NaNTA concentration for the FeNTA 
(1:3) complex. Data are expressed as  mean±SEM  (n=3). Non-linear regression analysis 
[log(inhibitor) vs. response-variable slope (four parameters)] was performed to calculate the IC50 
(GraphPad Prism 7 Software). Degrees of freedom (df) = 24. * p <0.05, *** p <0.001 compared to 
control cells (one-way ANOVA followed by Dunnett’s test). 
 
To summarise, MG132 was the most toxic to SH-SY5Y as evaluated by MTT assay with 
IC50 value of 352 pM. This was followed by 6-OHDA (IC50 = 39 µM) and H2O2 (IC50 = 222 
µM). FeNTA was the least toxic of all toxicants with IC50 value of 457 µM. The IC50 
concentrations for toxins were rounded up to the nearest whole number and was used as 
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Table 2.2.2: Summary of the toxin with their IC50 use in the in vitro neuroprotection study.  
Toxins IC50  
Hydrogen peroxide (H2O2) 220 µM 
6-Hydroxydopamine 40 µM 
MG132 350 pM 
FeNTA (1:3) 460 µM 
 
 3-hydroxy-4-pyridinones 
Several concentrations of HPOs (5, 50, 100, 500, 1250, 2500 and 5000 µM) were tested 
for their toxicity against SH-SY5Y cells and the cell viability was measured with MTT 
assay. Main stock solution for CP20 and novel HPOs (50 mM) were prepared in sterile 
distilled water except for CP84 that was dissolved in 100% (v/v) DMSO. The working stock 
solution for HPOs (5000 µM) was prepared in serum-free DMEM from the main stock 
solution. A series of HPOs concentrations ranging from 5 to 5000 µM were prepared in 
serum-free DMEM from the HPOs working stock solution and were added (100 µL) into 
the 96-well plate containing 1x105 SH-SY5Y cells/mL. The cells were exposed to the 
various concentration of HPOs for 20 h in a CO2 incubator. Cells incubated with serum-
free DMEM was served as a control. After 20h exposure to HPOs, the medium was 
removed and replaced with free-medium containing 0.5 mg/mL MTT and further incubated 
in the CO2 incubators for 4 h. At the end of the incubation, the medium was removed 
followed by cells lysis with 100% (v/v) DMSO and the absorbance was taken at 570 nm 
as described in Section 2.2.8. 
 
CP20 did not cause significant cell death when compared to control group for all of the 
concentrations tested (Figure 2.2.11a). Similarly, CN116 and CN118 also did not cause 
cell death up to the highest concentration (5000 µM) tested when compared to control 
(Figure 2.2.11c). CN126 and CN128 caused significant cell death when compared to 
control at the highest concentration tested (5000 µM; Figure 2.2.11d). Conversely, CN226 
and CN228 started to lower the cell viability at 2500 µM compared to control with almost 
complete cell death following 5000 µM (Figure 2.2.11e). Among all HPOs, only CP84 
significantly killed the cells at 500 µM and above suggesting that it is relatively toxic 
compare to other HPOs (Figure 2.2.11b). 
  CHAPTER 2: MATERIALS AND METHODS 
111 
 
Comparison between equimolar concentrations of CP20 with novel HPOs revealed that 
treatment with CN126 and CN128 significantly lowered cell viability at 5000 µM. On the 
other hand, treatment with CN226 and CN228 significantly lowered cell viability at 2500 
and 5000 µM compared to equimolar concentration of CP20. Additionally, CP84 lowered 
the cell viability in a concentration-dependant manner starting at 500 µM when compared 
with equimolar concentration of CP20.  
 
SH-SY5Y cells have been shown to be resistance towards toxicity of deferioxamine, a 
hexadentate iron chelator due to higher level of ferritin expressed in SH-SY5Y compared 
to non-cancerous cells (Castino et al., 2011, Selig et al., 1998).  In this situation, the 
intracellular iron was sequestered and tightly bound within ferritin complex and was 
released as intracellular free-iron as needed for cellular functions. Because of the high 
number of ferritins in SH-SY5Y cells, more iron chelators are needed to compete with 
ferritin to bind iron until free-irons are depleted and causing cell death.  
 
The IC50 values for HPOs rounded up to the nearest whole number were listed in Table 
2.2.3. The selected concentration of HPOs used for in vitro neuroprotection study were 
50, 100 and 500 µM which have been shown to be sufficient to protect SH-SY5Y cells 
from toxin-induced cell death (Selig et al., 1998). In neuroprotection study employing 
FeNTA (1:3), HPOs concentrations for up to 1250 µM were used to show neuroprotection 
due to the nature of co-ordination chemistry for iron chelation. For CP84, the concentration 
employed was limited for up to 100 µM due to its marked toxicity at 500 µM (Figure 
2.2.11b). 


































































































































l) C N 1 1 6














































l) C N 1 2 6



















































l) C N 2 2 6









Figure 2.2.11: Effect of CP20 and novel HPOs on SH-SY5Y cells viability. 
SH-SY5Y cells were exposed to  HPOs (5-5000 µM) for 24 hours. Cell viability was assesed by the 
MTT assay, where untreated cells was recorded as ~100% viable and served as a control. Data 
are expressed as  mean±SEM  (n=3). *** p <0.001 compared to control group; ### p <0.001 
compared to CP20 (one-way ANOVA followed by Holm-Šídák multiple comparison test)   
  CHAPTER 2: MATERIALS AND METHODS 
113 
 
Table 2.2.3: IC50 values for HPOs assessed by MTT assay. 









na = not applicable; for this HPOs, an accurate IC50 value cannot be determined due to absence of 
inflection point in the log(toxin) vs. response-variable slope. Data are expressed as  mean±SEM  
(n=3). Non-linear regression analysis [log(toxin) vs. response-variable slope (four parameters)] was 
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 HPLC method validation for evaluation of selected 
novel 3-hydroxy-4-pyridinone iron chelators in rat 
brain and plasma for pharmacokinetics application. 
 Introduction 
Biological fluid or matrix such as urine, plasma, milk and brain homogenate often 
contained analytes inherent to the matrix that might interfere with the separation and 
efficiency of drug extraction (Siddiqui et al., 2017). In addition, recovery of HPOs spiked 
into NRS supplemented with BSA and brain homogenate were less than 100 percent for 
some HPOs when extracted with TFA (Section 2.1.9b iii), which requires correction for 
recovery during HPLC data analysis. The Food and Drug Administration, USA (US-FDA) 
had released guidelines for analysis of analytes in biological matrices (US-FDA, 2001). 
The guidelines suggested preparation of standard calibration curve by spiking a standard 
analyte into the relevant biological matrix rather that water, followed by extraction 
procedures similar to the actual biological samples so that preparation error could be 
minimised. Additionally, a second standard (internal standard) preferably with the same 
physicochemical properties of the main standard but with different retention time was also 
added at a constant concentration prior to the extraction (Pitt, 2009). The HPLC response 
was taken as the ratio of area under the curve (AUC) or height of the peaks for the main 
standard and internal standard.  This step could minimise the error that might be 
introduced during sample preparation such as during pipetting or during sample injection 
into HPLC. To ensure accuracy and reproducibility (precision) of the HPLC analysis within 
day (intraday) or between days (interday), concentrations of standard that covers the low, 
middle and high concentration were selected as quality controls to be run along the 
standard calibration curve (US-FDA, 2001). Accuracy is defined as the closeness of the 
obtained response to the expected response. On the other hand, precision measures the 
reproducibility of HPLC response in between analysis (Kadian et al., 2016). 
 
This section described the improved sample preparation method for HPO analysis in 
matrix other than water according to the guidelines provided by the US-FDA (2001). This 
step was taken to minimise error that might be introduced during sample preparation 
and/or flaws in the HPLC machinery for application in the pharmacokinetic study. 
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 Experimental animals 
Male Wistar rats weighing between 300-350 g (Harlan UK Ltd) and were housed between 
2-4 rats per cage in the Biological Service Unit (BSU), King’s College London. The 
conditions of the holding unit at BSU and rat diet were described previously in Section 
2.1.2. The experiments were approved under Animal (Scientific Procedure Act) 1986 and 
performed under the project license number 70/0688. 
 
 HPLC method validation in plasma and brain 
The method validation for HPOs determination in plasma and brain was performed 
according to the US-FDA Bioanalytical Method Validation Guidance for Industry (US-FDA, 
2001) with CP20 was used as an HPO prototype. Blanked plasma and brain were obtained 
from naïve rats. Upon confirmation of loss of reflex by toe pinching, the rats were terminally 
anaesthetised with 600 mg/kg pentobarbital sodium (Merial Animal Health Ltd, UK) by i.p. 
injection, the chest was open with a pair of scissors to expose the heart. Whole blood was 
collected by cardiac puncture using 21G needle attached to a 5 mL syringe and transferred 
into a heparinised tube. Whole blood was centrifuged at 5400 g, 4 ºC for 20 minutes and 
plasma removed and stored at -20º C until analysis. The brain was removed and 
homogenised in PhyBS in 1:3 (w/v) dilution and stored in -20º C. 
 
 HPOs solution preparation 
CP20 and CN226 were dissolved in HPLC water at a concentration of 50 mM which was 
used as main stock solution.  Dilutions of CP20 (20 to 1250 µM) were prepared from the 
CP20 stock solution in HPLC water for calibration curve and quality control (QC) 
preparation. CN226 working stock solution at 200 µM was prepared from the CN226 main 
stock solution and was used as an internal standard (IS). 
 
 Standard calibration curve 
CP20 calibration curve with concentrations ranging from 2 to 125 µM were prepared in 
blank plasma and brain from naïve rats. CP20 (20-1250 µM; 20 µL) was spiked into 180 
µL blank matrices (plasma or brain) followed by 22 µL internal standard (CN226) working 
solution. TFA (22 µL) was added to the spiked matrices so that the final concentration of 
TFA was 9.1% (v/v). The mixture was vortexed and centrifuged at 20800 g, 4º C for 45 
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minutes. Clear supernatant was taken and injected (30 µL) into HPLC for analysis. The 
method for analysis of HPOs in the plasma and brain was performed as described in 
Section 2.1.9b. The ratio of the CP20 and CN226 peak height was calculated and plotted 
for linear regression analysis.  
 
𝐻𝑃𝐿𝐶 𝑠𝑖𝑔𝑛𝑎𝑙 =
𝑃𝑒𝑎𝑘 ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐶𝑃20
𝑃𝑒𝑎𝑘 ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐶𝑁226
     Equation 2.3.1 
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Figure 2.3.1: Representative chromatogram for CP20 and CN226 spiked into rat plasma or 
brain homogenate. 
CP20 and CN226 retention times were ~8.3 minute and ~9.1 minute respectively. 
 
Linear regression analysis was performed on the linear plot of CP20 to CN226 height ratio 
against CP20 concentrations to obtain the linear equation y = mx + C. 
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Figure 2.3.2: Representative standard calibration curve of CP20 spiked into blanked plasma 
and brain. Data was analysed by least-square linear regression analysis (GraphPad Prism 7 
Software). 
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Lower limit of detection (LOD) is defined as the lowest concentration in the standard curve 
that can be detected by the HPLC system, but cannot be accurately quantify (Armbruster 




        Equation 2.3.2 
Where, σ is standard deviation of the residuals of the calibration curve linear equation, y 
= mx + C, and m is the slope of the line. 
 
Lower limit of quantification (LOQ) is defined as the lowest concentration in the standard 
curve that can be accurately quantify (Armbruster and Pry, 2008). LOQ was calculated 




        Equation 2.3.3 
Where, σ is standard deviation of the residuals of the calibration curve linear equation, y 
= mx + C, and m is the slope of the line. 
 
LOD and LOQ for CP20 spiked into blanked plasma were approximately 0.5 and 2 µM 
(Table 2.3.1). On the other hand, LOD and LOQ for CP20 spiked into brain homogenate 
were about twice the value in plasma (Armbruster and Pry, 2008). Therefore 2 µM and 4 
µM were selected as the minimum concentration to construct standard calibration curves 
for CP20 spiked into plasma and brain respectively. 
 
Table 2.3.1: LOD and LOQ of CP20 spiked into rat brain and plasma. 
Matrices LOD (µM) LOQ (µM) 
Plasma 0.55±0.14 1.82±0.46 
Brain 1.19±0.14 3.95±0.8 
Data are expressed as  mean±SEM  (n=3 independent standard calibration curve). 
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 Quality control 
Three quality controls (QC) that covers low (4 µM), middle (16 µM) and high (64 µM) 
concentrations were prepared from the CP20 working solution in 3 different vials for each 
concentration. QC samples were prepared by spiking CP20 into blank plasma or brain 
homogenate, extracted and analysed by one working day for intraday analysis or by 3 
consecutive days for interday analysis. Accuracy gives an information on how far the 






  𝑋 100     Equation 2.3.4 
 
Precision gives an information on how close the similarity of the obtained concentration 





  𝑋 100     Equation 2.3.5 
Based on the guidelines provided by the US-FDA Bioanalytical Method Validation 
Guidance for Industry (2001), accuracy and precision for intraday and interday analysis 
should be within ±15-20% from the expected concentration. Intraday and interday analysis 
revealed that both accuracy and precision for CP20 spiked into blanked plasma or brain 
were within the accepted range as suggested by the guidelines (Table 2.3.2 and Table 
2.3.3). 
 
Table 2.3.2: Intraday assay precision and accuracy for CP20 in rat plasma and brain 
Matrices Concentration Accuracy (%) Precision 
(%) 
Plasma 
4 92.3 3.5 
16 109.7 7.5 
64 107.3 1.5 
Brain 
4 84.3 2.5 
16 98.2 1.7 
64 95.1 2.2 
Accuracy represent the mean values (n=3 injection in one day). 
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Table 2.3.3: Interday assay precision and accuracy for CP20 in rat plasma and brain 
Matrices Concentration Accuracy (%) Precision 
(%) 
Plasma 
4 92.6 7.1 
16 106.8 3.0 
64 103.9 2.8 
Brain 
4 90.8 14.2 
16 96.3 3.8 
64 92.5 7.7 
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 Determination of optimum 6-OHDA dose for striatal 
injection in rat 
 Introduction 
PD is pathologically characterised by loss of dopaminergic neurons in basal ganglia 
specifically the neurons that made up the nigro-striatal pathway in the midbrain area, with 
the cell bodies located within the substantia nigra pars compacta (SNPc) region and the 
axons projection terminate in the striatum (Alexander, 2004). In an animal model of PD, 
the loss of dopaminergic neurons was induced by injection of toxins either systematically 
or directly to the area associated with the nigro-striatal dopaminergic tract (Tieu, 2011, 
Bové et al., 2005, Duty and Jenner, 2011). Specific areas in this tract namely striatum, 
medial forebrain bundle (MFB) and SNPc have been targeted for induction of cell death 
depending on the aim of study (Duty and Jenner, 2011).  
 
Unilateral 6-OHDA rat model is extensively use during the early stage of drug discovery 
and development due to the model mirror some of the important aspect of pathogenesis 
and biochemistry of PD such as oxidative stress and reduced level of striatal dopamine 
and tyrosine hydroxylase (TH) (Duty and Jenner, 2011). 6-OHDA is the metabolite of 
dopamine that can generates oxidative stress via mechanism explained in detail in 
Section 2.2.1b. One main drawback of the 6-OHDA model is the need of substantial 
surgical training to administer the 6-OHDA into the brain using a stereotaxic technique due 
to the inability of 6-OHDA to cross the BBB in contrast to other toxins such as 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) that can be administered systematically 
creating bilateral lesion (Kostrzewa and Jacobowitz, 1974, Duty and Jenner, 2011). On 
the other hand, unilateral lesions by stereotaxic technique allow the use of the contralateral 
hemisphere as an internal control of cell loss measurement (Duty and Jenner, 2011). 
Furthermore, the unilateral 6-OHDA-lesion model shows a rotational pattern ipsiversive or 
contraversive to the lesion site when injected with amphetamine or apomorphine 
respectively, that can be used as an indicator of lesion severity (Torres and Dunnett, 2007, 
Jerussi and Glick, 1975).   
 
For neuroprotection studies, partial unilateral 6-OHDA lesions (40% to 60% cell loss in 
SNPc) are often generated to allow the assessment of efficacy of potential disease 
modifying agents.  By contrast, full lesion (>90% cell loss in SNPc) are more appropriate 
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to assess drug that is intended for symptomatic relief such as L-DOPA (Duty and Jenner, 
2011). This is because, partial lesion represents the early stage of PD where the cardinal 
motor symptoms are absent contrary to the full lesion that represents the late stage of PD 
where the cardinal motor symptoms are visible. Generation of partial or full lesion of 6-
OHDA model is largely depending on the doses used to create the lesions. Moreover, the 
location of the 6-OHDA injection for partial lesion dictate the rate of progression of the 
nigral cell loss with striatal injection showing slower progress (maximal cell loss within 3 
weeks after lesion) compared to injection into SNPc or MFB that have maximal cell loss 
within 2 weeks after the 6-OHDA treatment (Duty and Jenner, 2011).  
 
This section described the method used to create a partial unilateral 6-OHDA-lesioned rat 
model of Parkinson’s disease and the subsequent techniques to determine the extent of 
cell death. Three doses of 6-OHDA were employed to determine the optimum dose for 6-
OHDA that will be used in in vivo neuroprotection study. 
 
 Animals   
Male Wistar rats weighing between 225-250 g (Harlan UK Ltd) and were housed between 
2-4 rats per cage in the Biological Service Unit (BSU), King’s College London. The rats 
were allowed to acclimatise for at least a week after arrival at BSU before the striatal 
lesion. Only rats that reached the weight between 250 to 300 g after a week of 
acclimatisation were used for the lesion. The conditions of the holding unit at BSU and rat 
diet were described in Section 2.1.2. The experiments were approved under Animal 
(Scientific Procedure Act) 1986 and performed under the project license number 70/7977. 
 
 6-Hydroxydopamine (6-OHDA) preparation 
The concentration of 6-OHDA HCl (Sigma-Aldrich, UK) was calculated as a free base and 
dissolved in 0.9% (w/v) NaCl (Sigma-Aldrich, UK) containing 0.1% (w/v) L-ascorbic acid 
(Sigma-Aldrich, UK) on the day of surgery. Concentrations of 6-OHDA prepared for striatal 
injection were 1 mg/mL, 2 mg/mL or 3 mg/mL. Aliquots of 6-OHDA (1000 µL) were 
wrapped with aluminium foil to protect from light and was kept on ice. The prepared 6-
OHDA aliquots were used within 6 hours of preparation. 
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 Intrastriatal injection of 6-OHDA 
The aliquot of 6-OHDA (1 mg/mL, 2 mg/mL or 3 mg/mL) in a total volume of 4 µL was 
injected using a microsyringe into striatum to develop a unilateral lesioned of rat PD model. 
The dose for each concentration was listed in Table 2.4.1. The details of the surgical 
procedures performed under a sterile condition were outlined below. 
Table 2.4.1: The concentrations and doses of 6-OHDA injected into the rat left striatum. 
Concentration Dose injected 
1 mg/mL 4 µg 
2 mg/mL 8 µg 
3 mg/mL 12 µg 
6-OHDA was prepared in in 0.9% (w/v) NaCl containing 0.1% (w/v) L-ascorbic acid.  The dose 
volume was 4 µL/rat 
 
 Surgery 
Rats were anaesthesised with 5% (w/w) isoflurane (IsoFlo®, Abbott, UK), delivered in 
100% (w/w) O2 for 2 minutes in an anaesthetic chamber. Anaesthesia was confirmed by 
the absence of reflex to toe pinching and eye tapping. Following this, the head of the rat 
was shaved, and the rat was secured in a prone position with the ear bars placed 
symmetrically into a Kopf® stereotaxic frame (David Kopf Instruments, USA) and tooth-bar 
set at -3.3 mm (Paxinon and Watson, 2004). The isoflurane was delivered at 5% (w/w) 
through a nose cone to maintain anaesthesia. The temperature was maintained at 37 ºC 
during the entire procedure using a homoeothermic blanket with rectal probe. The secured 
rat was surgically prepared by disinfecting the scalp with diluted chlorhexidine gluconate 
[0.4% (w/v)] (Hibiscrub®, Mölnlycke Health Care Ltd, UK) and followed by s.c. injection 
with 1 mg/kg bupivacaine HCl (Marcaine®, AstraZeneca Ltd, UK) at the site of incision. 
Eye gel (Viscotears®, Alcon Laboratories Ltd, UK) was generously applied on the rat eyes 
to prevent eye dryness during the surgery. Subsequently, the isoflurane flow was reduced 
to 3% (w/w). The complete surgical set-up is illustrated in Figure 2.4.1.  
 




Figure 2.4.1: Surgical setup for stereotaxic brain lesion procedure. 
Flowing O2 (►) is mixed with isoflurane in the isoflurane chamber. Blue circuit (►) is activated for 
induction of anaesthesia by isoflurane in the anaesthesia induction chamber. Red circuit (►) is 
activated once the anaesthetised rat is placed on the heating pad for maintaining of anaesthesia. 
Flowing isoflurane was terminally adsorbed on the activated charcoal. 
 
 Lesion induction 
An incision was made on the scalp with a sterile disposable scalpel (SP Services Ltd, UK) 
to expose the skull. The skull was cleaned of tissues remnant with the scalpel blade and 
cleaned from blood with sterile cotton buds, exposing bregma. During this time, the 
isoflurane dose was reduced to and maintain between 1-2% (w/w). Coordinate of the 
striatum on the left hemispheres were taken from the bregma according to the rat brain 
atlas of Paxinos and Watson (2004): anterior = +1.0 mm, lateral = +3.0 mm, and ventral = 
-5.5 mm) (Figure 2.4.2) using a Vernier scale on the stereotaxic frame. A burr hole (0.5 
mm ID) was then made in the skull over the lesion site. The needle tip was slowly lowered 
to the lesion site, and the left striatum was injected with 6-OHDA (4 µL at 1 µL/min over 4 
minutes) using a 10 μL 1701ASRN Hamilton® microsyringe fitted with a 26s-gauge 
Hamilton needle (Essex Scientific Laboratory Supplies Ltd, UK). The total amount of 6-
OHDA injected was 4, 8 or 12 µg in a total volume of 4 µL. Sham rats were injected with 
vehicle [4 µL of 0.9% (w/v) NaCl containing 0.1% (w/v) L-ascorbic acid] using the same 
co-ordinates.  The needle was left at the injection site for 4 minutes to ensure complete 
diffusion of 6-OHDA into surrounding tissues and prevent reflux along the needle tract and 
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was then slowly removed. The incision was closed with 16 mm Ethicon-coated vicryl 
absorbable sutures (Johnson’s & Johnson’s, UK) and 5% (w/w) prilocaine and lidocaine 
cream (EMLATM, AstraZeneca Ltd, UK) was applied on the wound area. Glucose [5% (w/v) 
in 0.9% (w/v) NaCl, 10 mL] was injected i.p. to avoid dehydration. Subsequently, the rat 
was injected s.c. with 0.01 mg/kg buprenorphine HCl (Alstoe Animal Health, UK). The rat 
was taken out from the stereotaxic frame to the pre-warmth cage for recovery before 
returning to the housing unit at BSU. Surgical equipment was sterilised with autoclave 
machine (Prestige Medical Ltd, UK) prior to and in-between procedures. 
 
Anatomical location From the bregma (mm) 
Anterior-Posterior (AP) +1.0 
Medial-Lateral (ML) +3.0 
Dorsal-Ventral (DV) -5.5 
 
Figure 2.4.2: Site and co-ordinate of left striatum base on Paxinos and Watson (2004) for 
intrastriatal injection of 6-OHDA in rat.  The red dot (●) depicts the site of injection in the 
striatum. 
 
 Post-operative care 
Rats were given water-softened pellet and Recovery DietGel® (ClearH2O®, UK) for 3 days 
after surgery. The rats were weighed daily until reaching their pre-operative weight. If their 
weight was reduced by 5% of their pre-surgery body weight, the rats were injected i.p. with 
5% (w/v) glucose in 0.9% (w/v) NaCl. Figure 2.4.3 showed the body weight for rats before 
and after the brain lesion procedures. The body weights were slightly decreased a day 
after the procedures but slowly regained the pre-surgical body weight 4 to 5 days after the 
surgery and were steadily increased afterwards which suggest a good recovery.  
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Figure 2.4.3: Recorded body weight on the day of lesion and after lesioned for up to 14 days. 
n=4 rats. 
 
 D-amphetamine rotation test 
On the day 14th after the lesion, the rats were subjected to D-amphetamine rotation test 
using an automated rotometer system (RotoRatTM, Med Associates, Inc., USA). This study 
was performed to evaluate the effect of partial-lesioned in the rat striatum as D-
amphetamine induced imbalance in dopamine release from the presynaptic terminal 
between intact and lesioned sites. The imbalance of dopamine level between these two 
sites induce ipsilateral rotations towards the lesioned site (Torres and Dunnett, 2007). 
Figure 2.4.4 illustrates the principles of this behaviour assessment. 
 
Figure 2.4.4: Illustration of the 6-OHDA lesioned in the left striatum and the expected 
ipsilateral rotation after injection with D-amphetamine.  
 
To determine D-amphetamine induces rotations, rats were strapped with a tethered jacket 
attached to a sensor in the rotometer. The rats were allowed to acclimatise to the 
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rotometers for 30 minutes after which baseline activity was recorded using the RotoRatTM 
hardware and RotoRatTM software Version 2.0 for 30 minutes. Following this, the rats were 
injected i.p. with 2.5 mg/kg D-amphetamine sulphate (Tocris Bioscience, UK) prepared in 
0.9% (w/v) NaCl and the number of rotations were recorded for 3 hours. The sensor was 
set to record the 45˚ rotation in one-minute period. The numbers of complete 360o rotations 
were collated into 10-minutes time bin for the total of 3 hours. Data was automatically 
recorded into two columns, which display counter-clockwise and clockwise rotations. To 
calculate the complete circle rotation (360˚ rotation), the data were divided by eight since 
360÷45 = 8 followed by subtracting counter clockwise rotations from clockwise rotations 
to give the net ipsilateral rotations per 10 minutes per animal (Figure 2.4.5).  
 
There was no significant different of D-amphetamine induced ipsilateral rotations between 
6-OHDA treated group and vehicle treated group (Figure 2.4.5e). The lack of difference 
between groups was due to the high variation of rotational behaviour in 6-OHDA-treated 
group (Figure 2.4.5b, c, and d). Indeed, this observation is in accordance with previous 
reports that showed a lack of relationship between the number of net ipsilateral rotations 
and the size of lesion in the unilateral 6-OHDA partial lesion PD model (Hudson et al., 
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Figure 2.4.5: D-Amphetamine rotation test for 6-OHDA unilateral striatal lesioned rat. 
Individual net ipsilateral rotation of rat injected with D-amphetamine for a) Vehicle b) 4 µg/µL 6-
OHDA c) 8 µg/µL 6-OHDA and d) 12 µg/µL 6-OHDA. e) The mean AUC of net ipsilateral rotation 
for each treatment group. Data are mean+SEM (n=4 rats). 1-way ANOVA analysis showed no 
significant different. 
 
 Brain fixation 
Rats were terminally anaesthetised with 600 mg/kg pentobarbital sodium (Merial Animal 
Health Ltd, UK) two-days after D-amphetamine test. The brain was perfused-fixed with 50 
mL 4% (w/v) PFA in 0.1 M PBS, pH 7.4 by transcardial perfusion using a 19G needle 
attached to a 50 mL syringe. The brain was post-fixed with 4% (w/v) PFA for 3 days. The 
fixed brain was then cryoprotected with 30% (w/v) sucrose (Sigma-Aldrich, UK) containing 
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0.05% (w/v) sodium azide (NaN3; Sigma-Aldrich, UK) in 0.1 M PBS (pH 7.4) until the tissue 
sank (~3-5 days). 
 
 Brain sections 
Coronal sections (30 μm) of rat brains were cut using a freezing microtome (Leica SM 
2000R; Leica Biosystem, UK). Substantia nigra pars compacta (SNpc) was sectioned at 
the level of the third nerve and striatum was sectioned approximately between -1.4 mm to 
2.0 mm AP from the bregma (Paxinos G. & Franklin F., 2004). Striatum sections were 
categorised anatomically into caudal (AP: ~-1.4 mm from the bregma), medial (AP: ~1.0 
mm from the bregma) and rostral (AP: ~2.0 mm from the bregma). Free floating sections 
were collected into 24-well plates (5 sections/well) filled with 0.1 M PBS and 0.05% (w/v) 
NaN3 for immunohistochemical staining. 
 
 Immunohistochemical staining 
 Day 1 
Coronal brain sections (2-4 sections) of SNPc and striatum were incubated with 0.3% (w/v) 
H2O2 in 0.1 M PBS, pH 7.4 (1 mL) for 30 minutes on a shaker to block the endogenous 
peroxidase at room temperature. The sections were washed with 0.05% (w/v) Triton-X100 
in 0.1 M PBS, pH 7.4 (PBS-T) followed by incubation with 1% (w/v) BSA in PBS-T on a 
shaker for at least one hour. Subsequently, the sections were incubated for at least 12h 
on a shaker with 1 mL polyclonal rabbit anti-rat tyrosine hydroxylase (TH) primary antibody 
(Pel-Freeze Biologicals, USA) prepared in 1% (w/v) BSA in PBS-T [1:500 (v/v) and 1:200 
(v/v) dilutions for SNPc and striatum respectively]. 
 Day 2 
The sections were washed with 1 mL PBS-T followed by incubation for one hour on a 
shaker with 0.5 mL biotinylated goat anti-mouse IgG secondary antibody (Vector 
Laboratories, UK) prepared in PBS-T at room temperature. The sections were washed 
with 1 mL PBS-T followed by incubation with 1 mL avidin-biotin complex (ABC) reagent 
(Vector Laboratories, UK) for 45 minutes on a shaker. Subsequently, the sections were 
washed with 0.1M PBS followed by incubation with 1 mL 0.05% (w/v) 3,3'-
diaminobenzidine (DAB) prepared in 0.01% (w/v) H2O2 in 0.1 M PBS for ~3 minutes. The 
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sections were transferred into 1 mL PBS whereby the washing steps were repeated three 
times. Two to four sections were mounted onto coated adhesion slides (Polysine®, Thermo 
Scientific, UK) and were dried overnight. 
 Day 3 
Dried sections were dehydrated with three series of increasing ethanol concentrations [70, 
98 and 100% (v/v)] for 5 minutes each. Following this, the sections were immersed in 
Histoclear® clearing agent (Fisher Scientific, Leicestershire, UK) for 15 minutes. 
Immediately after taking out from the Histoclear® solution, the sections were covered with 
DePeX mounting medium (VWR International, UK). The sections were covered with a 
coverslip (22x50cm; VWR International, UK), and left to dry in fume cupboard overnight. 
 Quantification of immunoreactive cells  
Positively stained TH cells in the SNPc were counted bilaterally from three to five sections 
per rat at 10X magnification under a light microscope (Zeiss Axioskop, Carl Zeiss, UK) in 
a blinded manner. The number of positively labelled cells was expressed as the mean of 
the counts obtained from the representative sections (n=3-5). Positively stained TH cells 
in the striatum on the other hand were determined by measuring the optical density (OD) 
using ImageJ software (Version 1.32; National Institute of Health, USA) due to the high 
density of TH staining in this region (Schneider et al., 2012). SNPc images (Figure 2.4.6) 
were taken using the Axio Vision software, powered by the Zeiss Axiocam camera. 
Striatum images were taken with DSLR camera (Nikon, Japan) in AV mode (Figure 2.4.8, 
top panel). 




Figure 2.4.6: Representative photomicograph of brain coronal section at 2.5X magnification 
showing basal ganglia. 
The oval circle in a) indicates the SNPc region where TH+ cells were counted. Inset a’) shows the 
TH+ cells at 10X magnification. The black line on each photomicrograph marks the third cranial 
nerve that demarcate the dopaminergic neurons cell bodies in SNPc and VTA.  
 
The percentage of TH+ cells in SNPc relative to the contralateral site after striatal injection 
with 4 µg/µL, 8 µg/µL and 12 µg/µL 6-OHDA were 51%, 58% and 65% respectively (Figure 
2.4.7). Comparison of the ipsilateral sites in vehicle lesioned group with 6-OHDA lesioned 
groups revealed significant different in the percentage of TH+ cells for 4 µg/µL and 8 µg/µL 
6-OHDA, but not for 12 µg/µL which only showed a trend towards significant cell loss. It 
has been reported by Lee et al. (1996) that the TH+ cells did not necessarily correlate with 
the 6-OHDA dose infused into the striatum.  
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Figure 2.4.7: TH+ cell counts in the ipsilateral and contralateral SNPc. 
Data are expressed as mean+SEM (n=4 rats). Graph a) ** p < 0.01, *** p < 0.001 compared to the 
contralateral hemisphere.  # p < 0.05, ## p < 0.01 compared to the ipsilateral hemisphere of vehicle 
group (two-way ANOVA followed by Holm-Šídák multiple comparison test). 
 
Analysis of the intensity of TH staining in the caudal, medial and rostral striatum revealed 
a substantial lesioned in the medial striatum (AP: 1.0 mm from the bregma) in agreement 
with the co-ordinate where 6-OHDA was injected (Figure 2.4.8b, top panel); Paxinos G. 
& Franklin F., 2004). The percentage of optical density for TH staining in medial striatum 
relative to the contralateral site for 4 µg/µL, 8 µg/µL and 12 µg/µL 6-OHDA were 67%, 
52% and 53% respectively (Figure 2.4.8b, bottom panel). Based on these data, 8 µg/4 
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Figure 2.4.8: Top panel: Representative photomicrographs of TH+ striatum. Bottom panel: 
Optical density for TH immunostaining in a) caudal, b) medial and c) rostral striatum 
following intrastriatal administration of varying doses of 6-OHDA. 
Data are expressed as mean+SEM (n=4 rats). ** p < 0.01, *** p < 0.001 compared to the 
contralateral hemisphere.  # p < 0.05, ## p < 0.01 compared to the ipsilateral hemisphere of vehicle 
group (two-way ANOVA followed by Holm-Šídák multiple comparison test).  
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3 Evaluation of novel 3-hydroxy-4-pyridinone 
bidentate iron chelators penetration to the 
brain 
 Introduction 
In pilot clinical trials investigating the effect of orally active hydoxypyridinone (HPO) iron 
chelators in PD patients, deferiprone (CP20) has been shown to improve the motor 
symptom and slow disease progression (Devos et al., 2014, Abbruzzese et al., 2011). 
However, CP20 showed poor efficacy following oral administration as 85% of the 
administered dose undergoes extensive metabolism to inactive glucuronide metabolites 
(Singh et al., 1992). For this reason, repeated administration of large doses of CP20 (30 
mg/kg/day) is required to maintain effective plasma levels. However, large doses of CP20 
are associated with agranulocytosis and cytopenia that are prevalent in older patients 
(Andres et al., 2002, Mohan et al., 2015, Rajagopal, 2005). Since over 1% of general 
population over the age 60 years old are affected with PD (de Lau and Breteler, 2006), 
long-term treatment with CP20 is not viable. To overcome this problem, a set of CP20 
derivatives with chiral N-hydroxyalkyl substituent (CN compounds) were designed to limit 
glucuronidation and showed better efficacy than CP20 after oral administration in rats 
(Figure 3.1.1; Hider et al., 2011).  
                                                        
Figure 3.1.1: General chemical structure of CP20 chiral N-hydroxyalkyl derivatives (CN 
compounds). Structure in blue shows the main CP20 structure, while structure in red show 
additional functional group. Carbon atom marked with * is chiral centre and R represent alkyl 
functional group. 
 
Interestingly, these CP20 derivatives exhibited better toxicity profiles than CP20 as 
assessed in mice (Hider et al., 2011a). The combination of the better efficacy and reduced 
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toxicity profiles of the CN compounds prompts further investigation as potential drugs for 
the treatment of PD.  
 
In addition to the CN compounds, one derivative of CP20 (CP84) containing a N-phenyl 
substituent is also of interest. CP84 has iron affinity constant similar to CP20 and showed 
greater brain permeability than CP20 in in vitro study (Fuchs, 2015). CP84 inhibited 
aggregation of amyloid-β in presence of metals ion and showed superior antioxidant 
activity compare to α-tocopherol and butylated hydroxytoluene (BHT) (Schugar et al., 
2007). However, CP84 has poor brain penetrability, and so was modified to target the BBB 
glucose transporter.  Glucose transporters are abundantly express at BBB as described 
in detail in Section 1.1.9. As a proof of concept to specifically target glucose transporter 
at blood-brain barrier (BBB), glucose conjugated CP84 (FCF132) was sucessfully 
synthesised (Schugar et al., 2007, Roy et al., 2010) and investigated in these studies. 
 
The ability of theses iron chelators to cross the BBB in order to reach the target site is vital 
for potential treatment of PD. Indeed, the positive outcome with CP20 in PD patients was 
partly due to its ability to enter the brain via passive membrane diffusion (Glickstein et al., 
2005, Hider et al., 2011b). In fact, CP20 not only chelates excess iron in brain, but also 
the CP20-iron complex formed in the brain is also able to permeate out and redistribute 
iron to the circulated transferrin in the plasma (Evans et al., 2012, Abbruzzese et al., 2011, 
Ayton et al., 2016, Cabantchik et al., 2013). As the BBB is a complex lipid barrier with 
multitude of transport mechanisms as described in Section 1.1.9, single alteration in the 
CP20 chemical structure could alter brain permeability. The addition of chiral hydroxyalkyl 
or phenyl groups on CP20 molecule increase lipophilicity and might consequently improve 
simple membrane diffusion of novel HPOs as explained in Section 1.1.9. Likewise, 
presence of glucose on HPO molecule might enhance brain permeability via interaction 
with specific transporters at BBB. Therefore, it is crucial to determine the brain permeability 
for this new set of compounds.  
 
In this study, a set of CP20 derivatives with chiral N-hydroxylalkyl substituent were 
evaluated for brain permeability by using in situ brain perfusion technique. In addition to 
these chiral N-hydroxyalkyl derivatives, two other HPOs were also evaluated for brain 
permeability with one of them specifically target the glucose transporters at BBB. 




It was hypothesised that modification to the structure of CP20 can improve the efficiency 
of BBB transport because of increase in lipophilicity or addition of glucose moiety. 
 Aims 
To test this hypothesis, in situ brain perfusion studies were performed with the following 
aims: 
 To evaluate the brain permeability of novel HPO bidentate iron chelators in 
comparison with CP20. 
 To evaluate the effect of chirality of CN compounds to the brain uptake. 
 To evaluate the contribution of transporters to the HPO brain uptake. 
 To evaluate the relationship between brain uptake and HPO. 
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 Materials and methods 
In situ brain perfusion studies were performed to evaluate the brain permeability of CP84, 
FCF132, CN116, CN118, CN126, CN128, CN226 and CN228 (Table 3.2.1). Brain uptake 
and rate of brain uptake for all the HPOs were determined and compared with CP20. 
Selected HPOs were evaluated for interaction with transporters at BBB by using selective 
transport inhibitors. Finally, least-square regression analysis was performed between 
HPO brain uptake and selected HPO physicochemical properties namely lipophilicity 
(cLogP), molecular weight (MW) and total polar surface area (TPSA). Detailed 
methodology is described below. 
 Animals 
Male Wistar rats weighing between 250-300 g (Harlan UK Ltd) and were housed between 
2-4 rats per cage at BSU, King’s College London as described in Section 2.1.2. 
 HPO 
Nine HPOs including CP20 (Table 3.2.1) were evaluated for brain permeability using the 
validated in situ brain perfusion technique as described in Chapter 2. CP20 was 
purchased from Sigma (UK). All other compounds were donated by Professor Robert C. 
Hider to perform this study. The synthesis route and potential application of the novel iron 
chelators was patented under the patent number EP 2692724 A1 (Hider et al., 2011a). 
 Brain uptake studies 
HPOs listed in Table 3.2.1 were evaluated for their brain permeability. In order to 
determine the brain uptake of novel HPOs, in situ brain perfusions were performed with 
500 µM HPO as described in Section 2.2.15. Briefly, a polyethylene (PE) cannula was 
inserted into carotid arteries of anesthetised and heparinised rat one at a time. Jugular 
veins were cut to allow outflow drainage of NRS perfusion fluid from the perfused brain. 
After flushing of cerebral blood with perfusion fluid, perfusion with HPO was started for 20 
minutes as optimum perfusion time as described in detail in Section 2.1.14. At the end of 
20 minutes, the cannulas were removed from the rat carotid arteries and the perfusate 
was collected from the end of the cannula for HPO quantification in the perfusate by HPLC. 
Following this, the rat was decapitated, the brain was taken out and process as described 
in Section 2.1.7 for quantification of HPO in the brain by HPLC. 
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Table 3.2.1: List of HPOs, their chemical structures and selected physicochemical properties 
[lipophilicity (cLogP), molecular weight (MW) and total polar surface area (TPSA)]. 






































































































Chemical structure was drawn using ChemDraw Software (Version 15.1; Perkin-Elmer, USA). CP20 chemical 
structure was coloured red. Paired of CN compound was enantiomer at chiral carbon (*) with 6-suffixed 
indicate S-orientation while 8-suffixed indicate R-orientation. 
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 Brain uptake-inhibition studies 
Brain uptake-inhibition study was performed on selected HPO using either substrate 
inhibition or specific transporters inhibitor to evaluate the contribution of any transport 
mechanism to the brain uptake. CP20, CP84, FCF132, CN118, CN128 and CN226 were 
employed on this study. 
 Concentration-competition study 
CP84 (5, 50 or 250 µM) was perfused into the rat brain for 20 minutes to determine whether 
uptake was saturable. At the end of 20 minutes, the PE cannulas were removed from the 
rat carotid arteries and the perfusate was collected from the end of the cannula for HPO 
quantification in the perfusate by HPLC. Following this, the rat was decapitated, the brain 
was taken out and process as described in Section 2.1.7 for quantification of HPO in the 
brain by HPLC. 
 Transporter inhibition study  
i) CP84: competition with BCH (large neutral amino acid, LAT-1) 
analogue 
CP84 (50 or 500 µM) was co-perfused with 2-amino-2-norbornanecarboxylic acid (BCH; 
Sigma, UK), a known inhibitor for LAT-1 carrier for 20 minutes. The reported concentration 
of BCH (10 mM) that sufficiently inhibits LAT-1 was used in this study (Ennis et al., 1998). 
At the end of 20 minutes, the PE cannulas were removed from the rat carotid arteries and 
the perfusate was collected from the end of the cannula for HPO quantification in the 
perfusate by HPLC. Following this, the rat was decapitated, the brain was taken out and 
process as described in Section 2.1.7 for quantification of HPO in the brain by HPLC. 
ii) FCF132 (glycosylated HPO): Low-glucose study 
Experiments with lower concentration of glucose (1 mM) in the perfusate were performed 
to reduce substrate competition between glucose and FCF132 for GLUT-1. To support 
normal brain physiology and metabolism during perfusion with lower glucose, 1 mM 
pyruvate was supplemented in the NRS (Cater et al., 2001). At the end of 20 minutes, the 
PE cannulas were removed from the rat carotid arteries and the perfusate was collected 
from the end of the cannula for HPO quantification in the perfusate by HPLC. Following 
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this, the rat was decapitated, the brain was taken out and process as described in Section 
2.1.7 for quantification of HPO in the brain by HPLC. 
iii) Brain efflux-pump inhibition study for CP20, CN118, CN128 and CN226 
Selected HPO namely CP20, CN118, CN128 and CN226 (500 µM) were co-perfused with 
a P-glycoprotein (Pgp) efflux-pump inhibitor, cyclosprorin A (CsA) for 20 minutes. 
Concentration of CsA used was 5 µM to cause substantive inhibition of Pgp efflux-pump 
as reported in literatures (Avdeef and Sun, 2011). At the end of 20 minutes, the PE 
cannulas were removed from the rat carotid arteries and the perfusate was collected from 
the end of the cannula for HPO quantification in the perfusate by HPLC. Following this, 
the rat was decapitated, the brain was taken out and process as described in Section 
2.1.7 for quantification of HPO in the brain by HPLC. 
 Brain uptake calculation 
Brain uptake was calculated as described in Section 2.1.11. Brain uptake of total HPO in 
whole brain (RBr,u) and capillary depleted brain (RCd,u) were compared to evaluate the HPO 
trapping in BCEC. Additionally, brain uptake of unbound HPO in brain (RCd,uu) was used to 
describe the pharmacologically active HPO in brain. RCd,uu was transformed to rate of brain 
uptake (Kin,Cd,uu) by dividing with total perfusion time as described in Section 2.1.11.  
For concentration-competition study with CP84, total flux (Jin,total) was calculated as 
follows: 
𝐽𝑖𝑛,𝑡𝑜𝑡𝑎𝑙(𝑛𝑚𝑜𝑙/𝑚𝑖𝑛/𝑔) = 𝐾𝑖𝑛,𝐶𝑑,𝑢𝑢  ∗  𝐶   Equation 3.2.1 
Where Kin,Cd,uu is the rate of brain uptake for HPO perfused at a defined concentration, C. 
Jin,total was fitted into Michaelis-Menten kinetics which consist of saturable (facilitated 
diffusion) and unsaturable (membrane diffusion) components of brain uptake (Pardridge, 




+ (𝐾𝑑 ∗  𝐶)    Equation 3.2.2 
Where Vmax is the maximal velocity of brain uptake for saturable component, Km is the 
concentration of HPO at half-Vmax and Kd is the membrane diffusion constant of 
unsaturable component. The Kd was determined by calculating the slope of flux against 
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concentration for values after saturation using least-square linear regression analysis. 
Saturation points are the points which the values did not significantly different from each 
other. The Kd was multiplied with C to obtain the brain uptake of unsaturable component, 
i.e. membrane diffusion, Dm (Equation 3.2.3). 
𝐷𝑚 = 𝐾𝑑 ∗  𝐶       Equation 3.2.3 
Jin,net was obtained by subtracting Dm from Jin,total (Equation 3.2.4).  
𝐽𝑖𝑛,𝑛𝑒𝑡 = 𝐽𝑖𝑛,𝑡𝑜𝑡𝑎𝑙 − 𝐷𝑚     Equation 3.2.4 
Nonlinear regression analysis (Michaelis-Menten) were performed for Jin,net to obtain Vmax 
and Km for facilitated diffusion transport (Equation 3.2.5). 
𝐽𝑖𝑛,𝑛𝑒𝑡 = 
𝑉𝑚𝑎𝑥  ∗ 𝐶
𝐾𝑚+𝐶
      Equation 3.2.5 
 Relationship between brain uptake and HPOs physicochemical 
properties  
Brain uptake was plotted against HPO physicochemical properties [lipophilicity (cLogP), 
molecular weight (MW) and total polar surface area (TPSA)] derived from ChemDraw 
Software (Version 15.1). Least-square linear regression analysis was performed to 
investigate the relationship between brain uptake and the physicochemical properties. 
 Statistical and data analysis 
Data from all experiments are presented as mean + or ± standard error of the mean (SEM). 
Due to the broad range of experimental design and methods, specific details of statistical 
analyses performed on individual data sets will be presented in the context of the data. 
Statistical significance was taken as follows: Not significant p > 0.05, * p < 0.05, ** p < 
0.01, *** p < 0.001. All statistical analyses were performed using GraphPad Prism 7 








 Brain uptake of novel HPOs 
In order to compare the brain permeability of novel HPOs with CP20, in situ brain perfusion 
with the novel HPOs (500 µM) was performed for 20 minutes in rats. Brain uptake of total 
HPO in whole brain (RBr,u) and in capillary depleted brain (RCd,u) was calculated by finding 
a ratio between the total concentration of HPO in brain and unbound HPO in perfusate as 
described in Section 2.1.11. All the HPO evaluated penetrated the brain to some extent 
except FCF132 (Figure 3.3.1). RBr,u showed the sum of brain uptake of total HPO in brain 
capillary endothelial cells (BCEC) and brain parenchyma. On the other hand, RCd,u showed 
brain uptake of total HPO only in brain parenchyma. There were no significant differences 
between RBr,u and RCd,u; F (16, 87) = 5.218, for all of the HPOs perfused which indicate no 
trapping in BCEC. For this reason, only uptake into capillary depleted brain will be 
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Figure 3.3.1: Brain uptake of HPO iron chelators for total HPO in whole brain (RBr,u), total 
HPO in capillary depleted brain (RCd,u) and unbound HPO (RCd,uu) in capillary depleted brain 
over 20 minutes in situ brain perfusion. 
Data are expressed as  mean+SEM  (n=3-10 rats).* p < 0.05,  *** p < 0.001 HPOs RCd,u compared to CP20 
RCd,u. # p < 0.05,  ### p < 0.001 HPOs RCd,uu compared to CP20 RCd,uu. $$$ p < 0.001 compared between 
RCd,u and RCd,uu. No significant different, p > 0.05 compared i) between RBru and RCdu for matched HPO ii) 
between RCd,uu for enantiomer pair; CN116 vs CN118, CN126 vs CN128, CN226 vs CN228 (2-way ANOVA 
followed by Holm-Šídák multiple comparison test). 
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Brain uptake of total HPO in capillary depleted brain (RCd,u) includes the bound and 
unbound HPO in the brain parenchyma, therefore, it describes brain uptake beyond BBB 
and the affinity of HPO towards brain tissue (Figure 3.3.1). RCd,u for CP84 was 
considerably greater than CP20 (7.1-fold). FCF132 however was undetectable in brain 
after perfusion despite having glucose moiety attached to the parent molecule. CN116, 
CN118, CN126, CN128, CN226 and CN228 brain uptake showed no significant different 
compared to CP20. In addition, enantiomer pair of CN compounds (CN116 vs CN118; 
CN126 vs CN128; CN226 vs CN228) were also not different from each other, without any 
trend towards significant. 
Brain uptake for unbound HPO in brain (RCd,uu) described the uptake of pharmacologically 
relevant HPOs in brain tissue since only unbound HPO can chelate iron (Figure 3.3.1). 
The RCd,uu to RCd,u ratio for matched HPOs reflect the unbound portion of HPOs in the brain. 
The RCd,uu to RCd,u ratio for CP20 and CN116 were 1.0, and therefore were 100% unbound 
in the brain. The RCd,uu to RCd,u ratio for CP84, CN118, CN128, CN226 and CN228 were 
between 0.62 to 0.69 which translate into 62% to 69% unbound HPOs in the brain. The 
RCd,uu to RCd,u ratio for CN126 was the lowest among all HPOs, which was 0.56 (56% 
unbound in brain). Statistically, the unbound CP20 in the brain (RCd,uu) was not significantly 
different from the total CP20 in the brain (RCd,u).  Likewise, all other HPOs were also 
showed no significant difference except for CP84 where the RCd,uu was 1.6-fold lower than 
the RCd,u. Comparison of RCd,uu for HPOs with CP20 revealed that only RCd,uu for CP84 was 
higher than CP20 by 4.5-fold, while RCd,uu for other HPOs were not significantly different 
than CP20, although RCd,uu for CN116, CN118 and CN126 tended to be reduced 
suggesting a trend towards lower brain uptake than CP20. Additionally, RCd,uu and RCd,u for 
CN compounds enantiomer pair was not different from each other.  
The rate of brain uptake for unbound HPO in brain (Kin,Cd,uu) was calculated as described 
in Section 2.1.11. The Kin,Cd,uu ranked from the fastest to the slowest was: 
CP84>CN226>CN228>CP20>CN128>CN126>CN116>CN118<FCF132 (Table 3.3.1).  
The Kin,Cd,uu for CP84 was 4.5-fold faster than CP20. The Kin,Cd,uu for CN128, CN226 and 
CN228 were not different than CP20. On the other hand, the Kin,Cd,uu for CN126, CN116 
and CN118 were 3.6-, 5.2- and 9.4-folds slower than CP20. Additionally, Kin,Cd,uu for CN 
compounds enantiomer pair was not different from each other.  
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Table 3.3.1: Rate of brain uptake for unbound HPO in brain (Kin,Cd,uu) over 20 minutes in situ 
brain perfusion. 
HPOs Kin,Cd,uu (µL/min/g) n 
CP20 9.4±1.1 10 
CP84 42.3±2.6 5 
CN116 1.8±0.4 3 
CN118 1.0±0.2 3 
CN126 2.6±0.6 3 
CN128 5.6±1.1 3 
CN226 7.2±1.9 3 
CN228 7.1±0.4 3 
 
Data are expressed as mean±SEM (n=3-10 rats). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to CP20. No 
significant different, p > 0.05 when enantiomer pair was compared; CN116 vs CN118, CN126 vs CN128, 
CN226 vs CN228 (1-way ANOVA followed by by Holm-Šídák multiple comparison test). 
 HPO brain uptake relationship with lipophilicity (cLogP)  
Lipophilicity plays an important role in brain uptake for molecules that are not a substrate 
for any transporters via passive membrane diffusion and can be used to investigate the 
mechanism of HPOs transport across BBB. Predicted lipophilicity (cLogP) was employed 
in this study as a measured of HPOs lipophilicity. CP84 and CN compounds were between 
3 to 108-folds more lipophilic than CP20. On the other hand, FCF132 was 4-fold less 
lipophilic than CP20 (Figure 3.3.2).  
In order to see a relationship between HPO brain uptake and cLogP, least-square linear 
regression analysis was performed on the plot of HPO RCd,uu against cLogP (Figure 3.3.2). 
Overall the HPOs RCd,uu tended to have a positive linear relationship with cLogP although 
this was not significant. However, when comparing the CN compounds alone, there was 
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(all HPOs) 
b) Blue line 
(CN compounds only) 
r2 0.0625 0.6444 
df 36 16 
p 0.1391 <0.0001 
 
Figure 3.3.2: Regression analysis of RCd,uu plotted against HPO lipophilicity (cLogP). 
Black circle (○) represents RCd,uu for HPO. Black line (̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶ ̶̶̶̶ ̶̶̶̶̶̶̶̶ ̶̶̶̶) represents best-fit line for least-square regression 
analysis on compounds represented by black circle (○). Blue dotted line (…) represents best-fit line for least-
square linear regression analysis performed on CN compounds. HPOs cLogP were obtained using a 
ChemDraw Software version 15.1. Data are expressed as  mean±SEM  (n=3-5 rats). Significant difference (*) 
for least-square linear regression analysis was set at p <0.05. Co-efficient of variation (r2), degree of freedom 
(df: n-2) and p values for all lines were calculated using GraphPad Prism 7 software. 
 Brain uptake-inhibition studies 
To evaluate the contribution of transporters to the brain uptake of HPOs, selected HPOs 
were perfused with inhibitors of the proposed transporters. In addition, FCF132, an HPO 
that has a glucose moiety conjugated to the pyridinone ring (Table 3.2.1), was also 
evaluated for uptake in a lower non-physiological concentration of glucose in order to 
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 Evaluation of the carrier-mediated uptake of CP84 into brain 
CP84 showed a very high uptake into the brain compared to CP20 suggesting that it might 
be carrier-mediated. To ascertain whether CP84 was carrier-mediated by a specific 
transporter into the brain, a range of concentrations of CP84 (5-500 µM). RCd,uu for group 
perfused with 5 µM CP84 was 2.1-fold higher compared to brain uptake for group perfused 
with 500 µM CP84 (Figure 3.3.3). There was no different in RCd,uu for the groups perfused 
with 50 and 250 µM CP84 compared to group perfused with 500 µM CP84 which indicate 
saturation of transporter. There was a concentration related decrease in RCd,uu, such that 
with increasing concentration RCd,uu values reduced up to 250 µM. there was no further 




























Figure 3.3.3: Self-inhibition study for CP84 at various concentrations 
Data are expressed as  mean+SEM  (n=3-5 rats). The 500 µM CP84 data was taken from Figure 3.3.1. ** p 
< 0.01 compared to group perfused with 500 µM CP84 (1-way ANOVA followed by Dunnett’s test).  
 
There was a concentration-related decrease in rate of uptake with increasing 
concentration of CP84. The rate of uptake (Kin,Cd,uu) for 50 and 250 µM CP84 showed no 
different with CP84 Kin,Cd,uu perfused with 500 µM CP84 (Table 3.3.2). In contrast, CP84 
Kin,Cd,uu perfused with 5 µM CP84 was 2.1-fold faster than CP84 Kin,Cd,uu perfused with 500 
µM CP84. 
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Table 3.3.2: Rate of brain uptake for total CP84 in brain (Kin,Cd,uu) over 20 minutes in situ brain 
perfusion with various concentration of CP84. 
CP84 (µM) Kin,Cd,uu (µL/min/g) n 
5 87.8±11.0 3 
50 57.0±8.1 4 
250 32.0±7.3 3 
500 42.3±2.6 5 
Data are expressed as  mean±SEM  (n=3-5 rats). ** p < 0.01 compared to group perfused with 500 µM CP84 
(1-way ANOVA followed by Dunnett’s test). 
RCd,uu was converted to total flux that described the velocity of CP84 uptake at different 
concentration as showed in Figure 3.3.4. The membrane diffusion constant, Kd for CP84 
flux determined by the slope of unsaturable component (Figure 3.3.4, blue line) was 
29.6±0.8 µL/min/g. CP84 flux at 50 µM concentration showed initial saturation of the 
uptake process. Non-linear regression analysis following a Michaelis-Menten kinetics was 
performed on the saturable component to obtain the maximum velocity (Vmax) and half-
maximal concentration (Km) of CP84 transport (Figure 3.3.4, red line). Vmax and Km for 




















S a tu ra b le  (n m o l/m in /g )
U n s a tu ra b le  (L /m in /g )
T o ta l f lu x  (n m o l/m in /g )
 
Figure 3.3.4: CP84 flux derived from bar graph in Figure 3.3.4.  
Least-square linear regression analysis was performed on the unsaturable component (□) of CP84 flux to 
obtain membrane diffusion constant, Kd. For unsaturable component (□), the SEM were very small compared 
to the scale and was not visible in the graph. Nonlinear regression analysis following a Michaelis-Menten 
model was fitted for saturable component (∆) of CP84 flux to obtain Vmax and Km. Data are expressed as  
mean±SEM  (n=3-5 rats). * p < 0.05, compared to group perfused with 500 µM CP84 of the saturable 
component (1-way ANOVA followed by Dunnett’s test). 
** 
  CHAPTER 3: IN SITU BRAIN PERMEABILITY OF HPOs 
148 
 
CP84 was postulated to be a substrate for large amino acid transporter (LAT1) based on 
the N-phenyl group in the chemical structure. Therefore, a specific inhibitor of LAT1, 2-
amino-2-norbornanecarboxylic (BCH), was co-perfused with 50 or 500 µM CP84 for 20 
minutes. The reported concentration for BCH (10 mM) that sufficiently inhibit LAT1 was 
used in this study (Ennis et al., 1998). BCH caused reduction in CP84 brain uptake for rats 
perfused with 50 or 500 µM CP84 which confirmed contribution of LAT1 in CP84 brain 
















CP84             50            50        500  500 µM 
BCH (10 mM)               -        +           -      +  
Figure 3.3.5: Inhibition study of CP84 with 10 mM BCH. 
The data for 50 µM and 500 µM CP84 without 10 mM BCH were taken from Figure 3.3.4. Data are expressed 
as  mean+SEM  (n=3-5 rats). ** p < 0.01, compared to 50 µM CP84 perfused without 10 mM BCH; * p< 0.05, 
compared to 500 µM CP84 perfused without 10 mM BCH (2-way ANOVA followed by Holm-Šídák multiple 
comparison test). 
Kin,Cd,uu for 500 µM CP84 perfused with 10 mM BCH was 1.9-fold slower than perfusion 
without 10 mM BCH. On the other hand, Kin,Cd,uu for 50 µM CP84 perfused with 10 mM 
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Table 3.3.3: Rate (Kin,Cd,uu) of CP84 brain uptake co-perfused with 10 mM BCH over 20 
minutes in situ brain perfusion. 
CP84 
Kin,Cd,uu (µL/min/g) 
No BCH 10 mM BCH 
50 µM 57.0±8.1 19.3±1.1 
500 µM 42.3±2.6 17.4±3.8 
Data are expressed as  mean+SEM  (n=3-5 rats). * p< 0.05 compared to 500 µM CP84 perfused without 10 
mM BCH, ** p < 0.01 compared to 50 µM CP84 perfused without 10 mM BCH; (2-way ANOVA followed by 
Holm-Šídák test multiple comparison test).  
 
 
 Evaluation of FCF132 uptake into brain in low glucose 
In the previous section (Section 3.3.1), it was revealed that FCF132 failed to get into the 
brain. It was postulated that the physiological concentration of glucose (10 mM) might 
competitively inhibited the GLUT-1 transporter. Therefore, a lower concentration of 
glucose was used in the perfusion fluid (1 mM). Perfusion fluid was supplemented with 1 
mM pyruvate to compensate the lower glucose to support normal brain metabolism (Broer 
et al., 1998). It was determined from this experiment that none of the FCF132 was detected 
even though when lower concentration of glucose was used (Figure 3.3.6). 
a )   P e r fu s a te  (5 0 0 M ) b )  P e r fu s e d  w h o le  b ra in
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Figure 3.3.6: Chromatograms of FCF132 in lower glucose condition a) FCF132 perfusate b) 
FCF132 perfused whole brain c) FCF132 perfused capillary depleted brain d) blank (whole 
brain). FCF132 retention time was ~6.7 minute. 
** 
* 
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 Evaluation of the affinity of  CP20, CN118, CN128 and CN226 for the Pgp efflux 
pump 
In order to determine the role of the Pgp efflux pump in brain uptake, CP20, CN118, CN128 
and CN226 were co-perfused with 5 µM CsA, a Pgp efflux-pump inhibitor. RCd,uu for CP20, 
CN118 and CN128 co-perfused with CsA were not different from RCd,uu for CP20, CN118 
and CN128 perfused without CsA (Figure 3.3.7). By contrast RCd,uu for CN226 co-perfused 
with CsA were increased by 2.1-fold compared to RCd,uu for CN226 perfused without CsA. 
This observation confirmed that CN226 is a substrate for PgP efflux pump. RCd,uu for 
CN226 co-perfused with CsA was 2.1- and 2.6-folds higher than RCd,u for CP20 perfused 
without and with CsA respectively. Conversely, RCd,uu for CN118 perfused without CsA 
















5 0 0 M
C N 118
5 0 0 M
C N 226
5 0 0 M
CP20





$ = 0 .6 7
 
CsA 
 (5 µM) 
    - +   - + - + -  + 
Figure 3.3.7: Effect of Pgp inhibitor on the brain uptake of selected HPOs. 
The data for 500 µM CP20, CN118, CN128 and CN226 without 5 µM CsA were taken from Figure 3.3.2. Data 
are expressed as  mean+SEM  (n=3-5 rats). * p< 0.05 compared to group perfused without 5 µM CsA.  # p < 
0.05 compared to CP20 perfused without 5 µM CsA.  $$ p < 0.01 compared to CP20 perfused with 5 µM CsA 
(two-way ANOVA followed by Holm-Šídák multiple comparison test). 
Kin,Cd,uu for CP20, CN118 and CN128 co-perfused with CsA were not different from Kin,Cd,uu 
for CP20, CN118 and CN128 perfused without CsA (Table 3.3.4). In contrast, Kin,Cd,uu for 
CN226 co-perfused with CsA were faster by 2.0-fold compared to Kin,Cd,uu for CN226 
perfused without CsA. This observation confirmed that CN226 were substrates for Pgp 
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efflux pump transporters. Kin,Cd,uu for CN226 co-perfused with CsA was 1.6-fold faster than 
Kin,Cd,uu for CP20 with CsA. Conversely, Kin,Cd,uu for CN118 without CsA were 9.9-fold slower 
than Kin,Cd,uu for CP20 without CsA. 
Table 3.3.4: Rate (Kin,Cd,uu) of selected HPOs brain uptake co-perfused with 5 µM CsA over 20 




No CsA 5 µM CsA 
CP20 9.4±1.1 8.8±1.3 
CN118 1.0±0.2 2.1±0.04 
CN128 5.6±1.1 3.0±0.2 
CN226 7.2±1.9 15.1±2.8 
Data are expressed as  mean±SEM  (n=3-5 rats). * p < 0.05 compared to group perfused without 5 µM CsA.  
# p < 0.05 compared to CP20 perfused without 5 µM CsA.  $$ p <0.01 compared to CP20 perfused with 5 µM 
CsA (2-way ANOVA followed by Holm-Šídák multiple comparison test). 
 
 Relationship of brain uptake with physicochemical properties 
before and after inhibition studies. 
Brain uptake (RCd,uu) of HPOs before and after inhibition studies were plotted against their 
physicochemical properties namely lipophilicity (cLogP), molecular weight (MW) and total 
polar surface area (TPSA) followed by analysis with least-square linear regression 
analysis (Figure 3.3.8).  
 
Initially, there was no significant relationship between RCd,uu for HPOs and cLogP. 
However, after transport inhibition study with selected HPOs, a positive relationship 
emerged between RCd,uu and cLogP that was statistically significant (Table 3.3.8a).  
 
MW for novel iron chelators are between 1.4- to 2.6-folds higher than CP20. There was 
no significant relationship between RCd,uu and MW. Transport inhibition with selected HPOs 
did not improve the relationship (Table 3.3.8b). 
 
TPSA for CP84 is the same as CP20. TPSA for all CN compounds was 1.5-folds higher 
than CP20. FCF132 shows the highest TPSA which is 3.0-fold higher than CP20. There 
was a negative relationship between RCd,uu and TPSA both before and after inhibition 
studies (Table 3.3.8c). 
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Figure 3.3.8:   Regression analysis of brain uptake of total HPO in brain (RCd,u) plotted 
against HPO physicochemical properties. 
Graphs show selected HPO RCd,uu plotted against a) lipophilicity (cLogP) b) molecular weight (MW), c) total 
polar surface area (TPSA). Red circle (○) represents RCd,uu before perfusion with transport inhibitors. Blue 
square (□) represents RCd,uu after perfusion with transport inhibitors. Red dotted line (…) represents best-
fit line for regression analysed on compounds represented by red circle (○). Blue dotted line (…) represents 
best-fit line for least square-linear regression analysis performed on compounds represented by blue 
square (□). Data are expressed as  mean±SEM  (n=3-5 rats). HPO physicochemical properties were 
obtained using ChemDraw Software version 15.1. Significant difference (*) for linear regression analysis 
was set at  p < 0.05. Co-efficient of variation (r2), degree of freedom (Df; n-2) and p values were calculated 
using linear-regression analysis. 
* 
* * 




In situ brain perfusion was performed in rats in this study to evaluate the brain permeability 
of novel HPO iron chelators compared to CP20. It was hypothesised that the structure 
modification of CP20 could enhanced brain uptake. The current study revealed that, of the 
seven novel HPOs that permeated the brain, only CP84 showed marked increment 
increase in the rate of brain uptake compared to CP20. Indeed, FCF132, which contains 
the glucose moiety, was, by contrast unable to cross the BBB. 
 
 Summary of the findings 
CP20 successfully crossed the BBB by simple membrane diffusion which agrees with 
previous finding (Habgood et al., 1999, Hider et al., 2011b, Glickstein et al., 2005). Only 
CP84 has a faster rate of brain uptake than CP20 while the three HPOs (CN128, CN226 
and CN228) have equal rate of brain uptake with CP20.  On the other hand, the rate of 
brain uptake for the other three HPOs (CN116, CN118 and CN126) were slower than 
CP20. A glycosylated HPO, FCF132 did not permeate the brain at all. There was no 
different in the rate of brain uptake for the HPO chiral pair (CN116 vs CN118; CN126 vs 
CN128; CN226 vs CN228). Transport inhibition studies showed that CP84 is a substrate 
for L-type amino acid transporter-1 (LAT1), while CN226 is a substrate for Pgp efflux 
pump. Total polar surface area (TPSA) exhibit the best relationship with the rate of brain 
uptake followed by lipophilicity (cLogP). In contrast, molecular weight seems not to play 
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Table 3.4.1: Summary of the findings  
 Rate of brain uptake Physicochemical properties Unbound 
 














CP20 + + na nc + + + + + + + + 
CP84 + + + + + + + na + + + + + + + + + + 
FCF132 nd nd na + + + + + + + + na 
CN116 + na na + + + + + + + + + + 
CN118 + na nc + + + + + + + + + 
CN126 + na na + + + + + + + + + + 
CN128 + + na nc + + + + + + + + + + + 
CN226 + + na + + + + + + + + + + + + + + + 
CN228 + + na na + + + + + + + + + + + + 
CP20 is highlighted in green. nc=no change, na=not applicable, nd= not detected.  
Legend: + = low; ++ = mild; +++ = moderate; ++++ = high  
 
HPOs that leak into perivascular space (PVS) around brain arterioles and venules, which 
exhibits minimal barrier properties, do not penetrate the brain due to the presence of 
astrocytic end feet that surround the PVS (Sofroniew, 2015). These astrocytic end feet 
form a barrier similar to BBB termed the glial limitans which prevents the entry of HPOs 
into brain parenchyma. Additionally, specialised brain structure collectively known as 
circumventricular organs (CVOs), which include choroid plexus, are also supplied with 
‘leaky capillaries’ (Gross, 1992, Ganong, 2000). However, specialised epithelial wall that 
line these structures are sealed with tight junctions likened to BBB, preventing HPOs entry 
into brain parenchyma (Gross, 1992, Langlet et al., 2013). Methodologically, these routes 
of HPOs penetration has been considered in this study by subtracting the total brain 
uptake with the non-permeant BBB marker, 14C-sucrose (Section 2.1.14a). In addition, 
highly perfused choroid plexus that are easily accessible anatomically were removed 
during brain dissection before the brain homogenisation process to minimise experimental 
error (Section 2.1.7).  
 
 Brain uptake of CP20 
There was no difference in brain uptake of CP20 in brain between whole brain and capillary 
depleted brain. The distinction between uptake into whole brain and capillary depleted 
brain is important to avoid false positive interpretation of HPO uptake (Paris-Robidas et 
al., 2016). This is because, whole brain uptake comprised the HPO contained in brain 
capillary endothelial cells (BCEC) and brain parenchyma, whereas capillary depleted brain 
uptake showed HPO only in brain parenchyma (Triguero et al., 1990). This data showed 
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that CP20 did not accumulate in BCEC and successfully traverse beyond BBB into the 
brain parenchyma and is in agreement with previous findings of Roy et al. (2010).  
 
After 20 minutes in situ brain perfusion, CP20 was detected in capillary depleted brains 
with total and unbound brain uptake of 21%.  This study is not the first to report CP20 brain 
uptake in rats using in situ brain perfusion method.  An in situ brain perfusion with CP20 
performed in Wistar rat for 1 minute showed approximately 1% of CP20 perfused get into 
the brain (Habgood et al., 1999). Regardless of the lower CP20 uptake due to shorter 
perfusion, the rate of uptake per unit time of unbound CP20 in brain was not significantly 
different from the current study (12.9±1.2 vs 9.4±1.1 µL/min/g) which confirmed the validity 
of this technique across different laboratories. The rate of uptake for CP20 in this study is 
comparable to other CNS-targeted drugs such as the serotonin receptor (5HT1) agonist, 
rizatriptan (Summerfield et al., 2007) and the anticancer drug, vincristine (Greig et al., 
1990). A recent report on CP20 brain uptake using 20 minutes in situ brain perfusion in 
Dunkin-Hartley guinea pigs (Roy et al., 2010) showed 2-fold lower rate of CP20 brain 
uptake than previously reported in rats (Habgood et al., 1999). This was probably because 
of the interspecies difference as variation in brain uptake of the same drug between Wistar 
rats and Dunkin-Hartley guinea pigs can be as high as 7-folds (Tóth et al., 2014). Indeed, 
variations in gene sequences and level of protein expression across species including 
human may affect the activities of metabolic enzymes and transporters at BBB (Syvanen 
et al., 2009). For example, higher concentration of Pgp inhibitor were needed in Guinea 
pigs than in rats to achieve a similar increase in brain concentration of a Pgp substrate 
(Cutler et al., 2006). However, this does not explain the discrepancy of brain uptake 
observed for CP20 between rats and Guinea pig as the current study showed that CP20 
was not a substrate for Pgp. This may suggest the differential contribution of other efflux 
pumps families or alternatively enhanced brain metabolism in one but not in the other 
species (Syvanen et al., 2009). There is no systematic study or evidence on which rodent 
species better represents brain uptake in humans, and therefore it is not possible to 
conclude which species should be used to determine brain uptake. However, rats pose a 
number of advantages over other rodent species due to their wide use to model CNS 
associated diseases such as Parkinson’s disease, ischaemic stroke and traumatic brain 
injury which means comparison and translation between studies are possible (Duty and 
Jenner, 2011, Fluri et al., 2015, Xiong et al., 2013). Nevertheless, it has previously been 
reported than brain uptake of CP20 in rats was primarily governed by simple membrane 
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diffusion as reported by Habgood et. al. (1999), Glickstein et. al. (2005) and Hider et. al. 
(2011) which corresponds to the linearity of brain uptake for CP20 for up to 60 minutes 
perfusion showed in the current study (Figure 2.1.21). 
 
 Brain uptake of novel HPOs 
As for CP20, there was no difference in brain uptake of novel HPOs between whole brain 
and capillary depleted brain apart from FCF132, these data confirmed the successful 
penetration of HPO into the brain parenchyma. FCF132 was not detected in either whole 
brain or capillary depleted brain suggesting poor penetration of the BBB. In this section, 
brain uptake of novel HPO iron chelators will be discussed. 
 
 CP84 
Following 20 minutes in situ brain perfusion, CP84, a N-phenyl derivative of CP20 
perfused at 500 µM showed remarkably higher brain uptake than CP20. The rate of brain 
uptake for unbound CP84 in brain was 87.8±11.0 µL/min/g compared to CP20 (9.4±1.1 
µL/min/g). To put this into a perspective, rate of brain uptake for CP84 is comparable to 
other CNS active drug such as butanediol (Abbott, 2004), prazosin (Cisternino et al., 
2004), pramipexole (Okura et al., 2007), theophylline (Liu et al., 2004) and tolbutamide 
(Murakami et al., 2000). In addition, the rate of brain uptake for CP84 was also comparable 
to the essential amino acids, L-lysine and L-glutamine (Smith, 2000).  
 
The high rate of brain uptake for CP84 could not be explained by its lipophilicity, therefore, 
it can be concluded that CP84 may entered the brain via a carrier-mediated process in 
addition to the passive membrane diffusion. To confirm that CP84 brain uptake was by a 
carrier mediated transport, in situ brain perfusion with CP84 were performed for 20 
minutes over a wide concentration range to see if at high concentration of CP84, the 
transporter was saturated. It was revealed that the rate of brain uptake for CP84 showed 
concentration-related decrease suggesting that CP84 brain uptake was carrier-mediated 
(Greenwood et al., 1982, Chapy et al., 2016). Interaction with a specific transporter is not 
a sole indicator for a high brain uptake at the BBB. Diazepam and sertraline are a perfect 
example of CNS active compound that has extremely high rate of brain uptake just by a 
simple membrane diffusion and not carrier mediated (Dubey et al., 1989, Badhan et al., 
2014), therefore, it is possible that CP84 is also able to get into the brain via simple 
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diffusion in addition to the carrier-mediated process. To look on more detail on the 
transport kinetics of CP84, the rate of brain uptake was transformed into flux which showed 
the velocity of the transport process at the different CP84 concentrations. It was 
discovered that after a non-linear regression analysis using Michaelis-Menten model, the 
Vmax and Km for CP84 were 13.1±3.5 nmol/min/g and 135.7±2.8 µM respectively. The 
second mechanism was non-saturable uptake through membranes diffusion with Kd of 
29.6±0.8 µL/min/g. These results confirmed that CP84 crossed the BBB by carrier-
mediated transport process in addition to passive membrane diffusion.  
 
The chemical structure of CP84 is different from CP20 by a single additional phenyl moiety 
linked to the main 3-hydroxy-4-pyridinone ring (Table 3.2.1). This phenyl functional group 
can potentially interact with L-type amino acid transporter-1 (LAT1) that are abundantly 
expressed at the BBB (Boado et al., 1999, Boado et al., 2004). Indeed, several new 
compounds and pro-drugs bearing a phenyl group in the chemical structure have been 
successfully transported into the brain by targeting LAT1 (Peura et al., 2013, Peura et al., 
2011). Additionally, an established pro-drug in clinic that is used as the main line of 
treatment for Parkinson’s disease patients, L-dopa, utilises LAT1 at the BBB (Kageyama 
et al., 2000). As the evidence showed that CP84 brain uptake was partly carrier-mediated 
and its chemical structure contained N-phenyl group, it was proposed that CP84 is 
transported into the brain by means of the N-phenyl group interaction with LAT1 at the 
BBB. This appeared to be the case as brain uptake of CP84 was inhibited by BCH, the 
specific LAT1 inhibitor. Interestingly after BCH inhibition, the CP84 rate of brain uptake 
was about 20 µL/min/g which close to the Kd for CP84 which suggest the mechanism of 
CP84 brain uptake was mainly via membrane diffusion during LAT1 inhibition with BCH. 
 
In summary, the strategy of adding phenyl group to the N1 of hydroxypyridinine ring 
increased the brain uptake of CP84 compared to CP20 by interaction with LAT1, however, 








The glucose transporter under subfamily 1 (GLUT1) is highly expressed at the BBB to 
transport glucose into the brain (Zheng et al., 2010, Ojelabi and Carruthers, 2015, Qutub 
and Hunt, 2005, Dwyer and Pardridge, 1993). Due to the high expression of GLUT1 at the 
BBB, targeting GLUT1 to enhance brain uptake could be one of the best strategies to 
circumvent the BBB. In this study, CP84 was conjugated with a glucose moiety to the 2-
OH pyridinone ring to form FCF132 and evaluated for brain uptake with in situ brain 
perfusion. It was expected that brain uptake would be at least comparable to CP84 and 
higher than CP20. However, conjugation of glucose moiety to the parent molecules was 
showed to be counterproductive as FCF132 was not detected in the brain after 20-minute 
perfusion. The chromatogram of rat brain perfused with FCF132 also failed to show the 
presence of CP84, a metabolite of FCF132 which its presence might suggest FCF132 
permeability into brain followed by metabolism to CP84. Lacking chromatogram peaks for 
FCF132 and CP84 in the perfused brain homogenate conclude that FCF132 was not 
transported at all. Indeed, it was reported previously that iodinated FCF132 also showed 
inability to cross the BBB (Roy et al., 2010). In that study, it was suggested that the addition 
of I125 for radioactivity detection might cause steric hindrance for FCF132 interaction to 
GLUT1. However, that was not the case, since the current study also showed undetectable 
FCF132 in the brain after perfusion. Similar negative outcome has been reported for other 
glucosylated HPO iron chelators.  Glycosylated CP20 was undetectable in brain in contrast 
to the parent molecules which showed about 5% brain uptake (Roy et al., 2010). 
Nevertheless, there are reports of successful penetration of drug conjugated with glucose 
at BBB (Bonina et al., 2000, Bonina et al., 2003, Chen et al., 2009). In those studies, 
different glycol-conjugates such as 7-chlorokynurenic acid (Bonina et al., 2000), dopamine 
(Bonina et al., 2003) and ibuprofen (Chen et al., 2009) have been synthesized as 
candidates for the treatment of CNS diseases and showed increment in BBB permeability.  
 
From these studies, it was unclear why FCF132 was unable to penetrate the BBB. It may 
be that, due to low affinity for GLUT1, FCF132 uptake was blocked by high levels of 
glucose in the NRS perfusion fluid. However, following in situ brain perfusion with FCF132 
with lower concentration of glucose (1 mM) there was still no evidence of brain uptake. 
Due to the mix of report on success and failure of brain penetration by glycol-conjugates, 
a close examination of the mechanism of glucose binding to GLUT1 is warranted. This is 
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because, interaction for correct positioning and orientation of glucose molecules must 
occur for succesful transport (Deng et al., 2014). When the chemical structure of FCF132 
was examined, the OH group on C3 of the pyridinone ring form a glycosidic bond with the 
OH group on C1 of the glucose ring.  
 
According to a study by Mueckler and Makepeace (2009), the OH group on C1 of the 
glucose ring is vital for binding into the GLUT1 binding site via hydrogen bonds. Indeed, 
evidence based on competitive inhibition studies on erythrocyte GLUT1 showed that OH 
groups on C1 and C3 are paramount for glucose binding as they serve as hydrogen bond 
acceptor (Figure 3.4.1; Barnett et al., 1975, Carruthers et al., 2009). OH group on C4 is 
also capable to form hydrogen bond with GLUT1 and this was supported by the 
observation that galactose, which is an epimer of glucose at C4, has 10 times lower 
binding affinity than glucose for GLUT1. The most recent model of GLUT1 binding with 
glucose produced by Mucklear (2013) showed that OH group on C1, C3, C4 and C6 form 
hydrogen bonds with the active site, and this supported the earlier theory (Mueckler and 
Makepeace, 2009). Only the OH on C2 is free to form hydrogen bond within the GLUT1 
active site. Additionally, it has been shown that bulky substitution of OH at C1 prevent 
binding to GLUT1 on the active site, while similar-size substitution at C6 did not 





Figure 3.4.1: a) Interaction of –OH 
group on glucose molecule to the 
GLUT-1 active site. Taken from 
Mueckler and Makepeace (2009) b) 
FCF132 chemical structure. The 
circled OH-functional groups are 
vital for glucose recognition site at 
GLUT-1 activite site. 
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Furthermore, previous reported success of brain penetration of glycosyl conjugate was 
when the glucose forms a glycosidic bond with OH on C2 or C6 of glucose ring (Chen et 
al., 2009). This might explain the undetectable level of glycosylated CP20 and FCF132 as 
both HPOs form glyosidic bond with OH on C1 of glucose ring. Therefore, it seems that, 
although the OH on C2 and C6 on glucose ring form a hydrogen bond within the GLUT1 
active site, this binding can be compromised for successful glucose transport. Having said 
this, the selection of which OH on glucose ring to form the glycosidic bond is highly 
important for successful brain penetration of glycosylated HPO. Base on this observation, 
it can be concluded that, to design a new compound conjugated with glucose, OH on C2 
or C6 of glucose ring would be favourable for successful brain uptake. In summary, the 
strategy of adding glucose moiety by forming a glycosidic bond between the 1-OH of 
glucose and the 3-OH of hydroxypyridinine ring was counterproductive as it halts the brain 
uptake of FCF132 (glycosylated form of CP84).  It is already known that free OH-1 of the 
glycosyl group is most crucial for the identification of D-glucose by GLUT1 (Thérèse et al., 
1996; Mehdi et al., 1999). 
 
 CN compounds (CN116, CN118, CN126, CN128, CN226 & CN228) 
The CN compounds can be clustered into three groups namely CN 11, CN 12 and CN 22 
based on increasing lipophilicity. Each group contains two iron chelators with chiral alkyl 
substituent containing -OH functional group at N1 which are enantiomer pair: [CN 11: 
CN116 (S-) and CN118 (R-); CN 12: CN126 (S-) and CN128 (R-); CN 22: CN226 (S-) and 
CN228 (R-)]. In this study, brain permeability of the CN compounds was evaluated and 
compared to CP20. Additionally, the enantiomer pairs in each group were also compared 
to evaluate if there is any effect of optical stereoisomerism in the brain uptake. The results 
showed that there was no significant different of rate of brain uptake for CN128, CN226 
and CN228 and CP20 compared to CP20. Conversely, CN116 and CN118 showed slower 
rate of brain uptake than CP20. Comparison between enantiomer pairs showed no 
significant different in brain uptake suggesting that optical stereoisomerism in these set of 
molecules did not contribute to variation in brain uptake. Indeed, in general compounds 
that crossed the BBB via passive membrane diffusion, optical stereoisomerism seems not 
to be an important factor compare to compound that is carrier-mediated (Chang et al., 
2015, Fong, 2015).  
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The lack of relationship between brain uptake and lipophilicity has been reported 
elsewhere (Liu et al., 2011, Summerfield et al., 2007). It has been demonstrated in the 
earlier studies that prediction of brain permeability of HPOs based on lipophilicity was not 
sufficient (Habgood et al., 1999). In that study, a set of CP20 derivatives with N-alkyl or N-
hydroxyalkyl substituents with lipophilicity higher than CP20 were evaluated for brain 
permeability. However, two of the CP20 derivatives with N-hydroxyalkyl substituent that 
have lipophilicity 1.2 and 3.0-folds higher than CP20 were not detected in the brain. It was 
revealed in the study that only N-alkyl substituent of CP20 with cLogP 2.9- to 466-folds 
higher contributed to the positive relationship between brain uptake and lipophilicity. It was 
then suggested that the additional -OH caused the formation of extra hydrogen bond with 
surrounding water which requires more energy for breaking the bond. This mechanism 
contributes to additional barrier for brain penetration (Rafi et al., 2012). Indeed, the total 
polar surface area (TPSA) that account for the combined surface area between interaction 
of electronegative atom such as oxygen and nitrogen with hydrogen was 1.5-fold higher 
than CP20 for all of the CN compounds. Similarly, CN compounds are also a group of 
CP20 derivatives with N-hydroxyalkyl substituents which may explain the lack of 
relationship between brain uptake and lipophilicity. Moreover, Frieden et al. (2009) have 
argued against the traditional notion among the pharmaceutical scientist and clinicians 
that lipophilicity was the main driving force of BBB permeation. Their findings showed that 
the intermolecular hydrogen bond was the main driving force for the 41 CNS drugs tested 
for brain permeability and not the lipophilicity. Their findings were further substantiated by 
a larger set of 246 drugs which showed that intermolecular hydrogen bonding was 
certainly the primary driving force for brain permeability (Chen et al., 2011). 
 
Nevertheless, although extra hydroxyl group presented additional barrier for brain 
permeation, simultaneous increase in lipophilicity which is between 2.6- to 108-folds 
higher than CP20 may compensate for this as they were not significantly different than 
CP20 rather than not getting into the brain at all. Additionally, the lack of observable brain 
uptake for the N-hydroxyalkyl substituent of CP20 in the previous study might partly be 
because of the short perfusion time (1 minute) which did not allow sufficient duration of 
slowly permeable compounds through passive membrane diffusion. Furthermore, the 
study employed UV as the detection method for HPOs levels in brain after separation by 
HPLC which was less sensitive for such a short perfusion time compared to detection via 
liquid scintillation spectroscopy or mass-spectrometry (MS) (Habgood et al., 1999). 
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Besides the energy barrier conferred by the extra OH-group on the brain uptake of CN 
compounds, the interaction of the CN compounds with efflux pump such as Pgp 
abundantly expressed at BBB was also possible (Loscher and Potschka, 2005, Bartels, 
2011). Pgp efflux pump are abundantly expressed in rat BBB and is known to favour small 
lipophilic molecules as its substrate and lowering BBB permeation which offsetting their 
much higher partition into the BBB membrane (Mikitsh and Chacko, 2014, (Friden et al., 
2009, Fridén, 2014). The data revealed that out of the four HPO tested, only CN226 was 
showed to be a substrate for Pgp efflux pump where cyclosporin A caused approximately 
50% increase in brain uptake. This lead to increase in CN226 brain uptake by 2-folds 
compared to CP20. In order to decrease glucuronidation in the liver, CP20 chemical 
structure was altered to form CN compounds with the simultaneous increase in total polar 
surface area and lipophilicity which showed that increase in total polar surface area 
predominantly affect the rate of brain uptake for CN118 and CN126 (Hider et al., 2011a). 
However, in the case of CN226, the similarity in the rate of brain uptake compare to CP20 
was probably because of the combination of these two factors; the higher intermolecular 
hydrogen bond formation with the surrounding H2O that limit brain permeation and the 
increase in lipophilicity which made CN226 more permeable to cell membrane but was 
then favoured by efflux pumps. 
 
One interesting point to bring up is that, CN 12 and CN 22 group of compounds contained 
a phenyl functional group without enhancement of brain uptake seen on CP84. This might 
suggest that orientation of the phenyl functional group in these compounds not favour 
interaction with a specific carrier-mediated transporter such as LAT1 (Killian and Chikhale, 
2001). Rather surprisingly, there was indeed an interaction with LAT1, but without a 
subsequent internalisation into the brain (Killian et al., 2007). In summary, brain uptake of 
CN compounds was not different to CP20, except for CN226 which showed 2-fold higher 
brain uptake in the presence of Pgp efflux pump inhibitor, cyclosprorine A. 
 
 Brain distribution of novel HPO iron chelators 
CP20 showed negligible non-specific binding to brain tissue which suggest that 
theoretically, all CP20 in the brain can chelate iron. This assumption is in line with the free-
drug hypothesis, which stated that only drugs in the unbound form are pharmacologically 
relevant (Liu and Chen, 2015). Other novel HPOs except CN116 however, showed a 
certain degree of binding to brain tissue. Lipophilicity higher than CP20 for these novel 
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HPOs could be one of the determining factors to this observation as brain tissue contains 
approximately 11% of lipid by weight (Jeffrey and Summerfield, 2007). Indeed, evaluation 
of thirty-three CNS active drugs showed less unbound fraction in the brain compared to 
plasma which only contain around 0.7% lipid (Maurer et al., 2004). Interestingly, CN118 
showed a different profile of binding in the brain tissues compare to its enantiomer CN116 
with the former been 60% unbound while the latter been 100% unbound to brain tissues, 
although this was not eventually translated into differences between rates of brain uptake 
for CN116 and CN118. For some novel HPOs that showed a certain degree of affinity 
towards brain tissues, this in turn may be a factor that contributes to the lower iron 
chelation activity than CP20. In contrast, affinity of HPOs towards brain tissues could be 
therapeutically advantageous for prolong action of iron chelation as the brain tissues act 
as a reservoir that continuously released bound HPOs (Loryan and Hammarlund-
Udenaes, 2014).  
To summarise, CP20 was superior in term of rate of brain uptake compared to other novel 
HPOs as it was not bound to brain tissues. However, for the novel iron chelators, affinity 
towards brain tissue may benefit in term of longer exposure in brain tissues. 
 
 Advantages and shortcomings of this study 
The in-situ brain perfusion technique attempted to overcome the limitation of in vivo 
systemic injection for determination of brain permeability which are pharmacokinetically 
difficult to interpret due to wide peripheral distribution and metabolism (Boje, 2001, Smith 
and Allen, 2003b). Cannulation of carotid arteries in in situ brain perfusion allow direct 
delivery of artificial blood containing HPOs to the brain, thus avoiding peripheral 
distribution and metabolism (Murakami et al., 2000, Smith and Allen, 2003a). HPOs that 
get into the brain after perfusion at an optimum time can be determined by quantification 
method such as HPLC. By this technique, lower concentration of HPOs can be used and 
HPOs brain uptake can be confidently measured relative to the systemic injection. 
Furthermore, this technique offers a flexibility to manipulate the artificial blood for the 
identification and characterisation of transporters by inhibitors as described in this 
chapter. 
 
This technique is however technically challenging which requires substantial amount of 
training for isolation and cannulation of the carotid arteries. Secondly, the perfusion is 
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performed in anaesthetised rats and therefore does not truly represent brain uptake in 
awake animals. Thirdly, the artificial blood does not contain erythrocytes which have pH 
buffering capacity and helps in contributing to the viscosity of the actual blood (Boje, 2001, 
Jensen, 2004, Windberger et al., 2003). Some of these issues have been addressed in 
this study by continuous infusion of oxygen in the artificial blood, adding HEPES to 
maintain the pH at physiological level and adding physiological concentration of BSA to 
increase the solution viscosity. Data for optimisation as shown in Chapter 2 suggest that 
the perfused brain is viable, and the BBB is intact for up to 60 minutes. The capillary 
depletion technique to determine HPOs trapped in the brain capillary endothelial cells is 
prone to artefacts due to redistribution of trapped HPOs during centrifugation process 
(Bickel, 1998). However, this is very unlikely base on the molecular weight of HPOs that 
are small (<500 Da).   
 
The UV detection method for HPOs identification in perfused brain after separation by 
HPLC in the current study is the least sensitive method for biological measurement. The 
best option is by employing MS or MS/MS detection method for analysis. This technique 
offer sensitivity down to nanomole and picomole concentration in biological samples 
(Avdeef and Sun, 2011, Tabanor et al., 2016). Because of this, lower concentration of 
HPOs in artificial blood can be infused to more represent achievable HPOs concentration 
in human plasma. However, this requires sophisticated LCMS machine which is not 
available in all laboratory. Nevertheless, the current technique employed in this thesis to 
determine brain permeability is sufficient for brain uptake comparison between novel 
HPOs and CP20, and for determination of contribution of transporter-mediated uptake. 
 
 Conclusion 
The present study aimed to evaluate the rate of brain uptake of novel HPOs iron chelators 
and compare with CP20. From the results obtained, only CP84 showed faster rate of brain 
uptake than CP20 while six others novel HPOs showed no difference or slower rate of 
brain uptake. The glycosylated HPO FCF132 unexpectedly did not get into the brain at all 
suggesting lack of FCF132 affinity towards glucose transporter. Also, the brain uptake for 
S- and R- enantiomer pairs of CN compounds did not show any different indicating 
stereoisomerism had no effect for these set of compounds. In addition, CP84 was shown 
to be a substrate for LAT-1 transporter explaining its increased rate of brain uptake 
compared to CP20, while CN226 was a substrate for Pgp efflux-pump suggesting that it 
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was expelled from the brain after crossing the BBB. There was a positive linear relationship 
between brain uptake and lipophilicity only when transporters/pumps were inhibited, while 
negative linear relationship between brain uptake and polarity was observed both before 
and after inhibition, signifying that polarity is the best descriptors of brain uptake for this 
set of compounds. Therefore, in this study, the hypothesis that modification to the structure 
of CP20 can improve the efficiency of BBB transport was partly accepted as only CP84 
showed increase in the rate of brain uptake compared to CP20 while other novel HPOs 
rate of brain uptake were unchanged or lower than CP20. 
 
As a potential neuroprotection agent, brain permeability is only one of the prerequisites. 
To select the best candidate as a neuroprotection agent, an evaluation of the 
neuroprotective ability of novel HPOs is warranted. Therefore, in the following chapter, the 
evaluation of neuroprotection of these novel HPOs with neuroblastoma cell lines, SH-
SY5Y will be covered in detail.








NEUROPROTECTION STUDY OF 
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4 Neuroprotection study of novel HPOS with 
neuroblastoma cell line (SH-SY5Y) 
 Introduction 
In the preceding chapter, novel HPO iron chelators were evaluated for their brain 
permeability with in situ brain perfusion. As presented in Chapter 3, seven from eight of 
the novel HPO iron chelators tested crossed the BBB and get into the brain. Ability to cross 
the BBB is a prerequisite for Parkinsonian drugs to elicit their pharmacological effects in 
the brain (Smith et al., 2012, Bezard et al., 2013). Iron content in substantia nigra generally 
increases by 10-fold at 40 years of age compared to infants without any problem (Reeve 
et al., 2014). However, dysfunction of tightly regulated brain iron homeostasis occurs in 
PD which cause excessive accumulation of free iron (Double et al., 2000). A rise in the 
level of labile iron pool (LIP; Section 1.1.4) subsequently generates free-radicals through 
Fenton reaction and induce oxidative stress (Kruszewski, 2003). Oxidative stress has 
been implicated in the pathogenesis of PD as described in detail in Section 1.1.4. 
Transgenic mice that overexpressed ferritin were less prone to various PD toxins inducers 
through sufficient sequestration of LIP (Kaur et al., 2009). This further suggest the use of 
iron chelators as a potential treatment for PD (Perez et al., 2008, Mounsey and Teismann, 
2012). Indeed, synthetic and natural iron chelators have been shown to slow down disease 
progression in in vitro and in vivo PD models by attenuating dopaminergic neurons death 
(Mounsey and Teismann, 2012, Hatcher et al., 2009).  
 
Among the clinically available iron chelators (Section 1.1.6), deferiprone (CP20) is the 
most promising for PD treatment as it is orally active, can penetrate the brain, the CP20-
iron complex is neutral and can distribute iron to extracellular transferrin (Devos et. al., 
2014). Studies in in vitro and in vivo models of PD showed that CP20 conferred 
neuroprotection better than other clinically available iron chelators (Dexter et al., 2011; 
Molina-Holgado et. al., 2008; Devos et. al., 2014). In human, CP20 exhibited better motor 
performance as early as 6 months after treatment compared to control (Devos et. al., 
2014). Although CP20 is extensively metabolised in the liver, the 3,4-hydroxypyridinone 
scaffold of CP20 is easily functionalised for improvement of physicochemical and 
biological properties, while retaining their affinity to iron and other important characteristics 
for potential PD treatment (Santos et al., 2012). 
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To confirm that the brain permeable novel HPOs could also confer neuroprotection, SH-
SY5Y cell line was used to model the dying neurons in this study. SH-SY5Y cell line is a 
catecholaminergic which expresses DAT that closely resembles the affected 
dopaminergic neurons in the substantia nigra pars compacta (SNPc) in PD brain 
(Kovalevich and Langford, 2013b, Filograna et al., 2015). H2O2, 6-OHDA and MG132 were 
employed in this study to induce cell death. Selection of these toxins in this study is 
relevant due to the reported accumulation of iron in in vitro and in vivo models of PD that 
associate with the toxicity of the toxins (Wang et al., 2004, Panopoulos et al., 2005). Apart 
from that, ferric ion (Fe3+) in the form of co-ordination complex with NTA (FeNTA) was 
used as a direct source of iron and to evaluate the ease of novel HPOs to chelate iron. 
Therefore, based on the results from the experiment described in the preceding chapter, 
seven of the novel brain penetrant HPOs were chosen along with CP20 for in vitro 
neuroprotection study with SH-SY5Y cell lines.  
 
 Hypothesis 
It was hypothesised that novel HPOs iron chelators would confer protection against H2O2, 
6-OHDA, MG132 and FeNTA (1:3) induced toxicity in SH-SY5Y cells. 
 
 Aims 
To test the hypothesis, SH-SY5Y cells were pre-treated with HPOs before exposing to 
toxins with the following aims.  
 
a) Confirm the lack of cell death induced by HPOs iron chelators. 
 
b) Confirm the induction of cell death when exposed to IC50 concentrations of H2O2, 
6-OHDA, MG132 and FeNTA (1:3). 
 
c) Compare the effect of novel HPO iron chelators on toxin-induced cell death. 
 
d) Compare the neuroprotection of novel HPO iron chelators with CP20. 
 
e) Compare the neuroprotection between enantiomers pair of novel HPO iron 
chelators. 
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 Materials and methods 
 SH-SY5Y cells culture 
Human neuroblastoma cells line (SH-SY5Y) at passage 18 was obtained from the 
European Collection of Cell Cultures (ECCC). The cells were grown in T175 cm2 (T175) 
(ThermoFisher, UK) containing 20 mL Dulbecco's Modified Eagle medium (DMEM) 
supplemented with 10% (v/v) fetal bovine serum (FBS) and 0.01% (v/v) penicillin-
streptomycin-neomycin (PSN) antibiotic mixture (complete-DMEM) as described in 
Section 2.2.3. Briefly, at 80% confluence, the cells were washed with DPBS, trypsinised 
with 0.05% trypsin-EDTA in phosphate buffer and centrifuged at 200 g for 5 minutes. The 
cell pellet was re-suspended with 1 mL complete-DMEM at a density 1x105 cells/mL. One 
hundred microliters of working cell suspension were pipetted into 96-well plates and 
incubated in CO2 incubator at 37 ºC for at least 12 h. 
 
 Preparation of 3-hydroxy-4-pyridinones (HPOs) solution 
Main stock solution for HPOs were dissolved in sterile distilled water, except for CP84 
which was dissolved in 10% (v/v) DMSO. HPOs with concentration between 50 to 1250 
µM were prepared in serum-free DMEM and were used to incubate with the SH-SY5Y 
cells. The final DMSO concentration when exposed to cells was below 1% (v/v). 
 
 Preparation of neurotoxins solution 
Five different neurotoxins namely H2O2, 6-OHDA, MG132 and FeNTA (1:3) were 
employed in this study to induce cell death. The preparation of the toxins was outlined 
below:  




Working stock solution (2.2 mM) for IC50 concentration of H2O2 (220 µM) was prepared 
fresh in serum-free DMEM on the day of the experiment from the 200 mM H2O2 main stock 
solution in serum-free DMEM. Left-over of working stock solution was frozen at -20 ºC and 
was used within one month after preparation. 
 
 6-OHDA 
Working stock solution (400 µM) for IC50 concentration of 6-OHDA (40 µM) was prepared 
fresh in serum-free DMEM on the day of the experiment from the 40 mM 6-OHDA main 
stock solution in serum-free DMEM containing 0.06% (w/v) ascorbic acid. Left-over of 




Working stock solution (3500 pM) for IC50 concentration of MG132 (350 pM) was prepared 
fresh in serum-free DMEM on the day of the experiment from the 10 mM MG132 main 
stock solution in 100% DMSO. Left-over of working stock solution was not re-used as 
MG132 lost it activity after freezing-thawing cycles. 
 
 FeNTA (1:3) 
Working stock solution (4600 µM) for IC50 concentration of FeNTA (1:3) (460 µM) was 
prepared fresh in serum-free DMEM on the day of the experiment from the 125 mM FeNTA 
(1:3) main stock solution in serum-free DMEM. Left-over of working stock solution was 
frozen at -20 ºC and was used within one month after preparation. 
 
 In vitro neuroprotection studies 
After an overnight incubation in CO2 incubator, the cells were treated with 50, 100, 500 
and/or 1250 µM of HPOs in serum-free DMEM and were incubated for 20 h in the CO2 
incubator. Control cells were incubated with vehicle in serum-free DMEM. After 20 h 
incubation with HPOs, neurotoxins at 10-fold of the IC50 concentration were pipetted into 
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the well (11 µL) and incubated for 20 h. When 20 h incubation time had passed, the viable 
cells were estimated with MTT assay (Figure 4.2.1). 
 
 
Figure 4.2.1: Experimental timeline for in vitro neuroprotection study with SH-SY5Y. 
 
 Determination of cell viability with MTT assay 
Cell viability after SH-SY5Y co-treated with HPOs and toxin was estimated with MTT 
assay. After 20 h co-treatment with neurotoxins, the medium was replaced with serum-
free DMEM containing 0.5 mg/mL MTT and incubated for 4 h at 37 ºC in the CO2 incubator. 
At the end of the incubation, the medium was removed by quick inversion into the sink and 
lightly tapped on paper towel to remove excess liquid. The formed MTT formazan crystal 
was solubilised with 100 µL 100% DMSO and absorbance at 570 nm was taken with a 
microplate reader. The percentage of viable cells was calculated by finding a ratio between 
treated cells and control cells with serum-free DMEM as described in Section 2.2.8. 
 
 Comparison between pFe3+ for HPOs and cell viability after 
treatment with toxins 
The iron (Fe3+) affinity constant (pFe3+) values for HPOs were determined 
spectrophotometrically by automated potentiated titration (Kong et al., 2006) and was 
provided by Dr Xiao Kong from Institute of Pharmaceutical Science (IPS), King’s College 
London. The pFe3+ value is a negative logarithm of free Fe3+ concentration at physiological 
pH (pH 7.4) when the total Fe3+ concentration, [Fe3+]total is 1 µM and the total HPO 
concentration, [HPO]total is 10 µM. The higher the pFe3+ value indicates a higher affinity 
towards Fe3+ ion. The pFe3+ values for HPOs were outlined in Table 4.2.1.
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pFe3+ at pH 7.4 when [Fe3+]total is 1 µM and [HPO]total is 10 µM 
 
 Data analysis 
Experiments were performed in at least triplicate on three separate occasion with data 
expressed as mean+SEM (n=3). Two-way ANOVA followed by Holm-Šídák multiple 
comparison test was performed to compare between cells treated with toxin and cells co-
treated with HPOs and toxin. The same way of analysis was performed to compare 
between cells co-treated with CP20 and toxin with the rest of cells co-treated with HPOs 
other than CP20, and toxin. Comparisons between enantiomer pairs was also observed 













To evaluate the neuroprotective effect of the novel HPOs, the SH-SY5Y cells were pre-
treated with 50, 100 500 or 1250 µM HPOs for 20 h before being exposed to neurotoxins 
for a further 20 h. The cell viability of the SH-SY5Y after treatments was assessed by MTT 
assay. 
 
 Effect of HPOs on viability of SH-SY5Y cells exposed to H2O2 
In order to evaluate the neuroprotective ability of novel HPOs, SH-SY5Y cell were treated 
with various concentrations of HPOs (50 to 500 µM) with or without the IC50 concentration 
of H2O2 (220 µM). Control cells were treated with serum-free DMEM only or H2O2 in serum-
free DMEM. At the end of the treatment, the cell viability was measured by MTT assay as 
described in Section 2.2.8. 
 
Treatment of SH-SY5Y cells with 50, 100 and 500 µM HPOs only did not affect cells 
viability when compared to untreated control. By contrast, SH-SY5Y cells exposed to 220 
µM H2O2 for 20 h showed approximately between 47% to 52% cell viability compared to -
H2O2 (Figure 4.3.1).  In general, treatment of SH-SY5Y cells with HPOs 20 h prior to co-
treatment with H2O2 for a further 20 h protected against H2O2-induced loss of cell viability, 
but to different degrees. 
 
CP20 protected against H2O2-induced cell loss, with a significant 27% reduction at 100 µM 
compared to H2O2 alone (Figure 4.3.1a). By contrast, CP84 co-treated with H2O2 did not 
protect against H2O2-induced cell loss at any concentration (Figure 4.3.1b).  
 
Both CN116 and CN118 protected against H2O2 toxicity which was significant at 50 and 
100 µM (CN116) and 50 µM (CN118) respectively.  
 
Similarly, CN126 and CN128 appeared to protect against H2O2-induced cell death. CN126 
produced a non-concentration-related improvement in cell viability by approximately 30% 
compared to H2O2 alone (+H2O2), however the protection following CN128 was not 
significant. 
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Both CN226 and CN228 produced a significant, non-concentration-related protection of 
around 40% compared to +H2O2. 
 
There was no difference in cell viability when the equimolar concentrations of enantiomer 
pairs, (CN116 vs CN118, CN126 vs CN128 and CN226 vs CN228), co-incubated with 
H2O2 were compared. Likewise, comparison of equimolar concentrations between novel 
HPOs and CP20 reveals no significant different.  
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Figure 4.3.1: Effect of H2O2 on cell viability assessed by MTT assay after pre-incubation with 
novel HPO iron chelators. 
SH-SY5Y cells were pre-incubated for 20h with HPOs followed by 20h co-incubation with 220 µM H2O2. Data 
are expressed as  mean+SEM  (n=3). ** p < 0.05, *** p < 0.001 compared between HPOs treatments without 
H2O2 (-H2O2) and HPOs treatments with H2O2 (+H2O2). # p < 0.05, ### p < 0.001 compared between HPOs 
treatments with H2O2 (+H2O2) and control with H2O2 (+H2O2). No significant different, p > 0.05 compared i) 
between HPOs treatments without H2O2 (-H2O2) and control without H2O2 (-H2O2) ii) between CP20 treatments 
with H2O2 (+H2O2) and novel HPOs with H2O2 (+H2O2) iii) between HPO enantiomer pairs (CN116 vs CN118, 
CN126 vs CN128 and CN226 vs CN228) treatments with H2O2 (2-way ANOVA followed by Holm-Šídák 
multiple comparison test).
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 Effect of HPOs on viability of SH-SY5Y cells exposed to 6-OHDA 
SH-SY5Y cell were treated with various concentrations of HPOs (50 to 500 µM) with or 
without the IC50 concentration of 6-OHDA (40 µM) prepared in 0.006% (w/v) ascorbic acid. 
Control cells were treated with serum-free DMEM containing 0.006% (w/v) ascorbic acid 
only or 6-OHDA in serum-free DMEM containing 0.006% (w/v) ascorbic acid. At the end 
of the treatment, the cell viability was measured by MTT assay as described in Section 
2.2.8. 
 
As expected, treatment of SH-SY5Y cells with 50, 100 and 500 µM HPOs alone did not 
affect cells viability when compared to control and exposure to 40 µM 6-OHDA for 20 h 
showed between 48 to 57% cell viability which were significantly reduced compared to 
control (Figure 4.3.2). Generally, treatment of SH-SY5Y cells with HPOs 20 h prior to co-
treatment with 6-OHDA showed significant protection against 6-OHDA-induced cell loss. 
 
CP20 showed a protection against 6-OHDA toxicity in a concentration-dependant manner 
(22% and 51% improvement) at 100 µM and 500 µM respectively (Figure 4.3.2a). 
Similarly, CP84 protected against 6-OHDA induced cell death by approximately 30% in a 
non-concentration-dependant manner at 50 and 100 µM (Figure 4.3.2b).  
 
CN116, CN118, CN126, CN128, CN226 or CN228 exhibited a non-concentration related 
prevention of cell death in between 27 to 41% at all concentrations compared to 6-OHDA 
alone (+6-OHDA) (Figure 4.3.2c, d & e).  
 
There was no difference in cell viability when the equimolar concentrations of enantiomer 
pairs (CN116 vs CN118, CN126 vs CN128 and CN226 vs CN228), co-treated with 6-
OHDA were compared. However, comparison of equimolar concentrations between novel 
HPOs and CP20 co-incubated with 6-OHDA showed that CN118 (50 µM), CN226 (100 
and 500 µM) and CN228 (100 and 500 µM) improved cell viability.
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Figure 4.3.2: Effect of 6-OHDA on cell viability assessed by MTT assay after pre-incubation 
with novel HPO iron chelators. 
 
SH-SY5Y cells were pre-incubated for 20h with HPOs followed by 20h co-incubation with 40 µM 6-OHDA. 
Data are expressed as  mean+SEM  (n=3). *** p < 0.001 compared between HPOs treatments without 6-
OHDA (-6-OHDA) and HPOs treatments with 6-OHDA (+6-OHDA). # p < 0.05, ## p < 0.01, ### p < 0.001 
compared between HPOs treatments with 6-OHDA (+6-OHDA) and control with 6-OHDA (+6-OHDA). $ p < 
0.05, $$ p < 0.01 compared between CP20 treatments with 6-OHDA (+6-OHDA) and novel HPOs with 6-
OHDA (+6-OHDA). No significant different, p > 0.05 compared i) between HPOs treatments without 6-OHDA 
(-6-OHDA) and control without 6-OHDA (-6-OHDA) ii) between HPO enantiomer pairs (CN116 vs CN118, 
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 Effect of HPOs on viability of SH-SY5Y cells exposed to MG132 
SH-SY5Y cells were treated with various concentrations of HPOs (50 to 500 µM) with or 
without the IC50 concentration of MG132 (350 pM) prepared in 0.001% (v/v) DMSO. 
Control cells were treated with serum-free DMEM containing 0.001% (v/v) DMSO only or 
MG132 in serum-free DMEM containing 0.001% (v/v) DMSO. At the end of the treatment, 
the cell viability was measured by MTT assay as described in Section 2.2.8. 
 
Treatment of SH-SY5Y cells with 50, 100 and 500 µM HPOs only did not affect cells 
viability when compared to untreated control. Conversely, SH-SY5Y cells exposed to 350 
pM MG132 for 20 h showed approximately between 51 to 56% cell viability which were 
significantly lower compared to untreated control (Figure 4.3.3). Comparison of equimolar 
concentrations between HPOs without MG132 and HPOs with MG132 revealed significant 
reduction in cell viability except for CN128 at 50 µM concentration where there was no 
significant different (Figure 4.3.3). Overall, treatment of SH-SY5Y cells with HPOs for 20 
h prior had no effect on MG132-induced cell death.   
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Figure 4.3.3: Effect of MG132 on cell viability assessed by MTT assay after pre-incubation 
with novel HPO iron chelators. 
SH-SY5Y cells were pre-treated for 20h with HPOs followed by 20h co-treatment with 350 pM MG132. Data 
are expressed as  mean+SEM  (n=3). *** p < 0.001 compared between HPOs treatments without MG132 (-
MG132) and HPOs treatments with MG132 (+MG132). No significant different, p > 0.05 compared i) between 
HPOs treatments without MG132 (-MG132) and control without MG132 (-MG132) ii) between HPO 
enantiomer pairs (CN116 vs CN118, CN126 vs CN128 and CN226 vs CN228) treatments with H2O2 (2-way 
ANOVA followed by Holm-Šídák multiple comparison test).
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 Effect of HPOs on viability of SH-SY5Y cells exposed to FeNTA 
SH-SY5Y cell were treated with various concentrations of HPOs (50 to 1250 µM) with or 
without the IC50 concentration of FeNTA (460 µM) alone. Control cells were treated with 
serum-free DMEM or FeNTA (1:3) in serum-free DMEM. At the end of the treatment, the 
cell viability was measured by MTT assay as described in Section 2.2.8. 
 
None of the HPOs altered the viability of SH-SY5Y cells at any concentrations except for 
CN126 which showed reduced cell viability at the highest concentrations (500 and 1250 
µM) compared to untreated control. As expected, SH-SY5Y cells exposed to FeNTA (450 
µM) for 20 h produced between 43 and 48% loss in cell viability which were significantly 
lower compared to untreated controls (Figure 4.3.4). 
 
CP20 (1250 µM) reduced FeNTA-induced cell death by 23% (Figure 4.3.4a), however, 
CP84 (50 and 100 µM) failed to show any protection (Figure 4.3.4b).  
 
Although CN116 failed to show any protection against FeNTA-induced cell death (Figure 
4.3.4c), its stereoisomer CN118 (500 and 1250 µM) protected against FeNTA-induced cell 
death by 19 and 14% respectively (Figure 4.3.4d).  
 
By contrast, both CN126 and its stereoisomer CN128 protected the SH-SY5Y cell from 
FeNTA-induced toxicity (CN126: 26 and 29% protection; CN128: 33% and 23% protection) 
at 500 and 1250 µM (Figure 4.3.4e & f). 
 
Both CN226 and CN228 reduced FeNTA-induced cell death at 100, 500 and 1250 
concentrations, with almost complete protection at the highest concentration (Figure 
4.3.4g & h).  
 
Comparison of equimolar concentrations of enantiomer pairs, (CN116 vs CN118, CN126 
vs CN128 and CN226 vs CN228), on FeNTA-induced cell death showed no significant 
different. By contrast, comparison of equimolar concentrations between novel HPOs and 
CP20 reveals enhanced protection by 29%, 37% and 36% for CN128, CN226 and CN228 
respectively, at 500 µM (Figure 4.3.4).
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Figure 4.3.4: Effect of FeNTA (1:3) on cell viability assessed by MTT assay after pre-
incubation with novel HPO iron chelators. 
SH-SY5Y cells were pre-treated for 20h with HPOs followed by 20h co-treatment with 460 µM FeNTA (1:3). 
Data are expressed as  mean+SEM  (n=3). + p < 0.05, ++ p < 0.01 compared between HPOs treatments with 
FeNTA (1:3) [+FeNTA (1:3)] and control without FeNTA (1:3) [-FeNTA (1:3)]. *** p < 0.001 compared between 
HPOs treatments without FeNTA (1:3) [-FeNTA (1:3)] and HPOs treatments with FeNTA (1:3) [+FeNTA (1:3)]. 
# p < 0.05, ## p < 0.01, ### p < 0.001 compared between HPOs treatments with FeNTA (1:3) [+FeNTA (1:3)] 
and control with FeNTA (1:3) [+FeNTA (1:3)]. $ p < 0.05, $$ p < 0.01, $$$ p < 0.001 compared between CP20 
treatments with FeNTA (1:3) [+FeNTA (1:3)] and novel HPOs with FeNTA (1:3) [+FeNTA (1:3)]. No significant 
different, p > 0.05 compared i) between HPOs treatments without FeNTA (1:3) [-FeNTA (1:3)] and control 
without FeNTA (1:3) [-FeNTA (1:3)] ii) between HPO enantiomer pairs (CN116 vs CN118, CN126 vs CN128 
and CN226 vs CN228) treatments with FeNTA (1:3) (2-way ANOVA followed by Holm-Šídák multiple 
comparison test). 




In this study, in vitro neuroprotection study was performed in SH-SY5Y neuroblastoma cell 
lines exposed to the neurotoxins H2O2, 6-OHDA, MG132 and FeNTA, to evaluate the 
neuroprotective ability of novel HPO iron chelators. CP20 has been shown to be 
neuroprotective in in vitro and in vivo studies (Dexter et al., 2011, Molina-Holgado et al., 
2008). Therefore, it was hypothesised that modification to the structure of CP20 would 
retained the neuroprotective ability of CP20. The current study revealed that, all seven 
novel HPOs showed some degree of neuroprotection against toxins insults on SH-SY5Y 
cells except for cells exposed to MG132 which although appear to show a mild 
neuroprotection however was not significant. 
 
 Summary of the findings 
In general, all HPOs did not confer toxicity to SH-SY5Y on their own. Conversely, SH-
SY5Y exposed to the toxins H2O2, 6-OHDA, MG132 and FeNTA induced cell death as 
expected. The novel HPOs produced the greatest protection against toxin-induced cell 
death when 6-OHDA was used as a toxin, although they also protected SH-SY5Y cells 
from H2O2 and FeNTA. In these conditions, the neuroprotection was increasingly 
pronounced as the lipophilicity of the HPOs increased. Among all the toxins employed, 
MG132 toxicity was the least protected by HPOs. CN118, CN226 and CN228 showed 
more protection at 50 and/or 100 µM in 6-OHDA-induced cell death than equimolar 
concentration of CP20. CN128, CN226 and CN228 showed a better protection from 
FeNTA-induced cell death than CP20 at 500 µM. Comparison between HPOs enantiomer 
pair did not show any difference in neuroprotection ability. Summary of overall finding was 









CHAPTER 4: IN VITRO NEUROPROTECTION OF HPOs 
183 
 
Table 4.4.1: Summary of the findings for in vitro neuprotection study with SH-SY5Y cells 
Toxin H2O2 6-OHDA MG132 FeNTA (1:3) 
HPOs
µM 
50 100 500 50 100 500 50 100 500 50 100 500 1250 
CP20 nc ++ nc nc ++ ++++ nc nc nc nc nc nc ++ 
CP84 nc nc nd +++ +++ nd nc nc nd nc nc nd nd 
CN116 +++ +++ ++ +++ +++ +++ nc nc nc nc nc nc nc 
CN118 +++ nc nc ++++ 
$ 
+++ +++ nc nc nc nc nc ++ + 
CN126 ++ ++ +++ +++ +++ ++++ nc nc nc nc nc +++ +++ 
CN128 nc ++ nc +++ ++ ++++ nc nc nc nc nc ++++ 
$ 
+++ 




+++ nc nc nc + ++ ++++ 
$ 
++++ 




+++ nc nc nc ++ ++ ++++ 
$ 
++++ 
CP20 is highlighted in green. nc=no change, nd=not determined. + = low; ++ = mild; +++ = moderate; ++++ = 
high, neuroprotection compared to control with toxin only. $ = Better neuroprotection compared to equimolar 
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 Neuroprotection of HPOs against H2O2 toxicity in SH-SY5Y 
H2O2 was employed to model the SH-SY5Y cells death and to evaluate the effect of novel 
HPOs iron chelator due to its relationship with iron in producing OH●- radical through the 
Fenton reaction. OH●- radical is a highly reactive radical that caused disintegration of 
biological membranes through lipid peroxidation, caused protein misfolding and point 
mutations in DNA sequences (Guo et al., 2013). Therefore, the aim of this study was to 
determine whether co-treatment of HPOs with H2O2 would protect against SH-SY5Y cell 
death by minimising the toxic effect of OH●- radical formed through iron chelation. These 
data support the idea as CP20 and the novel HPOs reduced H2O2-induced cell death 
between 48 to 79%.  
 
This is the first time that the protective effect of CP20 on H2O2-induced toxicity in SH-SY5Y 
cells has been reported, therefore, direct comparison with the existing study is not 
possible. Nevertheless, CP20 has been shown to protect primary cortical neuronal 
cultures from H2O2- induced cell death as measured by reduced LDH release (Molina-
Holgado et al., 2008). Moreover, CP20 has been shown to reduce the production of OH●-  
radical through Fenton reaction by spectroscopy analysis which suggest that this is 
probably one of the main mechanism of CP20 protection against H2O2 toxicity (Devanur 
et al., 2008b, Timoshnikov et al., 2015). As expected due to their structural similarities with 
CP20, with the exception of CP84, the novel HPOs also showed significant protection 
against H2O2 toxicity in SH-SY5Y cells, and this was comparable to CP20. CN116, CN118, 
CN126, CN226 and CN228 co-treated with H2O2 significantly protected from H2O2 toxicity 
at 50 µM while CP20 only did so only at 100 µM which might suggest higher chelation 
potency for novel HPOs. The neuroprotection might be partly due to the pFe3+ as 
determined by potentiometric titration which were similar to that of CP20. Interestingly, the 
enantiomer pair of HPOs did not show any differences in neuroprotection suggesting little 
or no contribution of stereochemistry to the activity of HPOs. As for CP84, although there 
appeared to be a small protection against cell death, this was not significant.  
 
Although the existing studies of CP20 on H2O2-induced toxicity in vitro are scanty, 
neuroprotection studies with DFO and H2O2 can be compared with the current results. 
Although DFO is structurally different to the HPOs used in this study as it is in which it is 
a larger hexadentante molecule, DFO and HPOs are both Fe(III) iron chelator. Therefore, 
the reported mechanisms of neuroprotection of DFO is expected to be similar to HPOs 
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through their primary pharmacological action. Previous study showed that SH-SY5Y cells 
pre-treated with DFO for 2 hours completely abolished H2O2-induced autophagy (Castino 
et al., 2011). Besides DFO, a novel fluorinated derivative of CP20, Apo6856 (Figure 4.4.1) 
also protected SH-SY5Y against H2O2 toxicity in a concentration dependent manner 
(Premyslova et al., 2016, Tam et al., 2014). Treatment with Apo6856 also caused a 
concentration- and time-dependent up-regulation of Nrf2 activity in SH-SY5Y cells and 
modulated the expression of genes in a pattern consistent with downregulation of 






Figure 4.4.1: Chemical structure of a) CP20 and b) Apo6856, a fluorinated derivative of CP20. 
Functional group highlighted in red denotes the structural different from CP20. Atoms 
highlighted in blue indicates the pharmacophore that is important for the bidentate co-
ordination with iron. 
 
It is likely that CP20 and the novel HPOs would also act via the same molecular 
mechanism due to the close structural and functional similarity to Apo6856 in manifesting 
the neuroprotection in H2O2-treated SH-SY5Y cells. However, this is not conclusive and 
remain speculative until the molecular mechanism of CP20 and novel HPOs in H2O2-
treated SH-SY5Y are studied in detail. 
 
In summary, all novel HPOs except CP84 showed comparable neuroprotection to CP20 
against H2O2-induced cell death. Most of the novel HPOs started to show significant 
neuroprotection at 50 µM in contrast to 100 µM for CP20 suggesting better efficacy than 
CP20. It is suggested that the mechanism of neuroprotection of the novel HPOs against 
H2O2 toxicity was mainly through the chelation of excess intracellular iron which is 
associated with H2O2 toxicity. 
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 Neuroprotection of HPOs against 6-OHDA toxicity in SH-SY5Y 
6-OHDA was employed to induce SH-SY5Y cell death and to evaluate the ability of novel 
HPOs to protect SH-SY5Y from 6-OHDA-induced cell death. As a metabolite of dopamine, 
6-OHDA was used as a toxin to induce SH-SY5Y cell death through the generation of 
ROS through interaction with O2 (Section 2.2.1b). Furthermore, the oxidation product of 
6-OHDA, p-quinone, is a highly reactive electrophile that formed an adduct with 
nucleophilic groups of intracellular proteins (Soto-Otero et al., 2000, Napolitano et al., 
1995). Most importantly, 6-OHDA induced the accumulation of iron into the cells by 
enhancement of iron cell-uptake mechanisms which accelerate the process of cell death 
by producing more ROS via Fenton reaction. Therefore, SH-SY5Y cells treated with iron 
chelators are expected to slow down or inhibit cell death and reduce cell death.  
 
The data revealed that CP20 protected against 6-OHDA-induced cell death in a 
concentration dependent manner with significant protection at 100 and 500 µM 
concentration. Furthermore, cell viability for SH-SY5Y cells was also reverted to the control 
level at 500 µM concentration in agreement with a recent report (Workman et al., 2015). 
Interestingly, novel HPO iron chelators showed significant protection against 6-OHDA 
induced cell death at all of the concentration tested with CN118, CN226 and CN228 
inhibiting toxin-induced cell death to the control level at lower HPOs concentrations. These 
HPOs also showed significant reduction in cell death in comparison to equimolar 
concentrations of CP20. This observation supports the hypothesis made by Workman et 
al. (2015) that increasing the lipophilicity of HPO chelators enhances neuroprotection of 
SH-SY5Y cell death induced by 6-OHDA. It was suggested that increased in lipophilicity 
made the HPO more accessible to intracellular iron by crossing the biological membranes 
which include the mitochondrial membranes. Since the pFe3+ for the novel HPO iron 
chelators (pFe3+=19.80-20.40) was similar to the pFe3+ for CP20 (pFe3+=20.20), it is likely 
that this contributed less to the different in extent of iron chelation compare to lipophilicity. 
 
It has been demonstrated by Kobayashi et al. (2008) that 6-OHDA and iron mixture 
generates higher level of H2O2 and p-quinone than 6-OHDA alone. It was suggested that 
a semiquinone radical is formed through a reduction of Fe3+ as an intermediate before the 
semiquinone is oxidised to p-quinone by O2 with ROS produced along the course of the 
reaction (Figure 4.4.2).  




Figure 4.4.2: Production of ROS during 6-OHDA metabolism to p-quinone (Izumi et. al., 
2005). 
 
Indeed, ROS generated during p-quinone formation has been reported to be the primary 
contributor of 6-OHDA toxicity and reducing p-quinone level was found to be 
neuroprotective (Izumi et. al., 2005, Storch et al., 2000). Additionally, this observation was 
further supported by several neuroprotection studies in vitro using different type of iron 
chelators that managed to prevent the 6-OHDA induced cell death (Zheng et al., 2006, 
Cacciatore et al., 2013). In the situation where semiquinone formation is halted by efficient 
iron chelation, 6-OHDA would be the predominant species. 6-OHDA has been reported to 
inhibit Complex I and Complex IV of mitochondrial respiratory chain, but further experiment 
showed that these electron transport chain inhibitions did not lead to interruption in ATP 
production. This might explain the complete prevention of 6-OHDA-induced cell death in 
some of the treatment group with HPOs. 
 
To summarise, novel HPOs showed a pronounced neuroprotection against 6-OHDA-
induced cell death with some of them are a better neuroprotectant at equimolar 
concentrations (CN118, CN226 and CN228) of CP20. It is proposed that the mechanism 
of neuroprotection of the novel HPOs against 6-OHDA-induced cell death was through the 
inhibition of p-quinone metabolite formation from 6-OHDA that requires iron. 
 
 Neuroprotection of HPOs against MG132 
MG132 was chosen to induce SH-SY5Y cell death due to its proteasomes inhibition 
property that emulate the toxicity of mutant or aggregated α-synuclein found in 
dopaminergic neuron of patients with familial PD. α-Synuclein is targeted for degradation 
by the UPS pathway, however, mutant or aggregated α-synuclein can interact with the 
proteasomes active sites and inhibits its activity (McNaught et al., 2002, Snyder et al., 
2003). Inhibition of UPS also lead to accumulation of iron by decreasing the iron binding 
proteins (IRPs) degradation. IRP bind to iron response element (IRE) on mRNA of proteins 
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that involve with iron uptake, regulation and metabolism (Xie et al., 2010b, Wang et al., 
2007, Guo et al., 1995). Simultaneous accumulation of intracellular proteins and iron-
induced free-radicals could aggravate the oxidative stress through free-radical generation 
(Kalivendi et al., 2004). Therefore, the aim of this study was to determine whether by 
chelating iron in MG132-treated SH-SY5Y cells, the cell death could be prevented. Neither 
CP20 nor the novel HPOs protected against MG132-induced toxicity. This is consistent 
with the previous report that, the antioxidant N-acetylcysteine failed to protect against 
MG132-induced cell death (Cheng et al., 2016, Zafar et al., 2007). UPS inhibition results 
in the build-up of damaged and unwanted intracellular proteins. These data confirm that 
chelation of iron alone is not sufficient to prevent MG132-induced cell death. Remarkably, 
repression of p53 level by genetic silencing or inhibiting p53 activity prevented cell death 
resulted from proteasomes inhibition (Lopes et al., 1997, Nair et al., 2006, Dietrich et al., 
2003). This may suggest that, apart from iron-induced free radicals, other distinct factors 
might predominantly contribute to cell death after proteasomes inhibition. It may be argued 
that proteasome dysfunction is not a primary phenomenon in PD as seen using 
proteasomes inhibitors such as MG132, lactasystin or PSI, but rather a secondary 
phenomenon as a result of damaged caused by oxidative stress. Oxidative stress induces 
misfolding and aggregation of proteins such as α-synuclein that in turn inhibit proteasomes 
function. Therefore, the treatment approach might strictly depend on the nature of the 
cause of the UPS inhibition. 
 
To sum up, CP20 and the novel HPOs showed no neuroprotection against MG132-
induced cell death. It is proposed that the main pathogenesis of MG132 toxicity was not 
sufficiently prevented by treatment with HPOs iron chelator alone, which presumably 
because MG132 toxicity predominantly involved other pathways that do not involve iron. 
 
 Neuroprotection of HPOs against FeNTA 
In this study, the FeNTA (1:3) complex (shortened to FeNTA) was used to induce iron 
toxicity in SH-SY5Y cells. In addition, FeNTA can be used to evaluate the efficiency of iron 
transfer to HPOs in which case FeNTA act as non-transferrin bound iron (NTBI) to HPOs. 
High concentration of NTBI characterised the intracellular physiology of cells with iron 
overload. This is the first reported study of CP20 neuroprotection on FeNTA-induced cell 
death using SH-SY5Y cells. CP20 exhibited a concentration-dependant neuroprotection 
against FeNTA toxicity with significant protection at 1250 µM. This agrees with a previous 
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study where, CP20 prevented FeNTA toxicity in a concentration dependant manner in 
primary cortical neurons albeit at relatively lower concentrations (30 and 100 µM) (Molina-
Holgado et al., 2008). The discrepancies in the concentrations of CP20 that conferred 
neuroprotection was due to the different types of cells employed between these studies. 
Primary cortical neurones are more sensitive to FeNTA toxicity (IC50 = 10 µM) than SH-
SY5Y cells which require higher concentrations to incur cell death (IC50 = 460 µM). This is 
likely to be due to the buffering provided by the iron storage protein, ferritin, which is 
overexpressed in cancer cell lines (Guan et al., 2017, Selig et al., 1993). Nevertheless, 
both studies showed the same efficiency (about 3-folds of the IC50 concentrations for 
FeNTA) of CP20 to significantly chelate iron from NTA. Remarkably, novel HPOs CN116, 
CN118, CN226 and CN228 prevented cell death at or below the IC50 concentration of 
FeNTA which suggest that iron transfer and re-distributes from NTA to these HPOs. This 
redistribution more readily occurs at lower concentrations compared to CP20 which only 
significantly protected cells from FeNTA toxicity at the concentration of two-folds of FeNTA 
IC50 (1250 µM). On the other hand, CN116 and CP84 did not protect SH-SY5Y cells at all 
from FeNTA insult. 
 
Additionally, CN128, CN226 and CN228 were superior than CP20 neuroprotection at 
equimolar concentration (500 µM). It is even more interesting to emphasise that the degree 
of neuroprotection of novel HPOs used in this study are more related to the lipophilicity 
than the pFe3+. Similar observations were also found when other toxins were used to 
induced cell death as has been explained in the previous sections. It has been suggested 
that FeNTA complex can permeate through biological membranes (Bunescu et al., 2008) 
and bidentate chelators such as CP20 could competitively chelate iron in a concentration-
dependant manner from an existing iron complex (Devanur et al., 2008a). The suggested 
mechanism of iron transfer from FeNTA to HPOs is presented in Figure 4.4.3. Base on 
the current results, it can be proposed that FeNTA induced iron toxicity intracellularly and 
HPOs with higher lipophilicity could gain sufficient concentration in the cytoplasm to 
prevent iron-induced cell death. The results suggest the suitability of novel HPOs to treat 
localised brain iron accumulation as seen in PD brain. This is crucial as traditional iron 
chelator, DFO, although could efficiently chelate iron, has very low membrane permeability 
and has limited ability to cross biologicals membranes (Guan et al., 2017). 
 




Figure 4.4.3: Suggested mechanism of Fe(III) transfer-equilibration between NTA and 
HPOs. 
 
In summary, all the novel HPOs protected against FeNTA-induced cell death with some 
of them showing better neuroprotection (CN128, CN226 and CN228) than CP20 at 
equimolar concentrations. It is proposed that the neuroprotection of HPOs against FeNTA-
induced cell death was improved as the lipophilicity increased. 
 
 Advantages and shortcomings of this study 
Cell-based assay is widely employed for evaluating and screening potential 
neuroprotective agent due to their physiology and mechanisms closely related to the cells 
in living animals but with added flexibility (Burroughs et al., 2012, Zhang et al., 2014). 
Additionally, experiment on cell lines for testing neuroprotection agents are less expensive 
than testing in living animals. Homogeneous neuroblastoma cell lines such as SH-SY5Y 
is one of the important tools widely employed during the early stage for screening potential 
new drug in PD research. Importantly, SH-SY5Y cell line is a catecholaminergic 
neuroblastoma cell line from human origin. This cell line expresses both DAT and TH 
which resembles the affected dopaminergic neurons in the substantia nigra pars compacta 
(SNPc) in PD brain (Kovalevich and Langford, 2013b, Filograna et al., 2015). Being 
immortalised, the cells are easy to grow, rapidly reaches confluence in culture, stable for 
multiple passages and can be stored frozen in contrast to primary cell cultures. Because 
of these reasons, SH-SY5Y cells is suitable for initial screening for large set of potential 
neuroprotection agents for PD (Xicoy et al., 2017, Xie et al., 2010a). Moreover, large array 
of neurotoxins with different mechanisms of toxicity could be used to induce cell death by 
adding into the cell culture medium. As discussed in this chapter, novel HPOs prevented 
SH-SY5Y cell death when exposed to H2O2, 6-OHDA and iron, but not with MG132. This 
observation could be used to justify the primary mode of action of HPOs when oxidative-
stress is predominant in inducing cell death.  
 
However, in vitro cell lines are expected to behave differently than the cells in vivo due to 
their isolation from living system, that may affect the results in the current study. 
Additionally, cell lines such as SH-SY5Y are cancerous and therefore the cell cycle 
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regulations are atypical from mature neuron which has limited ability to divide. Indeed, the 
rapid cell proliferation of SH-SY5Y is due to the chronic activation of MAPK-ERK signalling 
pathway by mutated Ras and leads to alteration of genes transcription that are important 
for cell-cycles. Thus, SH-SY5Y may utilize different mechanisms of cell death than in 
mature primary neurons because of the MAPK-ERK overactivation (Abramova et al., 
2002). Moreover, cancerous cells such as SH-SY5Y are known to express multitudes of 
cell-survival mechanism that render the cells resistance to chemotherapeutic agent. For 
example, toxin such as iron (FeNTA) employed in the current study showed higher IC50 
value (50-fold) in comparison to primary neuronal culture that significantly more sensitive 
to these toxins (Molina-Holgado et al., 2008). Indeed, tumour cell lines such as SH-SY5Y 
and HepG2 are relatively insensitive to iron chelation by iron chelators due to increase 
ferritin level in these cells (Selig et al., 1993, Selig et al., 1998, Guan et al., 2017). In this 
situation, higher concentration of iron chelators is needed to completely deplete cellular 
iron and causing cell death. 
 
Continuously dividing cells like SH-SY5Y makes it difficult to determine whether the 
observed neuroprotection is solely because of prevention of cell death and not induction 
of cell proliferation (Datki et al., 2003). Because of this reason, serum which provide 
important biological factors for cell growth was omitted during the neuroprotection phase 
of this study. Serum removal helps to synchronise the development stage of the dividing 
SH-SY5Y cell line by enabling cells to enter the nondividing state (G0) characterised by 
low metabolic activity (Langan and Chou, 2011). Lower IC50 value for toxin is achievable 
when serum is removed as absence of serum in cell culture media retards cell growth. 
However, omission of serum introduces other disadvantages. Serum deprivation has been 
shown to cause progressive decline in SH-SY5Y cell viability with almost 50% cell 
reduction after 4 days without serum due to increase in pro-apoptotic and autophagic 
proteins (Kim et al., 2008, Bar-Am et al., 2005, Xu et al., 2013). This to some extent may 
have affected the degree of the measured cell viability in toxin-induced cell death but this 
has been considered in the current experiment design by running a simultaneous 
negative-control. 
 
Although SH-SY5Y cell lines shares some important characteristics of dopaminergic 
neurons that enable their usage to screen neuroprotection agents, array-based 
comparative genomic hybridization studies have identified significant chromosomal 
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aberration which contributes to different genetics information compared to dopaminergic 
neurones in brain (Do et al., 2007, Skibinski and Finkbeiner, 2011). This may explain lower 
expression of TH and DAT in SH-SY5Y cells, which may mean that the mechanism of 
toxicity and neuroprotection are different than primary dopaminergic neurons (Presgraves 
et al., 2004). For example, 6-OHDA could confer its toxicity both extracellularly and 
intracellularly as discussed in Chapter 2. Mechanism of intracellular toxicity of 6-OHDA is 
dependent on the expression of DAT, thus may create variations in the cellular response 
to exogenous stimuli between SH-SY5Y and primary neurones. In addition, SH-SY5Y cell 
that have undergone multiple passages could lose their neuronal and dopaminergic 
characteristic as they accumulate genetic and epigenetic alterations. Accumulated genetic 
and epigenetic alterations after multiple passage make it hard to get reproducible and 
reliable results. This could be prevented by using cells at low passage number as in the 
current study. 
 
Since SH-SY5Y cells grown in vitro is an open system as opposed to neurons in the brain 
that are separated from systemic circulation by BBB, question may arise on the validity of 
observed neuroprotection in vivo. This is because, potential neuroprotection agent that 
shows promising results in vitro might not work in vivo due to poor brain permeability. This 
issue has been addressed in Chapter 3 and 5, whereby HPOs were assessed for brain 
permeability by in situ brain perfusion and after i.p. injections. Besides the brain 
permeability issue, the concentration of compounds that showed neuroprotection may not 
necessarily achieved in the brain eventhough they could cross the BBB (Weber, 2015). 
 
Despite all the disadvantages and limitations discussed above, cell lines such as SH-SY5Y 
has served an important role for studying the mechanism of toxins in causing cell death in 
PD and also to explore neuroprotection strategies to prevent or delay cell death 
(Falkenburger and Schulz, 2006). It should be acknowledged that the effect of potential 
neuroprotection agents may not be fully represent to pharmacologic effects in vivo. For 
this reason, subsequent studies in animal model of PD is vital to confirm the results from 
in vitro cell cultures study. 
 
 




The differences of HPOs ability to exhibit neuroprotection in these in vitro models appears 
to be related to the pathogenesis that leads to cell loss. In this circumstance, it can be 
speculated that cell death pathogenesis that predominantly involved iron accumulation 
could be prevented by chelating excess iron with HPOs. Having said this, SH-SY5Y cell 
death caused by exposure to 6-OHDA could be prevented nearly 100% when treated with 
HPOs. Paradoxically, FeNTA-induced cell death was not prevented as efficiently as in 6-
OHDA-induced cell death. This could be explained based on the competition between 
NTA and HPOs to chelate iron. Iron chelation with HPOs also significantly prevented H2O2-
induced cell death possibly through the chelation of excess iron which subsequently 
reduced OH●- radical synthesis from the Fenton reaction. Toxicity of MG132 was not 
reduced by iron-chelation suggesting that the mechanism of toxicity does not involved 
ROS generated by iron alone. However, it needs to be emphasised that the data from the 
current study only come from a single method of detecting cell death. The MTT assay 
relies on measuring mitochondrial enzyme activity (Wang et al., 1996). It has been 
reported that some compounds can modulate the enzyme activity or directly interact with 
MTT which confound the final results (Hsu et al., 2003, Devika and Stanely Mainzen 
Prince, 2008). Other cell viability methods such as measurement of ATP level or trypan 
blue exclusion assay could be used for confirmation of the results. Additionally, molecular 
study to reveal the downstream mechanism towards neuroprotection of these novel HPOs 
is also of great interest. 
 
 Conclusion 
The present study aimed to evaluate the neuroprotection of novel HPOs and compare with 
CP20. Treatment of SH-SY5Y cell with HPOs alone did not induce cell death, while 
treatment with toxins only at the IC50 concentration induced cell death. Novel HPOs 
managed to prevent cell death associated with exposure to neurotoxins to various degree 
suggesting an involvement of iron in the promotion of cell death, except for MG132. 
CN118, CN226 and CN228 showed better neuroprotection than the equimolar 
concentration of CP20 in 6-OHDA-induced cell death. Similarly, CN126, CN226 and 
CN228 were superior than equimolar concentration of CP20 towards protection against 
FeNTA-induced cell death. Chirality in novel HPOs chemical structure did not cause 
different in neuroprotection capability.  In conclusion, the hypothesis that novel HPOs are 
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neuroprotective in in vitro model of PD are accepted. Due to the neuroprotection shown in 
vitro, it is not known whether these compounds will show neuroprotection in vivo.  For this 
reason, selected HPOs were chosen for a further neuroprotection study utilising an in vivo 
rat model of PD.   
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5 Neuroprotection study of novel HPOs with 
6-OHDA lesioned rat model of Parkinson’s 
disease 
 Introduction 
At the start of these studies it was hypothesised that the novel HPOs based on the 
structure of CP20 could cross the BBB and show neuroprotection in Parkinson’s disease 
(PD). In Chapter 3 of this thesis the first part of this hypothesis was tested. Studies were 
described that showed that, of all the HPOs studies, only CP84 had a superior rate of brain 
uptake compared to CP20, and that although the rate of brain uptake for CN128, CN226 
and CN228 were not different than CP20, those of CN116, CN118 and CN126 were lower.  
In Chapter 4, the second part of this hypothesis was tested. The neuroprotection ability of 
all brain permeable novel HPOs was investigated in vitro using toxin-treated SH-SY5Y 
neuroblastoma cells.  In this study, novel HPOs showed a tendency for positive correlation 
between their neuroprotective potency and lipophilicity, especially against 6-OHDA and 
FeNTA induced cell death.  
 
In the studies described in this chapter the overall hypothesis was tested by comparing 
the ability of selected HPOs to protect against cell death in vivo.  This assesses both the 
properties of CNS penetration and neuroprotection. From the previous results CP84, 
CN128 and CN226, along with CP20 were selected to take forward into these studies. 
Studies on the effect of CP20 in in vivo model of PD have been reported in the literature 
(Dexter et al., 2011, Devos et al., 2014). CP20 was found to be neuroprotective in 6-OHDA 
treated rats and MPTP treated mice. In addition, recently, clinical trials to assess the effect 
of CP20 in PD patients (FAIRPARK) showed reduction in iron level in the nigrostriatal 
system and improved motor score after 6- to 12-months treatment (Devos et al., 2014a, 
Martin-Bastida et al., 2017).  CP20 was therefore included in these studies as a positive 
control. 
 
Although CP84 showed limited neuroprotection compared to other novel HPOs, its high 
brain permeability relative to other HPOs, and significant protection against 6-OHDA 
toxicity warranted its inclusion in this in vivo study. Both CN128 and CN226 showed similar 
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or better CNS penetration and neuroprotection than CP20. Of the enantiomeric pair, 
CN126 and CN128, both showed similar neuroprotection in the in vitro models, but the 
latter showed a 2-fold greater brain uptake which was not significantly different to CP20.  
For this reason, CN128 was taken forward to the in vivo neuroprotection study. By 
contrast, the enantiomeric pair, CN226 and CN228, showed equal brain permeability and 
in vitro neuroprotection suggest that chirality did not play a role in brain permeability or 
neuroprotection against the selected toxins. However, only CN226 was selected due to its 
preferable physical property that remain dry at room temperature in contrast to CN228 that 
is hygroscopic. 
 
The choice of compounds taken forward was based not only on their brain penetrability 
and neuroprotective effect in vitro, but also on their pharmacokinetic profile and evidence 
of in vivo iron chelating activity. Previously, oral treatment with CN128 and CN226 in iron-
overloaded rat revealed ability of these HPOs to excrete iron (Hider et al., 2011a, Lu, 
2016). In addition, CN128 has been shown to be the most efficient iron-chelating agent 
among the novel iron chelators when assessed in iron-overloaded rat due to improved 
bioavailability than CP20 (Hider et al., 2011a, Lu, 2016, Paiboonsukwong et al., 2016). 
CN128 also exhibited better toxicity profile than CP20 in preventing reduction of 
leukocytes counts in rats and monkeys (Paiboonsukwong et al., 2016).  
 
Based on the current and previous findings along with toxicity profiles assessed in rats 
and monkeys (Paiboonsukwong et al., 2016), it is speculated that CP84, CN128 and/or 
CN226 would be neuroprotective and could perform better in human than CP20. However, 
before this can be tested in human, data from animal studies is needed to progress to the 
clinical phase. Therefore, to assess the neuroprotective ability of CP84, CN128 and 
CN226, neuroprotection study was performed along with CP20 as a positive control in 










It was hypothesised that CP84, CN128 and CN226 are neuroprotective against 6-OHDA-
induced degeneration of dopaminergic neurons in the rat nigrostriatal pathway in vivo. 
 
 Aims 
To test the hypothesis, rats were treated with equimolar doses of HPOs before, during and 
after a partial 6-OHDA lesion.  Using 6-OHDA- or sham-lesioned rats, these studies had 
the following aims: 
 
a) Confirm that CP20, CP84, CN128 and CN226 is absorbed into systemic 
circulation after i.p. injection. 
 
b) Assess the effect of selected HPOs on body weight. 
 
c) Evaluate the effect of selected HPOs on D-amphetamine-induced rotational 
behaviour. 
 
d) Investigate the effect of selected HPOs on striatal level of dopamine and 
serotonin and their metabolites. 
 
e) Determine the effect of selected HPOs on dopaminergic cell death in the SNPc. 
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 Materials and methods 
 Experimental animals 
Male Wistar rats weighing between 250-300 g (Harlan UK Ltd) and were housed between 
2-4 rats per cage at BSU, King’s College London as described in Section 2.2.2. 
 
 Pharmacokinetics evaluation of selected novel 3-hydroxy-4-
pyridinone iron chelators in rats 
Rats (n=3-4 per treatment group) were injected i.p. in a volume of 5 mL/kg with 200 
µmol/kg (CP84) or 500 µmol/kg (CP20, CP84, CN128 and CN226).  All HPOs were 
prepared in 0.9% (w/v) NaCl, except for CP84 that contained a final concentration of 0.1% 
(v/v) DMSO in 0.9% (w/v) NaCl. 
 
 Samples collection 
Blood sample were collected into heparinised tube at 5, 10, 20, 60, 120, 240, and 360 min 
after i.p. injection from the rat lateral vein using 23G wing infusion needle (Terumo®; 
MediSupplies, UK). Rat tail was immersed into warm (40 ˚C) tap water 2 minutes prior to 
blood sampling to visualise the lateral vein and to assist blood flow during sample 
collection. Plasma samples were obtained from the collected blood via centrifugation at 
5400 g for 10 min and were stored in -70 ˚C until use. Rats were terminally anaesthetised 
with 600 mg/kg pentobarbital sodium (Merial Animal Health Ltd, UK) at the terminal time 
point (360 min) and the brain was taken out. The brain was homogenised in PhyBS [1:1 
(w/v)] and stored in -70 ˚C until use. 
 
 Samples preparation and analysis 
Plasma and brain samples obtained from HPOs treated rats were prepared and analysed 
using a validated method as described in Section 2.3. In short, internal standard, IS (200 
µM; 10-fold concentration) was added into plasma and brain homogenate collected from 
the treated rats. Following this, the samples were extracted with TFA as described in 
Section 2.3.5. Briefly, clear supernatant was collected after centrifugation at 20800 g for 
45 minutes and 30 µL was injected into HPLC system along with standard calibration 
curve. The HPLC method for analysis of HPOs in the plasma and brain samples was 
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performed as described in detail in Section 2.1.9b. The HPLC response signal was taken 
as the ratio of HPO and IS peak height and converted into concentration (µM) using linear 
equation obtained from the standard calibration curve. The HPOs concentrations in 
plasma and brain from treated rats were corrected for protein binding as described in detail 
in Section 2.1.10. 
 
 Data analysis 
The pharmacokinetic parameters were calculated by non-compartmental analysis (plasma 
data after extravascular input) using Microsoft Excel Solver add-in, PK-Solver 2.0 (Zhang 
et al., 2010). One-way ANOVA followed by Dunnett’s test was performed to compare 
between the PK parameters. 
 
 6-OHDA model of PD for neuroprotection study 
Male Wistar rats (n=6 per group; 250-300 g) were pre-treated with CP20 or CN128 three 
days prior to 6-OHDA lesion and for four days after the lesion following a dosage regime 
reported by Dexter et al. (2011). CP20 and CN128 (70 µmol/kg) or vehicle (5 mL/kg; 0.9% 
(w/v) NaCl) were injected i.p twice daily with 12 h gap between treatments (doses at 9 
a.m. and 9 p.m). On the day of the surgery only the first i.p. injection was performed 30 
minutes prior to induction of the lesion. The dose of 6-OHDA-HCl (Sigma-Aldrich, UK) was 
calculated as a free base and dissolved in 0.9% saline containing 0.1% (w/v) L-ascorbic 
acid on ice on the day of surgery. Aliquots (1000 μL) were protected from light exposure 
and stored on ice until the surgical procedure. The intra-striatal lesion was induced by 
injection of 6-OHDA (8 µg/4 µL) as described in Section 2.4.4.  Similarly, control animals 
received sham injection (4 µL of 0.9% saline containing 0.1% (w/v) L-ascorbic acid. The 
weights of all the rats were recorded daily before and after surgery. At the end of the 
treatment period, the rats entered a ‘wash-out’ period for seven days. Behavioural 
assessment as described below (Section 5.2.4) was performed on day 12th of the 
experimental timeline as illustrated in Figure 5.2.1. 
 




Figure 5.2.1: Overview of experimental timeline. 
Rats were treated twice daily with CP20 or CN128 (70 µmol/kg, i.p.) or vehicle for 7 days. 
Intrastriatal 6-OHDA (8 μg/4 μL) or sham-lesions (vehicle) were performed 30 minutes after drug 
administration on the third day of HPOs treatment. Following a 7 days wash-out period, the rats 
were culled.  
 
 D-amphetamine rotation test 
On the day 9th after lesioned, D-amphetamine rotation test using a rotometer (RotoRatTM, 
Med Associates, Inc., USA) was performed on the rats as described in Section 2.4.5. In 
brief, the rats were injected i.p with 2.5 mg/kg D-amphetamine sulphate (Tocris 
Bioscience, UK) prepared in 0.9% (w/v) saline. The rotations were recorded for a total of 
3 h after D-amphetamine injection by a sensor attached to a tethered jacket that was 
strapped on the rats. Prior to injection with D-amphetamine, the rotational baseline was 
recorded for 30 minutes following acclimatisation to the rotometers. Data was collected 
using the RotoRatTM hardware and RotoRatTM software Version 2.0 followed by analysis 
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 Determination of dopamine and serotonin level by HPLC-ECD 
 Striatum dissection 
The brain was removed from the skull and cleaned of meninges and striatum dissected. 
The brain was cut laterally with single-edge blade (VWR International Ltd, UK) at the level 
of optic tracts (Figure 5.2.2a). 
 
 
Figure 5.2.2: Steps of striatum dissection on the isolated perfused brain. 
a) Rat brain at ventral position i = optic chiasma, ii = optic tracts, iii = middle olfactory tracts and iv 
= mammillary bodies (Ibe et al., 2014). Dotted straight line indicates the position of horizontal brain 
cutting into halve b) the coronal slice of the upper part of the halve brain. Dotted circled shows the 
location of striatum in the left and right hemispheres of brain c) Striatal tissues were separated from 
the rest of brain tissues d) Isolated striatal tissues with white matter mostly removed and stored in 
-70 ºC for HPLC analysis. 
 
The upper-half part of the brain was positioned into coronal section. White matter was 
pulled away with a pair of forceps and striatum as shown in Figure 5.2.2b was dissected 
out and put into a pre-weighed microcentrifuge tube stored on dry ice. Similar steps were 
repeated for contralateral side of striatum. The isolated striata were stored in -70 ºC until 
analysis with HPLC. 
 
 Sample preparation 
Striatum was weighed and diluted 1:9 (v/v) with 0.4 M perchloric acid containing 0.01% 
(w/v) sodium metabisulfite (Na2S2O5) and 1 mM EDTA (PCA). DHBA at a final 
concentration of 1 µM was added into the mixture and function as an internal standard. 
The mixture was homogenised with a sonic homogeniser for 30 to 60 seconds (Sonics & 
Materials Inc, USA). The homogenate was centrifuge for 10 minutes at 20800 g at 4 ˚C. 
Finally, the supernatant was collected and store at -70 ˚C. 
 
 




Main stock (1 mM) for dopamine and serotonin with their metabolites (DOPAC, HVA, 5-
HT & 5-HIAA) were prepared in PCA. A range of working stock solutions (10-640 µM) of 
dopamine and serotonin with their metabolites was prepared in PCA. The injected 
standards were prepared by 1:9 (v/v) dilution in PCA. 2,3-Dihydroxybenzoic acid (DHBA) 
was used as an internal standard. Similarly, 1 mM of DHBA main stock was prepared in 
PCA, diluted 1:99 (v/v) to 10 µM in 0.4 M PCA as working stock solution. Working stock 
solution of DHBA was added into individual standard at 1:9 (v/v) dilution (final = 1 µM). 
Additionally, a standard that consist of dopamine and metabolites at a selected single 
concentration was also prepared in PCA. All chemicals were obtained from Sigma-Aldrich, 
UK unless stated otherwise. 
 
 Mobile phase 
Mobile phase was 0.1 M sodium dihydrogen orthophosphate (NaH2PO4) containing of 1 
mM EDTA, 0.01% (w/v) octane sulfonic acid (OSA) in 12% (v/v) methanol, pH adjusted to 
3.2 with phosphoric acid. Mobile phase was filtered with polyamide membrane filters (0.45 
µm pore size; Sartorius Stedim UK Limited, UK).  
 
 HPLC conditions 
The quantification was performed on an Ultimate 3000 Standard LC Systems equipped 
with quaternary pump delivery system (LPG-3400SD), autosampler (WPS-3000(T)SL 
Analytical) and INTRO electrochemical detector (Antec Scientific, USA). A column set in 
the system was a Spherisorb ODS (2) 3 µm particle size HPLC column (SpheriClone 0.46 
cm x 10 cm; Phenomenex, UK) was equilibrated at 30 ºC. Sample elution was performed 
under isocratic mode at a flow rate of 1.0 mL/min. A potential of 0.72V was maintained 
across the electrode, filter was set at 5 seconds, sensitivity range was set at 20 nA/V and 
injection volume was 10 µL. Concentrations of catecholamines are calculated by using 
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Figure 5.2.3: Representative chromatogram and standard curves for dopamine and 
serotonin with their metabolites. 
The catecholamines of interest are DHBA (RT = ~4.4 min), dopamine (RT = ~6.1 min), DOPAC 
(RT = ~7.3 min), HVA (RT = ~18.7 min), 5-HT (RT = 13.4 min) and 5HIAA (RT = ~11.1 min) 
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 Brain fixation and sectioning 
Following dissection of the anterior part of the brain for removal of the striatum, the 
posterior part of the brain was post-fixed with 4% (w/v) PFA for 6 days. The fixed brain 
was then cryoprotected with 30% (w/v) sucrose containing 0.05% (w/v) sodium azide 
(NaN3) in 0.1 M PBS (pH 7.4) until the tissue sank (~3-5 days). The processed brains were 
cut coronally into 30 µm sections at the level of 3rd cranial nerve using a freezing 
microtome and collected into 24-well plates containing 0.1 M PBS, pH 7.4 with 0.05% (w/v) 
NaN3 as described in Sections 2.4.6 & 2.4.7. 
 
 Immunohistochemistry 
Coronal brain sections were assessed for TH immunoreactivity in the SNPc by 
immunoperoxidase staining, as described in detail in Section 2.4.8. In short, the coronal 
sections (30 μm) were incubated in 24-well plates with primary antibody against TH (1:500) 
overnight at room temperature. On the subsequent day, the sections were incubated with 
biotinylated secondary antibody (1:200) for 1 hour and further 45 minutes incubation with 
the ABC kit at room temperature. The antibody complex was visualised by exposing the 
sections to 1 mL 0.05% (w/v) DAB prepared in 0.01% (w/v) H2O2 in 0.1 M PBS for ~3 
minutes. The sections were then mounted onto coated adhesion microscope slides, 
dehydrated, cover slipped and examined as described in Section 2.4.9. 
 
 Data and statistical analysis 
Data are expressed as individual, mean+SEM or mean±SEM of experimental groups (n=6 
rats per group). Dopamine turnover was calculated by finding the ratio between the 
concentration of dopamine metabolites (DOPAC & HVA) over concentration of dopamine: 
 
𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 𝑡𝑢𝑟𝑛𝑜𝑣𝑒𝑟 =  
[𝐷𝑂𝑃𝐴𝐶]+[𝐻𝑉𝐴]
[𝑑𝑜𝑝𝑎𝑚𝑖𝑛𝑒]
      Equation 5.2.1 
 
Serotonin turnover was calculated by finding the ratio between the concentration of 
serotonin metabolite (5-HIAA) over concentration of serotonin (5-HT) 
𝑆𝑒𝑟𝑜𝑡𝑜𝑛𝑖𝑛 𝑡𝑢𝑟𝑛𝑜𝑣𝑒𝑟 =  
[5−𝐻𝐼𝐴𝐴]
[5−𝐻𝑇]
       Equation 5.2.2 
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GraphPad Prism 7 software was used for statistical analysis. Difference between control 
and treatment groups was analysed with one-way or two-way ANOVA followed by Holm-
Šídák multiple comparison test where appropriate. p<0.05 was considered significant. 




 Pharmacokinetics study for HPO dose justification 
In Chapter 3 it was shown that some of the novel HPOs can enter the brain, however, 
brain levels are determined not only by this ability, but also be the pharmacokinetics (PK) 
of a compound following parenteral administration. For this reason, prior to commencing 
the in vivo neuroprotection study, a PK study was performed to validate the dose selected 
and confirmation of brain penetration in a whole in vivo setup. Male Wistar rats were 
injected i.p. with 500 µmol/L CP20, CP84, CN128 and CN226 followed by plasma 
sampling for up to 360 minutes to determine the PK profiles. CP20, CN128 and CN226 
did not show any sign of acute toxicity after i.p. injections, except for rat injected with CP84 
that exhibited seizure within 5 minutes after injection. The dose for CP84 was reduced to 
200 µmol/kg with similar observation. Therefore, PK study for CP84 was discontinued, and 
CP84 was not used for further study. Apart from CP84 toxicity, rats injected with CP20 
exhibited increase in salivation that subsides 60 minutes after injection. This sign was not 
observed for rats treated with CN128 and CN226. The validated bioanalytical method was 
successfully applied to quantify the concentration of selected HPOs in plasma and brain 
homogenate after i.p. injection of 500 µmol/kg HPOs dose (Figure 5.3.1).  
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Figure 5.3.1: Concentration in plasma/brain against plasma sampling time after i.p. injection 
with 500 µmol/kg HPOs. 
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The PK parameters for plasma obtained after analysis with PK Solver (Zhang et al., 2010) 
are summarised in Table 5.3.1. CP20 was rapidly absorbed and reached maximum 
concentration in plasma (Tmax) in 27 minutes. Likewise, CN128 and CN226 also reached 
Tmax within 30 minutes after i.p. injection. The rapid absorption phase was followed by 
exponential declined in plasma which correspond to the short half-lives (t1/2) of 61, 40 and 
47 minutes after Tmax for CP20, CN128 and CN226 respectively. CP20, CN128 and CN226 
were also characterised by high volume of distributions (Vd) between 1.5 to 2.8 L/kg with 
rate of clearances (CL) between 0.02 to 0.03 L/kg/min.  The concentrations of CP20, 
CN128 and CN226 in plasma at the terminal time points (360 min) were between 2.9 to 
7.0 µM. Furthermore, HPOs appeared to accumulate in the brain at the terminal time point 
with concentrations approximately 2-fold of that found in plasma. Overall, there was no 
significant different when CN128 and CN226 pharmacokinetic parameters were compared 
with CP20. Nevertheless, CN128 showed a trend towards higher Cmax than CP20 (p=0.19). 
Since the PK profile following i.p. injection for CN128 and CN226 were not different than 
CP20 in addition to equal brain permeability and neuroprotection in vitro, only CN128 was 
selected for in vivo neuroprotection study. 
 
Table 5.3.1: Pharmacokinetic profile for CP20, CN128 and CN226 after 500 µmol/kg single 
i.p. injection. 
Parameter CP20 CN128 CN226 
MW 139.1 273.3 287.4 
Injected dose (µmol/kg) 500 500 500 
Injected dose (mg/kg) 70 160 160 
Tmax (min) 26.7±10.1 15.0±5.0 30.0±15.3 
t1/2 (min) 60.7±11.0 40.2±14.3 46.8±3.0 
Cmax (μmol/L) 149.8±69.7 369.4±123.2 193.8±36.2 
AUC0-t (mmol/L/min) 16.1±3.4 32.8±12.9 18.6±4.0 
AUC0-∞(mmol/L/min) 19.8±4.8 33.2±12.7 18.8±4.1 
Vd (L/kg) 2.8±1.3 1.5±1.0 2.0±0.5 
Cl (L/kg/min) 0.03±0.01 0.02±0.01 0.03±0.01 
Clast (plasma) (µmol/L) 7.0±1.3 4.3±1.5 2.9±0.8 
Clast (brain) (µmol/L) 13.2±1.1 9.6±3.0 7.4±0.5 
Pharmacokinetics parameters were derived from analysis using Excel solver add-in (PK Solver) 
provided by Zhang et al. (2010). Data are expressed as  mean+SEM  (n=3-4 rats). Statistical 
analysis (one-way ANOVA) showed no significant different. 
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 Effects of partial striatal 6-OHDA lesion and HPOs treatment on rat 
body weight 
The rat body weights steadily increased when the HPO/vehicle dosage regime started on 
day 1 (Figure 5.3.2). The body weight dropped by 3% a day after the brain lesion 
procedures but slowly attained the pre-surgical body weight about 4 days after the surgery. 
By day 9th after the surgery, all rats had exceeded their pre-surgical body weight. Rats 
treated with either 70 µmol/kg CP20 or CN128 twice daily for 7 days did not show any 
abnormal symptoms during the dosing regimen. 
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Figure 5.3.2: Weight of rats over the course of in vivo neuroprotection study.  
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 Effects of toxins and HPOs treatment on D-amphetamine-induced 
ipsilateral rotations 
There was no significant different on D-amphetamine induced ipsilateral rotations between 
saline/6-OHDA group and saline/sham, CP20/6-OHDA and CN128/6-OHDA groups 
(Figure 5.3.3) similar to the finding observed during the selection of 6-OHDA dose 
(Section 2.4.5).  
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Figure 5.3.3: D-Amphetamine rotation test for 6-OHDA unilateral striatal lesioned rat. 
Graphs a), b), c) and d) show data for net ipsilateral rotation shows individual data. Data are 
individual rat or mean±SEM (n=6 rats). Statistical analysis with one-way ANOVA showed no 
significant different. 
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 Effects of toxins and HPOs treatment on catecholaminergic 
neurotransmitters in striatum 
Striatum from non-lesioned (contralateral) and 6-OHDA-lesioned (ipsilateral) sides were 
dissected and processed for the measurement of dopamine or serotonin and metabolites 
levels by HPLC-ECD. Treatment with either CP20 or CN128 had no effect on the 
dopamine level in the contralateral side when compared to the saline-treatment groups 
(Figure 5.3.4).  
 
There was no different on the level of dopamine in the sham-lesioned striatum compared 
to the non-lesioned striatum in the saline-treatment group (negative control) (Figure 
5.3.4a). By contrast, intra-striatal injection of 6-OHDA caused depletion of dopamine in the 
ipsilateral side by 64% compared to the contralateral side in the saline-treatment group 
(positive control). Treatment with CP20 and CN128 protected against 6-OHDA induced 
dopamine depletion by only causing 38% and 31% dopamine depletion respectively in the 
6-OHDA ipsilateral side compared to the contralateral side of striatum, with no difference 
in the dopamine levels in the contralateral side of SNPc for rats treated with CN128 or 
CP20. 
 
Neither 6-OHDA lesioned nor HPOs treated group showed significant different on the level 
of DOPAC and HVA in the striatum when compared to the saline-treatment + sham-
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Figure 5.3.4: Dopamine and metabolites measurement in striatum. Level of dopamine, 
DOPAC and HVA in the striatum as determined by HPLC-ECD. Data are mean+SEM (n=6 rats). 
* p<0.05, *** p<0.001 compared to ipsilateral side; # p<0.05, ## p<0.01compared to Sal/6-OHDA 
ipsilateral side (two-way ANOVA followed by Holm-Šídák multiple comparison test). 
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Dopamine turnover was calculated by the formula described in Equation 5.2.1. Treatment 
of CP20 and CN128 did not have any effect on the dopamine turnover in the non-lesioned 
side (Table 5.3.2). Intra-striatal injection of 6-OHDA lead to significant 2.6-fold increase in 
dopamine turnover. Treatment with both CP20 and CN128 prevented the 6-OHDA-
induced increment in dopamine turnover in the ipsilateral side such that turnover values 
were not different to saline/sham treated controls or values on the contralateral non-
lesioned side. 
 





Sal/sham 0.82±0.05 0.90±0.08 ## 
Sal/6-OHDA 0.79±0.07 2.04±0.38 ** 
CP20/6-OHDA 0.69±0.03 0.84±0.13 ## 
CN128/6-OHDA 0.97±0.18 0.97±0.22 ## 
Data are mean or mean±SEM (n=6 rats). ** p<0.01 compared to contralateral side of the 
corresponding group; ## p<0.01 compared to Sal/6-OHDA ipsilateral side (two-way ANOVA 
followed by Holm-Šídák multiple comparison test). 
 
Treatment with either CP20 or CN128 had no effect on the serotonin level the on the 
contralateral side when compared to the saline-treatment groups. There was no different 
on the level of serotonin in the sham-lesioned striatum compared to the non-lesioned 
striatum in the sham-lesioned group (negative control) (Figure 5.3.5a). In contrast, intra-
striatal injection of 6-OHDA caused depletion on the level of serotonin in the ipsilateral 
side by 33% compared to the contralateral side in the 6-OHDA-lesioned group (positive 
control). By contrast there was no difference in the levels of serotonin between the 
ipsilateral and contralateral sides in either the CP20 and CN128 treatment group.  
However, there was a small but significant increase in the level of serotonin on the 
contralateral sides of the 6-OHDA-lesioned group and CN128 treated animals. 
 
Neither 6-OHDA lesioned nor HPOs treated group showed significant different on the level 
of 5HIAA in the striatum when compared to the saline-treatment + sham-lesioned group 
(Figure 5.3.5b). 
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Figure 5.3.5: 5-HT and metabolite measurement in striatum. 
Level of 5-HT and 5-HIAA in the striatum as determined by HPLC-ECD. Data are mean+SEM 
(n=6 rats). * p<0.05 compared to ipsilateral side; $$ p<0.01 compared between contralateral 
sides (two-way ANOVA followed by Holm-Šídák multiple comparison test). 
 
Serotonin turnover was calculated by the formula described in Equation 5.2.2. Treatment 
of CP20 and CN128 did not have any effect on the serotonin turnover in the non-lesioned 
side (Table 5.3.5). Intra-striatal injection of 6-OHDA not significantly changed serotonin 
turnover although there was a trend towards increase serotonin turnover (p=0.06). 
Treatment with CP20 and CN128 prevented 6-OHDA induced increased in serotonin 
turnover in the lesioned side compared to the non-lesioned side. 
 






Sal/sham 1.76±0.07 1.77±0.18 
Sal/6-OHDA 1.51±0.18 2.18±0.11 
CP20/6-OHDA 1.81±0.0.03 1.91±0.12 
CN128/6-OHDA 1.92±0.26 1.86±0.08 
Data are mean or mean±SEM (n=6 rats). Statistical analysis with two-way ANOVA showed no 
significant different. 
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 Effects of toxins and HPOs treatment on TH-positive cells in SNPc 
Brain coronal sections at the level of SNPc were stained for TH by immunoperoxidase 
method to quantify the number of TH+ cells. The TH+ cells in the non-lesioned 
(contralateral) and 6-OHDA lesioned (ipsilateral) sides of SNPc were counted manually 
for analysis in a blinded manner.  
 
Treatment with either CP20 or CN128 alone had no effect on the number of TH+ cells on 
the contralateral side when compared to the saline-treatment groups (Figure 5.3.6). There 
was no different on the number of TH+ cells in the SNPc of sham-lesioned compared to 
the contralateral side in the saline-treatment group (negative control) (Figure 5.3.7). By 
contrast, intra-striatal injection of 6-OHDA (8 µg) reduced the number of TH+ cells in SNPc 
by 46% compared to the contralateral side in the saline-treatment group (positive control). 
Treatment with CP20 and CN128 significantly protected against 6-OHDA-induced TH+ cell 
loss in the SNPc of ipsilateral side with only 20% and 14% loss of cells respectively 
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Figure 5.3.6: TH+ staining cells in the SNPc.  
Data are mean or mean+SEM (n=6 rats). ** p<0.01 compared to ipsilateral side; ##   p<0.01, 
###   p<0.001 compared to Sal/6-OHDA ipsilateral side (2-way ANOVA followed by Holm-Šídák 
multiple comparison test). Data are mean+SEM (n=6 rats). ** p<0.01 compared to ipsilateral 
side; ##   p<0.01, ###   p<0.001 compared to Sal/6-OHDA ipsilateral side (2-way ANOVA 
followed by Holm-Šídák multiple comparison test). 
 





Figure 5.3.7: Representative photomicograph of brain coronal section showing TH+ cells in 
SNPc region. 
The black line marks the third cranial nerve that demarcate the dopaminergic neurons cell bodies 
in SNPc and VTA. TH+ cells in ipsilateral SN in (a) vehicle-lesioned and saline treated rats; (b) 6-
OHDA-lesioned (8 μg/4 μl) and saline treated rats (c) 6-OHDA-lesioned (8 μg/4 μl) and CP20-
treated (70 µmol/kg/twice-daily/7 days, i.p) rats, (d) 6-OHDA-lesioned (8 μg/4 μl) and CN128-
treated (70 µmol/kg/twice-daily/7 days, i.p) rats. Inset a’) a typical TH+ cell. Scale bar = 500 μm and 
inset scale bar = 50 μm are representative of all images.




In this study, it was hypothesised that CP84, CN128 and CN226 would confer a 
neuroprotection against the 6-OHDA-induced dopaminergic neuron degeneration in basal 
ganglia. However, after preliminary assessment of pharmacokinetic (PK) profile of these 
HPOs, only CN128 was chosen for in vivo neuroprotection study. The effect of 
intraperitoneal injection of CP20 and CN128 on 6-OHDA induced degeneration of 
dopaminergic neuron in SNPc was investigated in vivo. The D-amphetamine induced 
ipsilateral rotation were first assessed one week after termination of CP20 and CN128 
treatment in rats, 12 days following the 6-OHDA or sham lesion. Secondly, striatal tissues 
from rat brains were dissected and processed two-days after rotational test to measure 
dopamine and serotonin together with their metabolites by HPLC-ECD. Finally, brain 
coronal sections at the level of SNPc and striatum for 6-OHDA lesioned rats treated with 
CP20 and CN128 were assessed by TH immunohistochemistry to establish whether they 
exert a protective effect by preventing dopaminergic cell loss in the SNPc. 
 
 Pharmacokinetic study 
CP20 has previously been assessed of its PK profile after systemic injection and was 
shown to penetrate the brain (Fredenburg et al., 1996b). Indeed, in situ brain perfusion of 
CP20 in rats as explained in Chapter 3 support these previous reports of CP20 brain 
penetration in in vivo set up. Additionally, it has been revealed from the in situ brain 
perfusion experiment that CN128 and CN226 brain permeability were not different than 
CP20.  Nevertheless, investigation of PK is important to gain a better understanding on 
the distribution and clearance for novel HPOs after a systemic injection, and to confirm 
brain penetration in in vivo rat model. Therefore, the aim of the study was to characterise 
the PK profile of the novel HPOs in plasma after i.p. injection and compared to CP20. 
Additionally, the level of HPOs in brain were measured at the terminal sampling time (360 
min). 
 
The reported CP20 dose employed that succesfully showed  neuroprotection in rats was 
70 µmol/kg  (single i.p.dose)  which was below the sensitivity limit of the current analytical 
method (Dexter et al., 2011). Nevertheless, since the aim of the current study is for the 
confirmation of plasma exposure and brain permeability of novel HPOs after i.p. injection 
in rats, a higher dose was preferred. The dose selected for this PK study (500 µmol/kg) 
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was based on a previous PK study on HPOs performed by Fredenburg et al. (1993 & 
1996). However, rats injected with 500 µmol/kg CP84 exhibited convulsion within 5 
minutes after injection which suggest a CNS-related toxicity (Schlag et al., 2000, 
Kontoghiorghes, 1991). This observation corresponded to the rapid brain permeability of 
CP84 in in situ brain perfusion experiment (Chapter 3). Additionally, convulsion after 
single dose administration of 4000 µmol/kg CP20 by intravenous route has been 
described, but this only occur within 2 to 8 h after treatment (European Medicines Agency, 
2005, Hider et al., 1990). The dose of CP84 was reduced to 200 µmol/kg with similar 
outcome, and therefore CP84 was dropped for further studies despite it showing promising 
result in term of brain permeability in in situ brain perfusion experiment, although only 
showed mild neuroprotection in in vitro study (Chapter 4). One noticeable observation in 
all rats after injection with CP20 was increased in salivation that diminished within 60 
minutes in line with the t1/2 for CP20. This observation was not seen in other rats treated 
with CN128 or CN226. Indeed, hypersalivation has been reported to be a unique symptom 
for rat treated only with CP20 and not for other derivatives of CP20 (Hider et al., 1990, 
European Medicines Agency, 2005). The cause of this observation is unclear, however 
increase in salivation is often associated with cholinergic toxicity (Takakura et al., 2003). 
Unfortunately, there are no studies that specifically focus on the interaction between CP20 
and cholinergic transmission has been reported partly because the hypersalivation was 
only observed in rats but not in human suggesting interspecies different in CP20 toxicity 
(Porter, 1996, Olivieri et al., 1998). CP20 has been shown to significantly deplete 
leukocytes counts in control and iron overloaded mice (Porter et al., 1991). Indeed, CP20 
appeared to induce neutropenia and agranulocytosis in 7% of Thalassemia patients within 
6 months of treatment, which ceased after discontinuation of the therapy (Devos et al., 
2014, Martin-Bastida et al., 2017). Remarkably, sub-chronic toxicity study of CN128 in rat 
and cynomolgus monkey revealed no reduction in leukocytes count and pathological 
changes in sternal bone marrow which was observed in CP20-treated animals, suggesting 
better toxicity profile for CN128 than CP20 (Paiboonsukwong et al., 2016). 
 
The selected dose was sensitive enough for the detection of CP20, CN128 and CN226 in 
the plasma and brain up to 360 minutes post-injection by the established HPLC-UV 
method. Blood sampling time was limited to 360 minutes based on the previous report of 
rapid elimination of CP20 in plasma and almost undetectable in the plasma after 12 h of 
intravenous injection (Fredenburg et al., 1993). This also allows sufficient HPOs levels 
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remained in the brain for sensitive measurement by HPLC-UV. CP20, CN128 and CN226 
reach maximal concentration in plasma (Tmax) in less than 30 minutes after i.p. injection. 
Half-life (t1/2) for CP20 in this study was 61 min which is within the range of previously 
reported t1/2 (72±30 minutes) after a single bolus injection in rats (Fredenburg et al., 1996). 
Likewise, CN128 and CN226 also rapidly cleared from the plasma with t1/2 less than 60 
minutes. The short t1/2  for CP20, CN128 and CN226 agreed with their high volume of 
distribution (Vd) which is approximately 2.0 L/kg. This suggest that the HPOs were  
disributed extravascularly since the Vd exceeded the total plasma volume in rat (31.6 
mL/kg) which is related to their lipophilicity (Bijsterbosch et al., 1981). Similar pattern of 
pharmacokinetic profile were observed in human when CP20 was ingested orally where 
the Tmax was less than 60 minutes and the t1/2 was between 1.5 to 2 h after the oral 
consumption (Hoffbrand, 2005). In addition to the high Vd, the HPOs were also rapidly 
cleared from the plasma with rate of clearance (CL) was aprroximately 0.03 L/kg/min which 
agreed with reported CP20 CL in rats and humans (Quanquan et al., 2010, Fredenburg et 
al., 1993, Thuma et al., 1998). Most importantly, novel HPOs level were successfully 
measured in the brain at 360 minutes post-injection, and the level was not different than 
CP20. This confirms brain penetration of CP20, CN128 and CN226 observed in in situ 
brain perfusion experiment as discussed in Chapter 3. 
 
The most recent study performed by intragastric administration of 1000 µmol/kg CP20 
showed a shorter half-life (21 min) (Quanquan et. al., 2010). This observation was 
expected  by the means of the CP20 administration which made it succeptible to the first-
pass metabolism in the liver. Indeed, CP20 has been reported to undergo extensive 
metabolism in the liver to glucuronide conjugate (85% of the administered dose) and 
rapidly excreted in the urine of man (Hoffbrand et al., 1998, Hoffbrand et al., 2003). The 
PK profiles in this study is of importance since CN128 was previously reported to have a 
better efficacy in mobilising iron from the liver in iron-loaded rats after an oral 
administration due CN128 slower rate of conversion to glucuronide metabolite (2-folds 
slower) than CP20, and therefore would be expected to show higher Cmax than CP20 (Lu, 
2016, Hider et al., 2011a, Paiboonsukwong et al., 2016). This could be further reflected 
by higher CN128 oral bioavailability in rats (82%) than CP20 (56%) (Paiboonsukwong et 
al., 2016, Singh et al., 1992). This contradiction in HPOs level could be explained by the 
route of administration of HPOs in this study that was by i.p. injection. In this circumstance, 
CP20 and  CN128 are readily reaching the systemic circulation after absorption through 
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the peritoneal tissues lining and rapidly distributed peripherally as showed by its high Vd 
which is 1.5 L/kg. In contrast, oral administration of CN128 would reaches the liver in the 
first instance where most of the metabolism occur, before entering the sytemic circulation 
(Badria et al., 2015). Nevertheless, in this study, CN128 showed a trend towards higher 
Cmax than CP20 (p=0.19) which might support the report of slower glucuronides formation 
in the liver (Lu, 2016, Hider et al., 2011a, Singh et al., 1992). 
 
This study provide a direct evidence of the presence of HPOs in plasma and brain after 
500 µmol/kg i.p. injection in rats. However, the dose employed in this study is not suitable 
for the sub-chronic experimental design for in vivo neuroprotection study. Furthermore, 
administration of high dose of HPO in non-systemic iron overlead rats sub-chronically 
often lead to toxicity due to depletion of systemic iron (Sauerbeck et al., 2013, Mounsey 
and Teismann, 2012). Neuroprotection study for CP20 performed by Dexter et al. (2011) 
used a lower dose of CP20 (70 µmol/kg) in in vivo PD model of rat in contrast to 600 
µmol/kg CP20 for iron-mobilisation study in iron-overload rat model (Crowe and Morgan, 
1994). In his study, a unilateral 6-OHDA rat model of PD were treated with CP20 at 70 
µmol/kg twice daily for 5 days. The treatment regime started a day before lesion and the 
study managed to show significant neuroprotection as assessed by TH+ cell counting in 
SNPc and dopamine level in sriatum (Dexter et al., 2011). Based on this reported study, 
the same dose regiment was emplyoed  for assesment of novel HPO neuroprotection in 
vivo. 
 
 Effect of unilateral partial 6-OHDA-lesioned on D-amphetamine 
induced rotation 
The current study showed that the D-amphetamine rotation test failed to cause significant 
different in rotational activity on the unilateral partial 6-OHDA-lesioned rats compared to 
sham-lesioned rats. This finding replicated the data presented in Section 2.5.5 whereby 
intra-striatal injection with 4 µg, 8 µg or 12 µg 6-OHDA were not significantly differed in 
rotational behaviour compared to sham-lesioned rats. Similarly, treatment with CP20 or 
CN128 also did not cause different in the rotation induced by D-amphetamine when 
compared to control.  
 
Amphetamine-induced rotations have previously been shown to correlate with the size of 
6-OHDA-lesion (Carmen et al., 1991, Przedborski et al., 1995, Kirik et al., 1998), however, 
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there is a threshold for induction of behavioural impairment. Amphetamine-induced 
rotation start to show in rats with 40-50% reduction in total striatal DA content, and 30-
50% loss of TH cell bodies (Hefti et al., 1980; Lee et al., 1996; Przedborski et al., 1995). 
In the present study, there was approximately 60% loss of striatal DA content and 50% 
loss of the number of nigral dopamine cell bodies, so one might expect to see some 
rotational activity.  However, the number of TH+ cells was only counted in one level of the 
SNPc, and the degree of cell loss may be less in more rostral and caudal areas, allowing 
compensation for the lesion. In addition, the degree of cell loss may be on the cusp of 
allowing rotations to be observed, with ipsilateral postsynaptic receptor changes balancing 
the contralateral DA release induced by amphetamine (Carmen et. al., 1991). Indeed, in 
agreement with the present study, the lack of significant rotational activity in partial-
lesioned compared to sham-lesioned rats has been previously reported (Robinson et al., 
1994). On the other hand, the site of the striatum where the profound lesion occurred may 
also contributed to the absence of asymmetrical rotational behaviour in this study. Olds et 
al. (2006) demonstrated that cell loss at the lateral portion of striatum lead to profound 
asymmetrical rotation in contrast to cell loss at the central and/or medial portion of striatum 
which showed very low asymmetrical rotations in rats after D-amphetamine injection. In 
the present study, striatum immuno-stained for TH showed profound dopaminergic fibre 
loss in the central portion of the striatum which correspond to the site where the syringe 
was lowered during 6-OHDA infusion (Figure 2.4.8, top panel in Section 2.4.9). 
Therefore, it seems inappropriate to use the amphetamine rotation test as an indication of 
lesion size and hence protection induced by the HPOs in the current study. Other 
spontaneous behavioural test that evaluate locomotor activities such as cylinder and 
rotarod tests could be explored to give insight on the effect of 6-OHDA lesion and 
treatment with HPOs (Carvalho et al., 2013, Decressac et al., 2012), however, these too 
require lesions of >50% (Kirik et al., 1998). Overall, it can be concluded that the size and 
site of 6-OHDA lesioned in the striatum are important for D-amphetamine rotation 
behavioural read-out to be consistently observed. 
 
As there was clearly loss of dopamine cell bodies and striatal dopamine levels in the 6-
OHDA-lesioned rats, it is apparent that no conclusion about the protective nature for 
CP128 or CP20 can be made from these data. It may be that the behavioural studies were 
performed before the full extent of the lesion had developed, or that the compensatory 
mechanisms such as increased dopamine turnover in the striatum had developed that 
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were sufficient to overcome the partial 64% lesion induced in these studies (Marinova-
Mutafchieva et al., 2009). 
 
 Effect of CP20 and CN128 on 6-OHDA-induced alterations of 
dopamine and serotonin levels in striatum 
Despite the fact that the D-amphetamine-induced rotation study failed to show a difference 
in 6-OHDA lesioned compared to sham-lesioned rats, 6-OHDA (8 µg) injected into the 
ipsilateral striatum caused depletion of dopamine level by 64% of control which suggest 
degeneration and loss of axonal projection of dopaminergic neurons in the striatum that 
originates from SNPc (Haber et al., 2000, Wall et al., 2013, Reynolds and Wickens, 2000). 
The observed depletion level of dopamine in ipsilateral striatum was consistent with 
previous studies targeting partial lesion and correspond to the early phase of PD (Zigmond 
et al., 1989, Walker et al., 2013, Branchi et al., 2010). Similarly, serotonin level in the 
ipsilateral striatum was also depleted although milder (33%) than dopamine depletion 
which was expected due to direct injection of 6-OHDA into the striatum would also killed 
the serotonergic terminals by oxidative stress (Smith and Cass, 2007). However, close 
inspection on the level of serotonin showed no significant different when ipsilateral sides 
were compared. This is further supported by lack of different in serotonin turnover between 
ipsilateral and contralateral sides in 6-OHDA-lesioned group. Therefore, the effect of CP20 
and CN128 on the level of serotonin in the striatum were inconclusive and may require 
additional experimental data for confirmation. Nevertheless, higher turnover rate of 
dopamine in the ipsilateral striatum compared to sham-lesioned suggesting increased in 
activity of the remaining dopaminergic terminals to synthesis dopamine in order to 
compensate for dopamine loss after 6-OHDA lesioned (Meiser et al., 2013, Robinson et 
al., 1994). 
 
Treatment with CP20 and CN128 had no effect on the basal level of dopamine and 
serotonin suggesting that the rate limiting enzyme in dopamine (tyrosine hydroxylase, TH) 
and serotonin (tryptophan hydroxylase, TPH) were not affected. This is important since 
iron is an important co-factor for those enzymes and inhibition of these enzymes would 
exacerbate rather than improve the symptoms of PD (Zhou et al., 2005, Daubner et al., 
2011). Indeed, previous report showed that measurement of dopamine and serotonin with 
their metabolites 2 h after 70 µmol/kg i.p. injection of CP20 in rats revealed no changed 
except for HVA and 5-HIAA that reduced approximately by 40 and 20% respectively, which 
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returned to control level within 6 h after injection (Waldmeier et al., 1993). As hypothesized, 
intraperitoneal injection of CP20 and CN128 protected against 6-OHDA-induced depletion 
of dopamine by approximately 30% compared to dopamine content in saline/6-OHDA-
lesioned rats which agreed with a finding reported by Dexter et al. (2011). In addition, 
CP20 and CN128 fully protected against the reduction in serotonin level induced by 6-
OHDA probably because a smaller density of striatal serotonergic compared to 
dopaminergic terminals (Zhou et al., 2005). Although CP20 and CN128 did not fully 
prevent dopamine level depletion to the level as in sham-lesioned rats, the dopamine 
turnover was not significantly different than the sham-lesioned rat which might suggest 
that functionally the dopamine neurons were normal.  Thus, the lesion threshold for an 
increase in activity of the remaining neurons was not reached due to the smaller level of 
dopamine loss which, therefore, did not interfere with the normal function of the nigro-
striatal pathway (Dexter et al., 2011, Robinson et al., 1994). Intraperitoneal injection of 
other novel iron chelator, VK28 also showed protection against 6-OHDA-induce dopamine 
reduction in striatum, although it did not maintain the dopamine turnover at the control 
level (Shachar et al., 2004).  
 
 Effect of CP20 and CN128 on 6-OHDA-induced dopaminergic cell 
loss in SNPc 
Depletion of dopamine after 6-OHDA intra-striatal injection was accompanied by a 
moderate 46% reduction in TH+ cell in the SNPc compared to control as would be expected 
for targeting partial lesion (Penttinen et al., 2016, Rodrigues et al., 2003). Although 6-
OHDA doses less than 8 µg can also create a partial lesion, this is less recommended as 
the variation in lesion size was higher with smaller amount of 6-OHDA (Duty and Jenner, 
2011). On the other hand, intra-striatal injection of 6-OHDA exceeding 10 µg has been 
reported to non-specifically causing tissue damaged and striatal cell loss around the lesion 
site (Bjorklund et al., 1997, Przedborski et al., 1995). The lower percentage of TH+ cell 
loss in SNPc agrees with the higher percentage of dopamine depletion in the striatum as 
reported by Debeir et al. (2005) and Penttinen et al. (2016). This is because, intra-striatal 
injection of 6-OHDA causes immediate degeneration of dopaminergic terminals in 
proximity to injection site by extracellular production of ROS (Ferger et al., 2001, Debeir 
et al., 2005). Some 6-OHDA was taken up by the surviving axon terminal through DAT 
and followed by slower retrograde loss of dopaminergic cell bodies through a combination 
of oxidative stress and inhibition of mitochondrial respiratory chain within a week after 
  CHAPTER 5: IN VIVO NEUROPROTECTIONS OF HPOs 
223 
 
lesion (Lu et al., 2014, Rodriguez-Pallares et al., 2007). Furthermore, the observed TH+ 
cell loss was prominent in the dorsal tier of the SNPc which correspond to the nigro-striatal 
dopaminergic projection which supports the retrograde degeneration mechanism of 6-
OHDA through interaction with DAT transporter (Storch et al., 2004). This observation 
confirmed that the axons of neuronal cell bodies in SNPc are terminated in the striatum 
(Reynolds and Wickens, 2000). The delayed loss of dopaminergic cell bodies mimics the 
dying back theory of PD pathogenesis and allow a therapeutic intervention well suited for 
a neuroprotection study with CP20 and CN128 (Tagliaferro and Burke, 2016, Dauer and 
Przedborski, 2003). Additionally, 6-OHDA-lesioned rats exhibited increased in iron level in 
striatum and SNPc which is relevant to investigate the neuroprotective effect using iron 
chelator (Wang et al., 2004, Virel et al., 2014b). To support this further, HPOs showed 
better neuroprotection in 6-OHDA-induced SH-SY5Y cell death compared to other type of 
toxins which suggest part if not full, involvement of iron in causing cell death as discussed 
in detail in Chapter 4. 
 
CP20 and CN128 have been shown to enter the brain as measured by in situ brain 
perfusion and systemic i.p. injection. In contrast to the observe milder effect of CP20 and 
CN128 in preventing reduction of dopamine level in the striatum, CP20 and CN128 fully 
protected against the loss of dopaminergic cell bodies in SNPc which agreed with previous 
study using CP20 (Dexter et al., 2011, Zhu et al., 2017a). It could be that higher 
concentration of 6-OHDA at the injection site and surrounding tissues prevented the action 
of CP20 and CN128 in reducing oxidative stress in the striatum. On the other hand, 
delayed retrograde axonal degeneration of dopaminergic neurons and distance from the 
injection site allow sufficient period for CP20 and CN128 to protect dopaminergic neurons 
in the SNPc. The ability of CP20 and CN128 to protect against 6-OHDA 
neurodegeneration was more likely by the iron chelation itself. Furthermore, oxidative 
stress after 6-OHDA or MPTP administration has been shown to increase iron level in 
basal ganglia (Virel et al., 2014a, Hall et al., 1992, He et al., 1996). However, the 
processes by which 6-OHDA causes iron accumulation in the basal ganglia is not 
conclusive and may involve multiple mechanisms such as release of iron from intracellular 
iron storage protein, ferritin (Jameson et al., 2004) and up regulation of the divalent metal 
transporter (DMT1) that translocate sequestered vesicular iron into cytoplasm as free-
labile iron (Jia et al., 2015, Jiang et al., 2010). Additionally, intracerebral injection of 6-
OHDA may disturbed the BBB integrity due to the invasive nature of the lesioned 
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procedure causing leakage of plasma iron that are normally transported into the brain by 
transferrin receptor (TfR) (Bien-Ly et al., 2014). This view is supported by Walker et al. 
(2013) who demonstrated brain oedema associated with deposition of iron along the 
needle path after intra-striatal injection of 6-OHDA in rats. Moreover, oxidative-stress 
causes by 6-OHDA could also make BBB more permeable to iron by microglial activation 
(Virel et al., 2014a, Zhu et al., 2017b). Free non-chelated irons are neurotoxic due to their 
contribution in exacerbating oxidative stress (Friedman, 2011). Indeed, free irons have 
been shown to cause brain inflammation by activation of NFkB, IL6 and TNF-α which can 
be prevented by iron-chelating drugs such as DFO, (−)-epigallocatechin-3-gallate (EGCG) 
and R-apomorphine (Li et al., 2016, Levites et al., 2001, Youdim et al., 2000, Grunblatt et 
al., 2001). To further support the involvement of iron in neurodegenerative mechanism, 
mice on restricted-iron diet were more resistance towards MPP+ toxicity and did not exhibit 
impaired in motor behaviour after MPTP treatment (Levenson et al., 2004). 
 
In theory, therefore, HPOs such as CP20 and CN128 could conferred neuroprotection by 
two mechanisms. First is by direct chelation of labile-iron pool thus minimised one of the 
reactants needed for Fenton reaction (Devanur et al., 2008b). Secondly is by mobilising 
intracellular chelated iron to systemic circulation. This is because, a completely chelated 
iron by bidentante iron chelators such as CP20 and CN128 has a net zero charge and 
therefore are membrane permeable (Hider et al., 1990, Paiboonsukwong et al., 2016). 
Furthermore, chelated-iron in systemic circulation are readily transferred to circulating 
apo-transferrin due to relatively lower pFe3+ of CP20 and CN128 compared to transferrin 
(Hider et al., 1990, Devanur et al., 2008a). Indeed, the most recent report evaluating CP20 
neuroprotection revealed almost 60% reduction of ferric iron deposits in the SNPc of 6-
OHDA-lesioned rats (Levenson et al., 2004).  
 
 Advantages and shortcomings of this study 
Testing neuroprotection agents in living animals may provide a better approximation of the 
pharmacological and physiological processes occur in humans than testing in in vitro cell 
lines. Over the years, several in vivo models of PD have been developed in laboratories 
to cater for the increasing needs for evaluation and discovery of the first functional and 
effective neuroprotection agent in clinic (Tieu, 2011, Duty and Jenner, 2011). Although 
none of the in vivo PD models reflects all the pathologies and symptoms of PD in man, 
these models play an important role for pre-clinical evaluation of potential treatment for 
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PD. Indeed, in vivo models of PD have successfully offered insights into the understanding 
of the cell death processes, aetiology, pathology as well as molecular mechanisms of 
neurodegeneration (Blesa et al., 2012). The decision of which in vivo PD models to choose 
is normally based on the type of investigation required. Here, the 6-OHDA rat model was 
chosen since 6-OHDA has been shown to promote abnormal iron accumulation in the 
basal ganglia which exacerbate oxidative stress by iron participation in Fenton reaction 
(Zhu et al., 2017, Virel et al., 2014, Wang et al., 2015). Indeed, elevated iron levels in the 
basal ganglia is one of the known pathological signs of PD brain (Mochizuki and Yasuda, 
2012). Therefore, this model would be relevant to evaluate the effect of HPO iron chelators 
in preventing loss of dopaminergic neurons in the basal ganglia. Additionally, in vitro 
neuroprotection study in Chapter 4 showed the neuroprotective effect of HPOs in reducing 
6-OHDA-induced cell death. The pathological events associated with 6-OHDA in vivo PD 
model mirror some of PD pathology in human such as mitochondrial impairment, increase 
in ROS level, increase in inflammatory markers, reduce striatal dopamine level, reduce 
TH protein expression and reduce of antioxidant enzymes level (Duty and Jenner, 2011). 
These pathological markers are highly reproducible in different species and laboratories 
(Duty and Jenner, 2011). Most importantly, this model allows assessment of degenerated 
dopaminergic neurons by behavioural observation, quantification of neurotransmitter level 
and immunostaining of dopaminergic markers as described in this chapter.  
 
Unilateral injection of 6-OHDA into the striatum was preferred in this study to create a 
partial lesioned associated with gradual loss of dopaminergic neurons over a period of 
weeks (~50% cell death) (Marinova-Mutafchieva et al., 2009, Moon et al., 2010). Less 
severe and progressive cell loss in this model represent a better approximate of the early 
stage and slow development of PD in humans. This provide a window of opportunity where 
administration of HPOs would be effective to confer neuroprotection. Injection of 6-OHDA 
into other sites of the nigro-striatal tract such SNPc or MFB to create partial lesioned is 
much difficult to construct due to smaller target area and therefore is easily off-target (Duty 
and Jenner, 2011). Additionally, injection into these areas cause extensive loss of 
dopaminergic neurons. Indeed, SNPc and MFB targeted lesioned is most often used to 
create full lesioned (>70% cell death) which is more appropriate for symptomatic study of 
PD (Duty and Jenner, 2011). 
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Despite all the advantages described above, 6-OHDA PD model unfortunately does not 
offer the full spectrum of PD pathology as in man. Lewy body primarily consist of α-
synuclein which serve as pathological hallmark in PD brain is absent (Bezard et al., 2013). 
Furthermore, neurodegeneration observed in 6-OHDA model is only restricted to the 
nigrostriatal tract and not in other part of the brain which are greatly affected in actual PD 
(Simola et al., 2007, Braak et al., 2003). Indeed, post-mortem studies on PD brain revealed 
that Lewy body accumulated in stages outside basal ganglia, and thus affected other part 
of the brain prior to the basal ganglia (Braak et al., 2003). In this sense, the neuroprotection 
seen in 6-OHDA PD model does not capture this stage of disease development and 
progression which might be important for early intervention or providing clue to the 
mechanism of neurodegeneration. Recent advances in PD model reveals that rats injected 
with proteasomes inhibitors exhibited neuronal loss in the locus coeruleus, dorsal motor 
nucleus of the vagus and nucleus basalis of Meynert which is associated with protein 
inclusion similar to Lewy body pathology (McNaught et al., 2004, Bentea et al., 2016). 
However, this model is not properly validated and is difficult to reproduce (Kordower et al., 
2006, Cook and Petrucelli, 2009). Hence, it might take several more years before 
construction of this model is refined and validated to be advantageous for a better model 
of PD.  
 
The 6-OHDA model is relatively more difficult to construct which requires stereotaxic 
surgical skills in contrast to MPTP which can be administered by systemic injections 
(Jackson-Lewis and Przedborski, 2007). This is because, 6-OHDA does not cross the BBB 
and therefore requires precise intracerebral injection. Implication from this invasive 
technique is that the BBB integrity may be compromised due to damage cause by the 
inserted needle. PD brain is associated with accumulation of iron in the basal ganglia and 
this is replicated in 6-OHDA model. It has been shown that misregulation of iron transport 
and BBB breakdown occur as results of oxidative stress and inflammation induced by 6-
OHDA (Carvey et al., 2005). However, a study revealed higher level of iron accumulated 
around the needle tract of 6-OHDA injection site in the striatum due to physical damage in 
addition to iron misregulation (Virel et al., 2014). Because of this, HPOs iron chelators may 
not be as effective in preventing cell death in the striatum compared to other area distance 
unaffected by the physical BBB damage such as SNPC. This suggest that inaccurate 
results could be obtained in this type of model such as underestimation of neuroprotection. 
An alternative model that could be used in this study to overcome this limitation is by using 
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MPTP-mice model of PD.  Like 6-OHDA, MPTP-treated mice also show abnormal iron 
accumulation in the basal ganglia due to iron misregulation (You et al., 2015, Mandel et 
al., 2004). Indeed, this model has been successfully employed to show the neuroprotective 
effect of CP20 (Devos et al., 2014).  
 
The motor behaviour of unilateral partial-lesioned is less robust than unilateral full-lesioned 
of 6-OHDA model as described in Chapter 2 and Chapter 5. Due to less reliable behaviour 
readout in unilateral partial 6-OHDA-lesioned, a slightly different approach could be taken 
in the current study. Bilateral partial 6-OHDA-lesioned offers additional brain samples for 
different purpose that might be advantageous in the current study (Roedter et al., 2001). 
For example, halves hemisphere could be dedicated for immunostaining and other halves 
could be used for biochemical analysis for both striatum and SNPc. This approach would 
generate and provide more comprehensive and valuable data from just a single treatment 
group. Furthermore, the bilateral degeneration of the nigro-striatal tract is more reflective 
of that seen in PD. On the negative side, this model would take more time to construct and 
additional sham-lesioned groups for the studied compounds. 
 
Even though intrastriatal 6-OHDA-lesioned provides a reproducible model of nigrostriatal 
degeneration, there is still variability in the extent of the lesion depending on the striatal 
co-ordinate and amount injected (Duty and Jenner, 2011). Interestingly, even different size 
of needle employed (26 vs 30G) to create lesion following an exact protocol also lead to a 
significant variation in lesion size (Penttinen et al., 2016). Most recently, Penttinen et al. 
(2016) had evaluated and classified the neurodegeneration after 6-OHDA lesioned at 
various co-ordinate into progressive, stable and regressive based on behavioural 
observation for up to 14 weeks following striatal lesion. This study provides an excellent 
guidance for the selection of co-ordinate for striatum that best represent PD progression 
in human. In this sense, co-ordinate for striatum that lead to progressive 
neurodegeneration shown in this study is of interest.  
 
In conclusion, none of the toxin induced neurodegeneration model able to recapitulate all 
features of PD in human. Proteasome-inhibition model appeared to have more complete 
features of PD, however this model is hard to reproduce and therefore its validity is 
questioned (Cook and Petrucelli, 2009). In the absence of a perfect PD model, the 6-
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Based on the data obtained, CP20 and CN128 showed a comparable pharmacokinetics 
profile after a single i.p. injection. D-amphetamine rotation test failed to show any different 
to control group which include the 6-OHDA-lesioned rats. Nevertheless, CP20 and CN128 
managed to prevent the dopamine level depletion in rat striatal tissues by approximately 
30%. This was further supported by prevention of nigral cell death assessed in SNPc. 
Therefore, it can be concluded that CP20 and CN128 were neuroprotective against 6-
OHDA-induced nigrostriatal degeneration as shown by unaltered dopamine and serotonin 
turnovers and prevention of dopaminergic cell loss in SNPc.  The protection against 
dopamine depletion seen after treatment with iron chelators might suggest a potential 
disease modifying effect due to the iron chelation. Indeed, focal administration of 
deferasirox (DFX), a tridentate iron chelator and deferioxamine (DFO), a hexadentate iron 
chelator into a striatum of 6-OHDA lesioned rats abolished the production of hydroxyl 
radicals by Fenton reaction as measured by microdialysis (Dexter et al., 2011). 
Additionally, CP20 also has been shown to diminish OH● radical production in the 
presence of iron and H2O2 in vitro (Devanur et al., 2008b). Therefore, the mechanism of 
neuroprotection was likely by the iron chelating property of CP20 and CN128. 
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6 General Discussion 
 Thesis hypothesis and aims 
Accumulating lines of evidence have demonstrated the neuroprotective ability of iron 
chelators in PD (Kaur et al., 2003, Youdim et al., 2004, Zheng et al., 2005, Ben-Shachar 
et al., 1991, Xu et al., 2008, Avramovich-Tirosh et al., 2007, Dexter et al., 2011, Devos et 
al., 2014, Martin-Bastida et al., 2017, Wang et al., 2017, Gotsbacher et al., 2017). 
Specifically, CP20, an orally active HPO bidentate iron chelator, has undergone early 
stage clinical trials showing promising results (Devos et al., 2014, Martin-Bastida et al., 
2017). However, the associated neutropenia and agranulocytosis of CP20 treatment 
reported in 15% of the recruited PD patients could limit it usage in a wider population 
(Devos et al., 2014). In order to address this problem, several HPO analogues (CN 
compounds) have been developed based on the chemical structure of CP20 in order to 
retain their iron binding ability (Hider et al., 2011). In addition, a glycosylated HPO together 
with the parent HPO were also developed to target the GLUT transporter at BBB (Roy et 
al., 2010). Acute studies in mice revealed that the toxicity for these novel HPOs (CN 
compounds) were lower than CP20 (Hider et al., 2011). As CP20 has been shown to cross 
the BBB and neuroprotective in animals and humans, it was hypothesised that the novel 
HPO iron chelators based on the CP20 structure and glycosylated HPO are able to cross 
the BBB and show neuroprotection in PD. Consequently, the aims of the studies described 
in this thesis were to investigate the brain permeability of novel HPOs in rats and their 
neuroprotection ability in in vitro and in vivo model of PD. Data obtained from the current 
studies revealed that the novel HPOs can cross the BBB as long as there is a balance 
between intermolecular hydrogen bond and lipophilicity as well as recognition by transport 
system at BBB. Modification of CP20 structure for brain permeable HPOs did not eliminate 
the neuroprotection capability as seen in in vitro and in vivo neuroprotection studies as the 
affinity towards iron (pFe3+) is only slightly altered as well as maintaining permeation 
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 Summary of the findings 
The present study examined the brain permeability of novel HPOs in rats. Additionally, the 
effect of the novel HPOs on toxin-induced cell death in SH-SY5Y cell line and rats were 
evaluated. The following results were obtained in the individual studies: 
  
 Rate of brain penetration for three novel HPOs (CN128, CN226 and CN228) were 
comparable to CP20 in rats.  CP84 showed higher brain uptake while CN116, CN118 
and CN126 showed lower brain uptake than CP20. In contrast, glycosylated HPO 
(FCF132) failed to get into the brain. 
 Novel HPOs showed different degrees of neuroprotection in toxins-induced SH-SY5Y 
cell death with the best neuroprotection observed in 6-OHDA-induced cell death while 
no protection was observed in MG132-induced cell death. 
 Chirality in the chemical structures of novel HPOs neither contributed to the 
differences in brain uptake in rats nor in in vitro neuroprotection study with SH-SY5Y 
cell lines. 
 Selected HPOs (CP20, CN128 and CN226) did not show any signs of acute toxicity 
in rats when injected i.p. at 500 µmol/kg dose, while CP84 was toxic at 200 and 500 
µmol/kg doses. 
 CP20 and CN128 prevented the toxin-induced neuron cell loss in the nigrostriatal 
dopamine pathway in 6-OHDA-lesioned rats. 
In conclusion, these studies showed that the novel HPOs developed based on the 
chemical structure of CP20 were able to cross the blood brain barrier in rats. However, 
attachment of glucose moiety to CP84 (FCF132) was counter-productive and prevented 
brain uptake. Additionally, novel HPOs conferred neuroprotection in H2O2, 6-OHDA and/or 
FeNTA-induced cell death but not in MG132-induced cell death in vitro. CN128 was further 
evaluated for neuroprotection in 6-OHDA PD model and replicated the neuroprotection 
observed in in vitro study. This confirms that iron plays a role in degenerative process of 
dopaminergic neurons and that targeting free labile-iron pool (LIP) in brain using the novel 
iron chelators might be neuroprotective against progressive dopaminergic cell loss in PD. 
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 Did the modifications of the chemical structure of 
CP20 permit BBB permeability and show 
neuroprotection? 
The primary motivation for alteration of CP20 chemical structure by adding extra functional 
group was to make the novel HPOs more resistance to metabolism in the liver especially 
from glucuronidation after oral ingestion, hence increase their bioavailability and lower oral 
dose could be possible (Hider et al., 2011, Hider et al., 1990, Singh et al., 1992, Singh et 
al., 1996). Additionally, the novel HPOs were designed to preserve the oxygen ligands on 
the molecule that are important to chelate iron and therefore the affinity towards iron 
determined by potentiometric measurements are within the same range as CP20 (Kong 
et al., 2006). The bioavailability, toxicity and efficacy of novel HPOs have been evaluated 
in rodents and primates in the previous studies (Paiboonsukwong et al., 2016, Hider et al., 
2011, Lu, 2016). Novel HPOs that showed good oral bioavailability as assessed by iron 
excretion efficiency in iron overloaded rat were taken forward for evaluation of brain 
permeability in this study with the aim to develop as a neuroprotection agent in PD. This 
is because, changing the chemical structure also changed the physicochemical properties 
such as lipophilicity, molecular size and hydrogen bond formation with surrounding water 
which could affect BBB permeability and therefore the extend of iron chelation in the brain 
that is important for neuroprotection (Mikitsh and Chacko, 2014). 
 
 Brain permeability of novel HPOs 
The current study showed that the physicochemical properties play a role in brain 
permeability of HPOs that crossed the BBB via membrane diffusion. The total polar 
surface area (TPSA) for HPOs which indicate the propensity to form hydrogen bonds 
appears to show a better relationship with brain uptake compare to lipophilicity (cLogP, 
Chapter 3). Hence, a general increase in lipophilicity of novel HPOs does not necessarily 
guarantee a proportional increase in rate of brain permeability when compare to CP20 as 
one might expect (Hider et al., 2011, Liu et al., 2011, Habgood et al., 2000, Habgood et 
al., 1999). This observation is supported by recent finding that showed brain permeability 
for CNS drugs used in clinics are primarily dictate by their intermolecular hydrogen bond 
rather than lipophilicity (Frieden et al., 2009, Chen et al., 2011). Nevertheless, it seems 
that as the lipophilicity increases, it does helps to counter the effect of increase hydrogen 
bonding between novel HPOs and surrounding water so that the rate of brain permeability 
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was not different than CP20. This is obvious among the CN compounds which have higher 
but constant TPSA than CP20 in addition to increasing lipophilicity. 
 
In addition, functional group that is recognised by endogenous transport systems may 
improve or deter brain uptake as seen for CP84 and FCF132 respectively. It was revealed 
that CP84 not only crossed the BBB via membrane diffusion but is also a substrate for 
large amino acid transporter (LAT) which enhance the rate of brain uptake. Several CNS 
drugs used LAT to cross the BBB which include L-DOPA (antiparkinsonian), melphalan 
(anticancer) and gabapentin (anticonvulsant). Indeed, the LAT appear more versatile in 
accommodating pseudo-nutrients and drug conjugates when compare to GLUT (Pavan et 
al., 2008, Yang et al., 2001). Although targeting LAT as means to deliver HPOs to the 
brain in PD sounds promising, it would pose another challenge. This is due to the fact that 
L-DOPA, the primary drug for the treatment of PD is also a substrate for LAT (del Amo et 
al., 2008, Geier et al., 2013). It is not a good idea to co-administer drugs that target the 
same transporters to treat PD as drugs that target LAT1 would require dose adjustment 
due to competition between drugs for the transport binding site (Bitner et al., 2015, Jost 
and Bruck, 2002). Dose increment of L-DOPA, for example, could lead to unpredictable 
levels of the drug in plasma and brain and thus increase the risk of severe adverse effects 
such as peripheral cardiovascular and gastrointestinal symptoms, and central motor and 
non-motor side effects (eg dyskinesias, insomnia, hallucinations and psychosis) (Foster 
and Hoffer, 2004, Barbeau, 1976). In contrast to CP84, FCF132, a glucose conjugated 
form of CP84 was specifically designed to target GLUT but failed to cross the BBB. 
FCF132 lost membrane diffusion capacity due to decrease in lipophilicity and increase 
molecular weight after conjugation with glucose. Additionally, the conjugated glucose did 
not in any way facilitated brain uptake of FCF132. It is apparent from this and other studies 
targeting the glucose transporter (GLUT) at BBB that is not the best option due to several 
reasons. Firstly, glucose recognition site in GLUT1 at BBB is very restrictive and therefore 
only allow conjugation of HPOs at C2 and C6 for substrate recognition (Mueckler and 
Thorens, 2013, Mueckler and Makepeace, 2009, Carruthers et al., 2009). Several 
attempts using various synthetic method to conjugate HPO at C6 of glucose molecule 
have failed to yield HPO 6-glycoconjugate (Fuchs, 2015). Secondly, glucose is exclusively 
served as the energy source at BBB and brain under normal physiologically condition 
which explain the high affinity of GLUT1 at BBB (Km= 1 mM) (Gorovits and Charron, 2003). 
Under normal physiological concentration of glucose, GLUT1 is always saturated with 
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glucose which compete with glucose conjugated HPOs which translate into higher 
concentration of HPO glycol-conjugate in plasma are required for successful brain 
crossing (Giknis and Clifford, 2008, Subramanian et al., 2013).  
 
 In vitro neuroprotection of brain permeable HPOs 
As various iron chelators including CP20 have been shown to be neuroprotective in in vitro 
and in vivo model of PD (Dexter et al., 2011, Forni et al., 2008, Zorzi et al., 2011, Youdim 
et al., 1999, Shachar et al., 2004, Gal et al., 2005, Zheng et al., 2005, Zhu et al., 2007, 
Yassin et al., 2000, Kaur et al., 2003, Reznichenko et al., 2010, Leaver et al., 2009, Xu et 
al., 2008, Xu et al., 2011), these brain penetrant novel HPOs were evaluated for their 
neuroprotective potential. It was clear from the in vitro neuroprotection study with SH-
SY5Y cell lines that brain permeable HPOs are neuroprotective towards all the toxins 
employed except for MG132 which indirectly suggest the involvement of iron in cell death 
(Chapter 4). As explained in Chapter 1, iron participates in the Fenton reaction producing 
highly reactive hydroxyl radical (OH●-). However, it can be speculated that extensive 
accumulation of intracellular proteins with multiple signalling routes causes cell death 
which cannot be prevented by iron chelators alone. This is supported by accumulation of 
pro-apoptotic signalling protein p53 in dopaminergic cells exposed to MG132 due to 
decrease degradation by proteasomes system (Lopes et al., 1997, Nair et al., 2006, 
Dietrich et al., 2003). Genetics silencing of p53 or inhibition of p53 activity however 
protected against MG132-induced cell death (Lopes et al., 1997, Nair et al., 2006). 
Besides, it can generally be observed in the current study that the efficacy of novel HPOs 
positively correlate with lipophilicity and less with iron affinity constant (pFe3+) which might 
suggest better ability to penetrate SH-SY5Y cell membrane for chelating more iron 
(Workman et al., 2015). 
 
 Pharmacokinetics of brain permeable HPOs 
Selected novel HPOs (CP84, CN128 and CN226) were administered intraperitoneally (i.p.) 
in rats to confirm the brain distribution seen in in situ brain perfusion experiment and to 
see the pharmacokinetics profile of novel HPOs. Although, novel HPOs were intended for 
oral consumption, oral administration of crude drugs would require large doses to attain 
therapeutic concentration in plasma especially for drugs such as CP20 that have very high 
first-pass effect in the liver (Singh et al., 1992, Bellanti et al., 2014). The requirement for 
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oral large doses for compound that still unknown to show neuroprotection in animal model 
of PD is not feasible in term of time and resources for chemical synthesis. Nevertheless, 
the aim of the current study is to confirm the neuroprotection ability in animal model of PD 
and not the oral bioavailability which justify the method of HPOs administration by 
intraperitoneal route. In this study CP84 was neurotoxic through the unknown 
mechanism(s) in rats as shown by sudden aggressive behaviour and seizure after 
intraperitoneal injection. However, this was not the case for other novel HPOs. It might be 
that the massive uptake of CP84 as showed in in situ brain perfusion study caused rapid 
depletion of free iron in the brain and interfere with the activity of essential enzymes. 
Aldehyde oxidase, an enzyme responsible for serotonin degradation requires iron 
(Mackler et al., 1979, Mackler et al., 1978) and depletion of iron would increase serotonin 
level in the brain which has been shown to be associated with seizure (Bidabadi and 
Mashouf, 2009, Idro et al., 2010, Baf et al., 1994). Interestingly, despite structural 
alteration, total brain concentration for novel HPOs in rats were not different than CP20. 
This observation could be due to the high volume of distribution (Vd) which is common for 
lipophilic HPOs (Bijsterbosch et al., 1981, Quanquan et al., 2010, Fredenburg et al., 1993, 
Thuma et al., 1998). Furthermore, CN226 was shown to be a substrate for Pgp efflux 
pump at BBB which might limit brain distribution despite being more lipophilic than CP20 
(Chapter 3). 
 
 In vivo neuroprotection of brain permeable HPO 
Although three novel HPOs were initially selected, only CN128 was further tested for 
neuroprotection in 6-OHDA rat model of PD. CP84 was discarded due to toxicity while 
CN226 PK profile was not different to CP20 in addition to be a substrate for Pgp efflux 
pump (Chapters 3 & 5). In this study, CN128 along with CP20 were shown to be 
neuroprotective by preventing the depletion of dopamine level in striatum and nigral cell 
loss in SNPc in 6-OHDA rat model of PD. This finding corroborates the study performed 
by Dexter et. al. (2010) in which three clinically available iron chelators (deferoxamine, 
deferasirox and CP20) exhibited neuroprotection in 6-OHDA rat with CP20 being the most 
potent. The most recent finding also showed remarkable neuroprotection of CP20 in 
MPTP-mice model (Devos et al., 2014). Indeed, Phase I and II randomised double blinded 
placebos controlled clinical trial for 6 months to assessed CP20 neuroprotection in early 
stage PD patients (mean age 65 years old) showed promising results which suggest the 
applicability of PD models as a tool for selecting promising neuroprotective agents (Martin-
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Bastida et al., 2017, Devos et al., 2014a). One major limitation of the current study is that 
no measurement of labile iron pool (LIP; Chapter 1) were performed in in vitro and in vivo 
neuroprotection studies, thus the mechanism by which the HPOs elicited their 
neuroprotective effect is not conclusive (Jiang et al., 2010). 
 
One problem associated with CP20 therapy is the extensive glucuronidation in the liver 
which in turn require large oral dose to attain therapeutic concentration in plasma (Singh 
et al., 1992, Bellanti et al., 2014). CP20 is also associated with blood toxicity with 
agranulocytosis is the prominent one (Elalfy et al., 2012, Tricta et al., 2016). In the 
aforementioned clinical trials, although the dose given to the PD patients were 3-fold lower 
than Thalassemia patients, 15% of the recruited PD subjects were dis-continued from the 
treatment due to agranulocytosis and neutropenia. Furthermore, the incident of 
agranulocytosis and neutropenia increases with age (Andres et al., 2002, Mohan et al., 
2015, Rajagopal, 2005). Therefore, while CP20 could delayed progression of PD, the 
associated toxicities would limit its used in PD patients which the majority age of onset is 
over 60 years old (Mourot-Cottet et al., 2016). Interestingly, equimolar dose of CN128 
when administered to iron-loaded rodents and primates showed 3-fold better iron excretion 
suggesting improved oral bioavailability (Hider et al., 2011a, Lu, 2016, Paiboonsukwong 
et al., 2016). Analysis of glucuronide metabolite for CN128 in rat urine revealed 21-fold 
less glucuronide compare to CP20 (Paiboonsukwong et al., 2016, Singh et al., 1992). 
Remarkably, CN128 also exhibited better toxicity profile than CP20 in preventing reduction 
of leukocytes counts in rats and monkeys (Paiboonsukwong et al., 2016). Higher oral 
bioavailability and lower rate of glucuronidation in the liver than CP20 in experimental 
animals provide additional advantage for the development of CN128 as an efficient and 
less toxic orally active iron chelator for neuroprotection in PD (Paiboonsukwong et al., 
2016). However, the data reported in this thesis could not support the improved 
bioavailability of CN128 compare to CP20 due the route of administration was 
intraperitoneal and not oral. Nevertheless, current study confirmed equivalent brain 
permeability and neuroprotective ability of CN128 to CP20 despite structural modification. 
 
 Conclusion 
Taking all things together, structural modification of CP20 still allow brain uptake of novel 
HPOs except for glucose conjugated HPOs which was not optimally designed for substrate 
recognition at GLUT. It appears that additional polar group in novel HPOs limit brain 
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permeability but increasing lipophilicity help to overcome the problem. Novel HPOs 
showed neuroprotection in in vitro PD models with some showing better protection than 
CP20. Of these, CP128 was chosen for assessment of in vivo neuroprotection in a rat 
model of PD.  Interestingly the neuroprotection shown by CP128 was similar to that of 
CP20 despite higher lipophilicity and reported improve bioavailability possibly due to high 
volume of distribution and route of HPOs administration (i.p.) employed in the current 
study. However, with the lower potential for neutropenia, these studies suggest that this 
compound may be a candidate for future clinical trials for disease modification on man.   
 
 PD models to evaluate neuroprotection 
Searching for effective neuroprotection agents in human has proceeded up to this time 
with little success.   MAO-B specific inhibitor selegiline, for example, was previously 
thought to be the first successful neuroprotective agent in clinic. However, studies in 
human reveal that the effect of MAO-B inhibitor was primarily symptomatic rather than 
neuroprotective (LeWitt, 1994, Stocchi and Olanow, 2003, Athauda and Foltynie, 2015). 
Many factors have been suggested to contribute to this failure such as animal models that 
do not reflect widespread pathology of PD and poor experimental design in preclinical and 
clinical research. Consequently, there is a dire need for better animal models that cover 
overall pathology and symptoms in human PD as well as providing prediction of effective 
neuroprotective agents for successful translation in clinical trial (Duty and Jenner, 2011). 
Currently available animal models only impart part of the overall pathology of PD with each 
model hold certain degree of relevance to answer the research question (Bezard et al., 
2013). Most importantly, Lewy body inclusion which serve as the pathological hallmark in 
autopsied PD brain is absent in all animal models. The finding that Lewy body mainly 
compose of aggregated α-synuclein leads to creation of transgenic mice that expressed 
mutant α-synuclein or overexpress wild-type α-synuclein with the propensity to aggregate 
(Fernagut and Chesselet, 2004, Kurz et al., 2012). Unfortunately, these mice showed mix 
results in term of relationship between α-synuclein and neuronal death which makes them 
unreliable and not robust as a model for neuroprotection study. 
 
 Validity of the PD models to study neuroprotective ability of HPOs 
It was suggested that dopaminergic neurons are susceptible to oxidative stress due to 
metabolism of dopamine by monoamine oxidase (MAO) that produces hydrogen peroxide 
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(Nicolaus, 2005, Zucca et al., 2017, Gerlach et al., 2003). This condition exacerbates when 
the capacity of iron storage protein become limited due to accumulation of iron in aging 
brain. Iron has a central role in generating the highly destructive hydroxyl radical (OH●-) 
which damage biomolecules and initiate neurodegeneration processes as seen in PD 
(Berg et al., 2001, Medeiros et al., 2016). Furthermore, dopamine could also react with 
iron to produce dopamine-o-quinones that is also redox active and able to promote α-
synuclein aggregation (Bisaglia et al., 2010, Lee et al., 2011).  Although the level of iron 
in the SH-SY5Y cells and rat brain after exposure to toxins was not determined in this 
study, previous reports revealed that exposure to H2O2, 6-OHDA, MG132 or MPTP 
increase iron level inside the cells in in vitro and/or in vivo models of PD by modulating 
expression of protein that regulates iron such as transferrin, transferrin receptor, divalent 
metal transporter 1 (DMT1), ferroportin and/or ferritin (Dev et al., 2015, Andriopoulos et 
al., 2007, Wang et al., 2009, Kobayashi et al., 2008, Howitt et al., 2009, Li et al., 2012). In 
regard to 6-OHDA rat model of PD that was employed in this study, this model is relevant 
to study the neuroprotective effect of iron chelator such as HPOs since multiple studies 
have shown iron accumulation in striatum and SNPc in this model which suggest 
dysregulation of iron (He et al., 1996, Kondoh et al., 2005, Virel et al., 2014). Furthermore, 
autopsy and radiological studies have reported accumulation of iron in the basal ganglia 
of PD patients which confirmed the translational characteristic of this model into human 
(Dexter et al. 1994; Berg 2006; Wypijewska et al. 2010). It has been shown that 
dysregulation of iron transport and BBB breakdown occur as results of oxidative stress 
and inflammation induced by 6-OHDA (Carvey et al., 2005). Although 6-OHDA rat model 
exhibited iron accumulation, but the effect of iron accumulation is only secondary to the 6-
OHDA administration. Since, CP20 and/or CN128 treatments in 6-OHDA model and 
human suggested neuroprotection, a more relevant and applicable PD model for testing 
HPOs iron chelator would be iron rat model of PD (Devos et al., 2014, Dexter et al., 2011). 
This iron rat model of PD can be used to evaluate the direct effect of iron chelation as well 
as dose-response relationship (Junxia et al., 2003). 
 
 Suggestion for improvements in neuroprotection studies 
Bezard et al., (2013) criticised the widely used experimental design for neuroprotection 
study in animal model of PD. Most often, the putative neuroprotective agent is 
administered before or during brain lesion. According to the authors, the experimental 
design fails to represent the actual situation whereby the agent is likely to be administered 
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in PD patients only when about 50% of neurons had already loss. Proposal for ideal 
experimental design in pre-clinical research was further suggested. This includes the use 
of progressive animal model of PD instead of acute model, administration of putative 
neuroprotective agents after creation of lesion and finally the use of non-human primates 
to verify the neuroprotection of promising neuroprotection agents (Bezard et al., 2013). 
The second proposal is only possible when progressive animal models are made available 
to test neuroprotective agents. For example, 6-OHDA administered intrastriatally as 
discussed in this thesis cause rapid cell death and treatment with HPOs after creation of 
lesion would evaluate neurorestorative potential rather than neuroprotection. This justify 
the approach taken in the current study whereby HPOs were administered i.p. two days 
and within 1h before 6-OHDA lesion so that HPOs reaching the striatum can protect from 
acute cell death. In addition to these, a better tools and biological markers for early 
definitive diagnosis of PD in clinic is as equally important as better animal models. PD 
diagnosis is usually made when the disease has reached a stage where more than 70% 
of dopaminergic neurons in SNPc had diminished (Lohle and Reichmann, 2010, Schapira, 
2009). This stage of PD may be considered too late to observe an effective 
neuroprotection if there is any. This could be one of the reasons that until now, none of 
the promising neuroprotective agent tested pre-clinically succeeded in clinical trials, in 
addition to not having better animal models. 
 
 Future outlook 
It can be seen from this study that by modifying HPOs chemical structure could lead to no 
change, enhance or diminish brain uptake independent on the physicochemical properties 
of the compound, recognition by efflux pump as well as being a substrate for carrier-
mediated transporters. Chemical modification of drug requires knowledge in synthetic 
chemistry and the synthetic route is tailored base on the chemical structures. Chemical 
modification also needs to take into account the size of the molecule so that the molecular 
weight not exceeding 400D for good BBB membrane permeability (Hitchcock and 
Pennington, 2006, Lipinski et al., 2001). Additionally, steric hindrance introduce by the 
ancillary functional group may prevent substrate recognition when carrier-mediated 
transporter is targeted (Li et al., 2015). To rationalise the molecular design of novel HPOs 
to target the BBB, computational modelling should be incorporated during drug 
development process. This computational approach predicts how molecular changes 
  CHAPTER 6: GENERAL DISCUSSIONS 
240 
 
affect the free-energy of solvation in which case low free-energy indicates better BBB 
crossing (Goncalves and Stassen, 2003, Jia et al., 2002). Similarly, computational method 
can be used to evaluate the likelihood of ligand-transporter interaction for successful drug 
uptake into the brain (Matsson and Bergström, 2015, Schlessinger et al., 2013).  
 
In respect to method of drug delivery to the brain, brain permeable nanoparticle vesicles 
such as liposomes, polymersomes and exosomes are recently received much attention 
(Saraiva et al., 2016). This method avoids the chemical modification of HPOs that has 
been pharmacologically optimised since the HPOs are incorporated into the brain 
permeable nanoparticles. Additionally, the nanoparticle can be designed to increase brain 
uptake by attaching with ligand or antibody for receptor-mediated endocytosis (Chapter 
1). One ligand of interest which is relevant for iron chelation is transferrin. This transferrin 
coated nanoparticles with incorporated HPOs could be recognised by transferrin receptors 
(TfR) that abundantly expressed at BBB (Liu et al., 2006, Ayton et al., 2016). Additionally, 
the trancytosed transferrin could also chelate and help with iron distribution in addition to 
incorporated HPOs. One major drawback of this approach is that nanoparticles are not 
orally stable and hence limits their application if oral route is the method of choice for 
convenience and compliance among aging PD patients (Pridgen et al., 2015).  
 
It is unclear whether iron chelation only is sufficient to prevent neurodegeneration in PD. 
It would be likely sufficient if the neurodegeneration is primarily cause by abnormal iron 
accumulation and not a secondary phenomenon. Since the current clinical diagnosis 
cannot determine which factors is the main contributors in neurodegeneration of PD, wide 
spectrum neuroprotection agents with limited side effects is coveted. It would be 
interesting if drugs could target more than one mechanism apart from iron chelation for 
disease improvement in PD. Premyslova et al. (2016) has recently reported that a brain-
penetrant fluorinated derivative of CP20 modulated multiple genes expression that led to 
downregulation of inflammation and ROS production and increased cellular antioxidant 
defence capacity in SH-SY5Y cells. Other researchers have taken an approach by 
combining an iron chelator with MAO-B inhibitor pharmacophores in a single molecule with 
promising results (Bar-Am et al., 2015, Gal et al., 2006, Youdim et al., 2005). One potential 
molecule exenatide, a synthetic glucagon-like-peptide-1 (GLP-1) was shown to affect a 
wide range of pathological processes in PD which has led some to speculate that this 
class of agent has the greatest potential to be a successful neuroprotection agent in 
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human (Athauda and Foltynie, 2015, Bertilsson et al., 2008, Aviles-Olmos et al., 2013). 
However, although this may sound promising, compound that act on multiple target may 
exert multiple side effects when introduce into the systemic circulation. Therefore, another 
area of research that focus on targeted drug delivery to the brain especially to the site 
where neuroprotection is needed (basal ganglia) is likewise important. 
 
 Suggested further studies 
With respect to the current study, CN128 merits further investigation in order to confirm it 
neuroprotective effect. The suggested further studies are: 
 
 Evaluate the neuroprotection of CN128 after oral administration and compare 
with CP20. 
Administration of CN128 in the current study to 6-OHDA rat model of PD was performed 
through intraperitoneal (i.p.) injection. This route of administration require much less dose 
than oral route with the aim to confirm the neuroprotection capability of CN128 in 
comparison with CP20. Data from the current study showed that CN128 was 
neuroprotective as CP20 after i.p. injection. However, CN128 was designed to resist 
glucuronidation in the liver better than CP20 after oral consumption (Hider et al., 2011). 
Supporting data from previous studies showed that CN128 has profound bioavailability 
than CP20 after oral administration in rodents and primates (Hider et al., 2011, 
Paiboonsukwong et al., 2016). This would suggest that CN128 which has been confirmed 
to exhibit neuroprotective capability in this study may show better neuroprotection when 
administered orally at equimolar dose of CP20 in animal models of PD. 
 Evaluate different doses of CN128 to see if the neuroprotection is dose 
dependent and to evaluate the limit of toxicity in PD models. 
Current study only tests a single dose of CN128 which and therefore the dose-response 
relationship could not be elucidated. Dose of CN128 at 70 µmol/kg (i.p.) in the current 
study protected against 6-OHDA induced cell death by 32%. However, it is not known 
whether this was the maximum neuroprotection possible and whether the neuroprotection 
was dose-dependent. Additionally, the suggested future study will provide toxicity profiles 
at different doses by evaluating effect of CN128 on total body iron content and the extend 
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of inhibition on iron containing biomolecules in comparison to CP20. Supporting data 
revealed that CN128 is less toxic at equimolar dose in rodents and primates despite much 
CN128 reaches the blood stream after oral administration, however, the cause of reduce 
toxicity remains unknown (Paiboonsukwong et al., 2016, Hider et al., 2011). 
 
 Evaluate the neuroprotection of CN128 in PD models induced by different 
toxins. 
Different toxins have unique mechanisms to induce Parkinson’s disease that are 
associated with iron toxicity. This provide proof, justification and confirmation of the use of 
iron chelators as neuroprotection agent. 
 
i) MPTP 
MPTP crosses the BBB and is metabolise by monoamine oxidase B (MAOB) in astrocytes 
to MPP+ (Sai et al., 2013). MPP+ mechanism of toxicity is primarily through inhibition of 
Complex I of mitochondrial transport chain in dopaminergic neurons which lead to increase 
concentration of reactive oxygen species (ROS; Marella et al., 2009, Choi et al., 2011). 
cDNA microarray study in mice model of MPTP also revealed upregulation of cytotoxic 
cytokines which include IL-1β, IL-6, IL-7 and IL-10 (Mandel et al., 2000, Youdim et al., 
2002). These pro-inflammatory mediators have recently been shown to cause iron 
accumulation in neurons (explain further below in (ii); You et al., 2017). Combination of 
increase ROS and iron accumulation induce oxidative stress in this model. 
 
ii) Lipopolysaccharide (LPS) 
LPS induces neuroinflammation and activates microglia to release the pro-inflammatory 
mediator IL-6 (You et al., 2017, Urrutia et al., 2013). Released IL-6 in turn causes an 
increase in expression of iron-regulator protein (hepcidin) that inhibit iron transporter 
(ferroportin) on neuron membranes. This cause accumulation of iron in neuron that involve 
in oxidative stress and eventually cell death. 
 
Clearly both these models could be used to evaluate the in vivo neuroprotective effect of 
iron chelators.  To increase the predictability of preclinical in vivo assessment, the effect 
of the iron chelator should be evaluated in a number of models using toxins that induce 
cell death by different mechanisms of action. 




 Evaluate the effect of CN128 treatment on other neurovascular units such as 
astrocytes and microglia. 
The study reported in this thesis only look at the effect of CN128 on dopaminergic neurons. 
However, surrounding cells such as astrocytes and microglia are also involved in the 
pathogenesis of dopaminergic cell death in animal models of PD (Sai et al., 2013, You et 
al., 2017). Comprehensive understanding on the overall effect of CN128 on these 
important neurons associated cells will provide in-depth mechanisms on CN128 
neuroprotection. 
 
 Evaluate the effect of CN128 on the brain level of iron and on the expression of 
iron regulatory proteins. 
Previous studies suggested that iron is accumulated in PD brain especially in basal ganglia 
and contributes to oxidative stress (Hartmann, 2004, Wang et al., 2016). The accumulated 
iron is likely to be caused by metabolism of dopaminergic neurons and dysregulation of 
iron transport and storage (Zucca et al., 2017). Indeed, 6-OHDA, LPS and MPTP animal 
model of PD exhibit accumulation of iron in the basal ganglia which is translated to what 
occurrs in man (Dev et al., 2015, Andriopoulos et al., 2007, Wang et al., 2009, Kobayashi 
et al., 2008, Howitt et al., 2009, Li et al., 2012). Current study did not evaluate the effect 
of CN128 on the level of iron and expression of iron regulatory proteins in the basal ganglia 
to support the mechanism of neuroprotection observed in PD model, and so this should 
be addressed in a future study. 
 
 Assess the inhibitory property of CN128 onto iron containing enzymes 
especially in the basal ganglia such as tyrosine hydroxylase (TH) and catechol-
O-methyl transferase (COMT). 
Many of the enzymes in basal ganglia require iron as a co-factor for reaction. In particular, 
TH is responsible for the hydroxylation of tyrosine to L-DOPA, the precursor for dopamine 
in dopaminergic neurons (Rausch et al., 1988). Iron is also a co-factor for COMT, the 
enzyme responsible for dopamine degradation in synaptic cleft (Waldmeier et al., 1993, 
Bastos et al., 2014). It is important to determine the extent of the inhibition of these 
enzymes by the iron chelator to give insight into the potential inhibitory effect on dopamine 
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formation or dopamine metabolism as this could distinguish between neuroprotection and 
symptomatic improvement in PD models. 
 
 Final conclusion 
As hypothesised, data from the current study revealed that novel HPO iron chelators 
based on the CP20 structure can crossed the BBB, except for glucose conjugated HPO 
which suggest limitation of targeting GLUT at BBB. The brain permeable HPOs also 
exhibited neuroprotection in SH-SY5Y cell lines and this was confirmed in vivo using 
CN128 as the best representative of the novel HPOs. It is too early to confirm that HPOs 
iron chelator such as CP20 and CN128 are neuroprotective in human until clinical trials 
with PD subjects that may take years are completed (Ravina et al., 2003, van der Brug et 
al., 2015). It is important to highlight again that PD is a multifactorial disease, and until 
today the exact cause that initiate neurodegeneration in PD brain is unknown (Sheikh et 
al., 2013, Schlossmacher et al., 2017). Nevertheless, abnormal iron accumulation has 
been repeatedly observed in the post-mortem brain of PD patients which suggest that iron 
accumulation could be one of the culprits either primary or secondary to the 
neurodegeneration and treatment with iron chelators are therefore potentially 
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